

The evolution of phosphatidylinositol 3-kinases as regu

Nature Reviews Genetics

7, 606-619

DOI: [10.1038/nrg1879](https://doi.org/10.1038/nrg1879)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Signalling through Class I PI3Ks in mammalian cells. <i>Biochemical Society Transactions</i> , 2006, 34, 647-662.	1.6	502
2	PI3K β inhibition: towards an 'aspirin of the 21st century?'. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 903-918.	21.5	220
3	Tumor metabolism: new opportunities for cancer therapy. <i>Clinical and Translational Oncology</i> , 2006, 8, 711-716.	1.2	35
4	Isoform Specific Inhibitors of PI3 Kinase in Glioma. <i>Cell Cycle</i> , 2006, 5, 2301-2305.	1.3	33
5	Conditional Akt activation promotes androgen-independent progression of prostate cancer. <i>Carcinogenesis</i> , 2006, 28, 572-583.	1.3	51
6	Sjogren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16882-16887.	3.3	68
7	Cardiovascular Actions of Insulin. <i>Endocrine Reviews</i> , 2007, 28, 463-491.	8.9	685
8	The Obesity-Cancer Link: Lessons Learned from a Fatless Mouse: Figure 1.. <i>Cancer Research</i> , 2007, 67, 2391-2393.	0.4	105
9	Rare cancer-specific mutations in PIK3CA show gain of function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5569-5574.	3.3	345
10	Mitochondrial Reactive Oxygen Species Signal Hepatocyte Steatosis by Regulating the Phosphatidylinositol 3-Kinase Cell Survival Pathway. <i>Journal of Biological Chemistry</i> , 2007, 282, 21327-21336.	1.6	60
11	Reversine increases the plasticity of lineage-committed mammalian cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 10482-10487.	3.3	99
12	Proto-oncogene TCL1: more than just a coactivator for Akt. <i>FASEB Journal</i> , 2007, 21, 2273-2284.	0.2	61
13	Cyclosporin A and FK506 Inhibit IL-12p40 Production through the Calmodulin/Calmodulin-dependent Protein Kinase-activated Phosphoinositide 3-Kinase in Lipopolysaccharide-stimulated Human Monocytic Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 13351-13362.	1.6	29
14	Activation of Nonreceptor Tyrosine Kinase Bmx/Etk Mediated by Phosphoinositide 3-Kinase, Epidermal Growth Factor Receptor, and ErbB3 in Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 32689-32698.	1.6	32
15	Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. <i>British Journal of Cancer</i> , 2007, 96, 1595-1604.	2.9	55
16	A Novel Function of eIF2 β Kinases as Inducers of the Phosphoinositide-3 Kinase Signaling Pathway. <i>Molecular Biology of the Cell</i> , 2007, 18, 3635-3644.	0.9	79
17	The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation. <i>Cancer Research</i> , 2007, 67, 4287-4294.	0.4	87
18	The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications. <i>Current Genomics</i> , 2007, 8, 271-306.	0.7	206

#	ARTICLE	IF	CITATIONS
19	Rac1 is required for reorientation of polarity and lumen formation through a PI 3-kinase-dependent pathway. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F1633-F1640.	1.3	37
20	The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor- κ B inhibition and enhanced by the presence of PTEN. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2477-2486.	1.9	74
21	The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 4637s-4640s.	3.2	33
22	Targeted drug therapy for meningiomas. <i>Neurosurgical Focus</i> , 2007, 23, E12.	1.0	46
23	Quantitative Measurement of Phosphatidylinositol 3,4,5-trisphosphate. <i>Methods in Enzymology</i> , 2007, 434, 117-130.	0.4	33
24	Altered Innate Immune Functioning of Dendritic Cells in Elderly Humans: A Role of Phosphoinositide 3-Kinase-Signaling Pathway. <i>Journal of Immunology</i> , 2007, 178, 6912-6922.	0.4	358
25	The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3169-3179.	1.9	77
26	Live-cell Molecular Analysis of Akt Activation Reveals Roles for Activation Loop Phosphorylation. <i>Journal of Biological Chemistry</i> , 2007, 282, 36634-36641.	1.6	47
27	Phosphoinositide 3-kinases as a common platform for multi-hormone signaling. <i>Journal of Endocrinology</i> , 2007, 194, 243-256.	1.2	121
28	Molecular Mechanisms Underlying FIP1L1-PDGFR α -Mediated Myeloproliferation. <i>Cancer Research</i> , 2007, 67, 3759-3766.	0.4	67
29	Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19011-19016.	3.3	94
30	Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 293, C509-C536.	2.1	390
31	The Biology Behind mTOR Inhibition in Sarcoma. <i>Oncologist</i> , 2007, 12, 1007-1018.	1.9	163
32	Common and Distinct Genomic Events in Sporadic Colorectal Cancer and Diverse Cancer Types. <i>Cancer Research</i> , 2007, 67, 10736-10743.	0.4	64
33	Integrative Genomic Analysis of Phosphatidylinositol 3-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5314-5321.	3.2	111
34	The neuronal Arf GAP centaurin β 1 modulates dendritic differentiation. <i>Journal of Cell Science</i> , 2007, 120, 2683-2693.	1.2	41
35	A Dual Phosphoinositide-3-Kinase β /mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in <i>PTEN</i> -Mutant Glioma. <i>Cancer Research</i> , 2007, 67, 7960-7965.	0.4	199
36	Energy Balance and Carcinogenesis: Underlying Pathways and Targets for Intervention. <i>Current Cancer Drug Targets</i> , 2007, 7, 484-491.	0.8	55

#	ARTICLE	IF	CITATIONS
37	Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase β . Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14354-14359.	3.3	57
38	G protein-independent Ras/PI3K/F-actin circuit regulates basic cell motility. Journal of Cell Biology, 2007, 178, 185-191.	2.3	208
39	The p110 β Isoform of Phosphatidylinositol 3-Kinase Is Essential for Polyomavirus Middle T Antigen-Mediated Transformation. Journal of Virology, 2007, 81, 7069-7076.	1.5	28
40	PTEN: Its Dereglulation and Tumorigenesis. Biological and Pharmaceutical Bulletin, 2007, 30, 1624-1627.	0.6	70
41	Exploring the specificity of the PI3K family inhibitor LY294002. Biochemical Journal, 2007, 404, 15-21.	1.7	368
42	Metabolic switching of PI3K-dependent lipid signals. Biochemical Society Transactions, 2007, 35, 188-192.	1.6	15
43	Role of class II phosphoinositide 3-kinase in cell signalling. Biochemical Society Transactions, 2007, 35, 211-214.	1.6	158
44	Non-invasive visualization of the lipid product of class I PI3K in transgenic mouse models. Biochemical Society Transactions, 2007, 35, 215-218.	1.6	6
45	Neutrophil activation via β 2 integrins (CD11/CD18): Molecular mechanisms and clinical implications. Thrombosis and Haemostasis, 2007, 98, 262-273.	1.8	93
46	Novel functions of thyroid hormone receptor mutants: Beyond nucleus-initiated transcription. Steroids, 2007, 72, 171-179.	0.8	27
47	Activation of phosphatidylinositol 3-kinase and protein kinase B/Akt in dorsal root ganglia and spinal cord contributes to the neuropathic pain induced by spinal nerve ligation in rats. Experimental Neurology, 2007, 206, 269-279.	2.0	109
48	PTEN Enters the Nuclear Age. Cell, 2007, 128, 25-28.	13.5	143
49	AKT/PKB Signaling: Navigating Downstream. Cell, 2007, 129, 1261-1274.	13.5	5,261
50	mTOR Complex1/S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends in Molecular Medicine, 2007, 13, 252-259.	3.5	431
51	PI3K Charges Ahead. Science, 2007, 317, 206-207.	6.0	42
52	Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs. Drugs of the Future, 2007, 32, 0537.	0.0	21
53	Cellular Response to Hyperosmotic Stresses. Physiological Reviews, 2007, 87, 1441-1474.	13.1	635
54	Radiation-induced cell signaling: inside-out and outside-in. Molecular Cancer Therapeutics, 2007, 6, 789-801.	1.9	313

#	ARTICLE	IF	CITATIONS
55	The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy: Fig. 1.. <i>Clinical Cancer Research</i> , 2007, 13, 3109-3114.	3.2	239
56	Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. <i>Human Molecular Genetics</i> , 2007, 16, 129-141.	1.4	283
57	Human Neural Stem Cells Over-Expressing VEGF Provide Neuroprotection, Angiogenesis and Functional Recovery in Mouse Stroke Model. <i>PLoS ONE</i> , 2007, 2, e156.	1.1	217
58	Size assessment and growth control: how adult size is determined in insects. <i>BioEssays</i> , 2007, 29, 344-355.	1.2	354
59	Early biochemical events in leukocyte activation through receptors for IgG. <i>Signal Transduction</i> , 2007, 7, 415-426.	0.7	3
60	Oncogenic re-wiring of cellular signaling pathways. <i>Oncogene</i> , 2007, 26, 1268-1275.	2.6	114
61	Recognizing and exploiting differences between RNAi and small-molecule inhibitors. <i>Nature Chemical Biology</i> , 2007, 3, 739-744.	3.9	260
62	PTEN: a promising pharmacological target to enhance epithelial wound healing. <i>British Journal of Pharmacology</i> , 2007, 152, 1141-1144.	2.7	27
63	Suicide prevention: disruption of apoptotic pathways by protozoan parasites. <i>Molecular Microbiology</i> , 2007, 64, 904-916.	1.2	80
64	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 1263-1284.	1.9	1,858
65	Structural determinants of LL5 β subcellular localisation and association with filamin C. <i>Cellular Signalling</i> , 2007, 19, 817-824.	1.7	12
66	<i>Schistosoma mansoni</i> : Expression of Fes-like tyrosine kinase SmFes in the tegument and terebratorium suggests its involvement in host penetration. <i>Experimental Parasitology</i> , 2007, 116, 225-232.	0.5	28
67	Ultrastructural analysis of the interaction between F-actin and respiratory syncytial virus during virus assembly. <i>Virology</i> , 2007, 369, 309-323.	1.1	60
68	Cancer-specific mutations in phosphatidylinositol 3-kinase. <i>Trends in Biochemical Sciences</i> , 2007, 32, 342-349.	3.7	155
69	The PI3K inhibitor arsenal: choose your weapon!. <i>Trends in Biochemical Sciences</i> , 2007, 32, 450-456.	3.7	77
70	Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. <i>Advances in Enzyme Regulation</i> , 2007, 47, 64-103.	2.9	77
71	Nuclear phospholipid signaling: phosphatidylinositol-specific phospholipase C and phosphoinositide 3-kinase. <i>Pflugers Archiv European Journal of Physiology</i> , 2007, 455, 19-30.	1.3	29
72	Genetic modelling of the PTEN/AKT pathway in cancer research. <i>Clinical and Translational Oncology</i> , 2008, 10, 618-627.	1.2	19

#	ARTICLE	IF	CITATIONS
73	Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules. <i>Journal of Chemical Biology</i> , 2008, 1, 49-62.	2.2	28
74	Extracellular ATP is a pro-angiogenic factor for pulmonary artery vasa vasorum endothelial cells. <i>Angiogenesis</i> , 2008, 11, 169-182.	3.7	62
75	Crystal structures of PI3K-C2 β PX domain indicate conformational change associated with ligand binding. <i>BMC Structural Biology</i> , 2008, 8, 13.	2.3	9
76	Chromosome instability and tumor lethality suppression in carcinogenesis. <i>Journal of Cellular Biochemistry</i> , 2008, 105, 1327-1341.	1.2	3
77	PI3K/PTEN signaling in tumorigenesis and angiogenesis. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2008, 1784, 150-158.	1.1	282
78	Targeting phosphoinositide 3-kinase—Moving towards therapy. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2008, 1784, 159-185.	1.1	491
79	Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3603-3606.	1.0	15
80	Critical roles of the PI3K/Akt signaling pathway in T cell development. <i>Immunology Letters</i> , 2008, 116, 104-110.	1.1	127
81	Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1851-1863.	1.9	1,095
82	Different roles of SHIP1 according to the cell context: The example of blood platelets. <i>Advances in Enzyme Regulation</i> , 2008, 48, 240-252.	2.9	17
83	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. <i>Advances in Enzyme Regulation</i> , 2008, 48, 113-135.	2.9	20
84	Endosomal Phosphoinositides and Human Diseases. <i>Traffic</i> , 2008, 9, 1240-1249.	1.3	125
85	Function and dysfunction of the PI system in membrane trafficking. <i>EMBO Journal</i> , 2008, 27, 2457-2470.	3.5	183
86	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. <i>Leukemia</i> , 2008, 22, 686-707.	3.3	337
87	Essential roles of PI(3)K β 110 2 in cell growth, metabolism and tumorigenesis. <i>Nature</i> , 2008, 454, 776-779.	13.7	654
88	Oncogenic signaling of class I PI3K isoforms. <i>Oncogene</i> , 2008, 27, 2561-2574.	2.6	99
89	PTEN signaling in brain: neuropathology and tumorigenesis. <i>Oncogene</i> , 2008, 27, 5416-5430.	2.6	193
90	Post-translational regulation of PTEN. <i>Oncogene</i> , 2008, 27, 5454-5463.	2.6	88

#	ARTICLE	IF	CITATIONS
91	Class I PI3K in oncogenic cellular transformation. <i>Oncogene</i> , 2008, 27, 5486-5496.	2.6	528
92	PI3K pathway alterations in cancer: variations on a theme. <i>Oncogene</i> , 2008, 27, 5497-5510.	2.6	1,621
93	The PTEN-PI3K pathway: of feedbacks and cross-talks. <i>Oncogene</i> , 2008, 27, 5527-5541.	2.6	778
94	PI3K/Akt: getting it right matters. <i>Oncogene</i> , 2008, 27, 6473-6488.	2.6	611
95	Cell polarity proteins: common targets for tumorigenic human viruses. <i>Oncogene</i> , 2008, 27, 7031-7046.	2.6	95
96	Phosphoinositide 3-OH kinase p85 α and p110 β are essential for androgen receptor transactivation and tumor progression in prostate cancers. <i>Oncogene</i> , 2008, 27, 4569-4579.	2.6	72
97	Common corruption of the mTOR signaling network in human tumors. <i>Oncogene</i> , 2008, 27, S43-S51.	2.6	275
98	Structural comparisons of class I phosphoinositide 3-kinases. <i>Nature Reviews Cancer</i> , 2008, 8, 665-669.	12.8	82
99	Lipid signalling in disease. <i>Nature Reviews Molecular Cell Biology</i> , 2008, 9, 162-176.	16.1	1,091
100	Outside-in Signaling through Integrins and Cadherins: A Central Mechanism to Control Epidermal Growth and Differentiation?. <i>Journal of Investigative Dermatology</i> , 2008, 128, 501-516.	0.3	138
101	Delayed neuronal preconditioning by NS1619 is independent of calcium activated potassium channels. <i>Journal of Neurochemistry</i> , 2008, 105, 1115-1128.	2.1	60
102	Genomics: a preview of genomic medicine. <i>BJU International</i> , 2008, 102, 1221-1227.	1.3	8
103	The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF- κ B pathway. <i>Biochemical Pharmacology</i> , 2008, 75, 1515-1525.	2.0	45
104	Taming the PI3K team to hold inflammation and cancer at bay. , 2008, 118, 192-205.		61
105	Akt signaling: a damaging interaction makes good. <i>Trends in Biochemical Sciences</i> , 2008, 33, 356-359.	3.7	16
106	PtdIns5P regulation through evolution: roles in membrane trafficking?. <i>Trends in Biochemical Sciences</i> , 2008, 33, 453-460.	3.7	72
107	Endosomal colocalization of melanocortin-3 receptor and β -arrestins in CAD cells with altered modification of AKT/PKB. <i>Neuropeptides</i> , 2008, 42, 355-366.	0.9	12
108	Angiogenesis and Vascular Remodeling in Inflammation and Cancer: Biology and Architecture of the Vasculature. , 2008, , 17-33.		16

#	ARTICLE	IF	CITATIONS
110	Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. <i>Breast Cancer Research</i> , 2008, 10, R101.	2.2	186
111	NVP-BE2235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. <i>Cancer Research</i> , 2008, 68, 8022-8030.	0.4	726
112	Integrin-linked kinase: A potential therapeutic target for the treatment of glioma. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 1079-1084.	0.8	12
113	Comprehensive Identification of PIP3-Regulated PH Domains from <i>C. elegans</i> to <i>H. sapiens</i> by Model Prediction and Live Imaging. <i>Molecular Cell</i> , 2008, 30, 381-392.	4.5	150
114	Lipidomics analysis of essential fatty acids in macrophages. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2008, 79, 123-129.	1.0	54
115	Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth. <i>Developmental Biology</i> , 2008, 321, 197-204.	0.9	316
116	Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment. <i>Drug Resistance Updates</i> , 2008, 11, 63-76.	6.5	215
117	Targeted therapies in breast cancer: Where are we now?. <i>European Journal of Cancer</i> , 2008, 44, 2781-2790.	1.3	78
118	Association of the PIK3C2G gene polymorphisms with type 2 DM in a Japanese population. <i>Biochemical and Biophysical Research Communications</i> , 2008, 365, 466-471.	1.0	52
119	Casein Kinase I epsilon positively regulates the Akt pathway in breast cancer cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2008, 368, 801-807.	1.0	13
120	A new evaluation method for quantifying PI3K activity by HTRF assay. <i>Biochemical and Biophysical Research Communications</i> , 2008, 377, 941-945.	1.0	13
121	SnapShot: PTEN Signaling Pathways. <i>Cell</i> , 2008, 133, 550-550.e1.	13.5	14
122	PI3K Enters Beta-Testing. <i>Cell Metabolism</i> , 2008, 8, 179-181.	7.2	7
123	Targeting the PI3K-“AKT”-mTOR pathway: progress, pitfalls, and promises. <i>Current Opinion in Pharmacology</i> , 2008, 8, 393-412.	1.7	488
124	Platelet-Derived Growth Factor. , 2008, , 99-111.		0
125	PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations. <i>Neoplasia</i> , 2008, 10, 534-541.	2.3	208
126	Akt as a therapeutic target in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1139-1165.	1.5	125
127	PTEN in brain tumors. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 599-610.	1.4	12

#	ARTICLE	IF	CITATIONS
128	Synthesis and Structure-Activity Relationships of Ring-Opened 17-Hydroxywortmannins: Potent Phosphoinositide 3-Kinase Inhibitors with Improved Properties and Anticancer Efficacy. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1319-1323.	2.9	33
129	Negative Regulation of Class IA Phosphoinositide 3-kinase by Protein Kinase C Limits Fc Receptor-Mediated Phagocytosis in Macrophages. <i>Journal of Biochemistry</i> , 2008, 145, 87-94.	0.9	10
130	The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8585-8590.	3.3	160
131	Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?. <i>Annals of Oncology</i> , 2008, 19, vii281-vii288.	0.6	4
132	Critical Roles of the p110 β Subtype of Phosphoinositide 3-Kinase in Lipopolysaccharide-Induced Akt Activation and Negative Regulation of Nitrite Production in RAW 264.7 Cells. <i>Journal of Immunology</i> , 2008, 180, 2054-2061.	0.4	52
134	Cancer Cell-Derived Clusterin Modulates the Phosphatidylinositol 3-Kinase-Akt Pathway through Attenuation of Insulin-Like Growth Factor 1 during Serum Deprivation. <i>Molecular and Cellular Biology</i> , 2008, 28, 4285-4299.	1.1	56
135	Transrepressive Function of TLX Requires the Histone Demethylase LSD1. <i>Molecular and Cellular Biology</i> , 2008, 28, 3995-4003.	1.1	115
136	PIK3IP1, a Negative Regulator of PI3K, Suppresses the Development of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 5591-5598.	0.4	98
137	WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase. <i>Genes and Development</i> , 2008, 22, 866-871.	2.7	135
138	Mutation of the PDK1 PH Domain Inhibits Protein Kinase B/Akt, Leading to Small Size and Insulin Resistance. <i>Molecular and Cellular Biology</i> , 2008, 28, 3258-3272.	1.1	115
139	Cancer therapy: staying current with AMPK. <i>Biochemical Journal</i> , 2008, 412, e3-e5.	1.7	16
140	The mTOR Signaling Network: Insights from Its Role During Embryonic Development. <i>Current Medicinal Chemistry</i> , 2008, 15, 1192-1208.	1.2	28
141	A Tobacco Calcium-Dependent Protein Kinase, CDPK1, Regulates the Transcription Factor REPRESSION OF SHOOT GROWTH in Response to Gibberellins. <i>Plant Cell</i> , 2008, 20, 3273-3288.	3.1	124
142	Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 4162-4167.	3.3	90
143	ADP-ribosylation Factor 1 Controls the Activation of the Phosphatidylinositol 3-Kinase Pathway to Regulate Epidermal Growth Factor-dependent Growth and Migration of Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 36425-36434.	1.6	83
144	Differential regulation of AMP-activated kinase and AKT kinase in response to oxygen availability in crucian carp (<i>Carassius carassius</i>). <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008, 295, R1803-R1814.	0.9	47
145	Dietary Energy Balance Modulates Signaling through the Akt/Mammalian Target of Rapamycin Pathways in Multiple Epithelial Tissues. <i>Cancer Prevention Research</i> , 2008, 1, 65-76.	0.7	153
146	Defining the blueprint of the cancer genome. <i>Carcinogenesis</i> , 2008, 29, 1087-1091.	1.3	57

#	ARTICLE	IF	CITATIONS
147	CSIG Inhibits PTEN Translation in Replicative Senescence. <i>Molecular and Cellular Biology</i> , 2008, 28, 6290-6301.	1.1	47
148	Phosphatidylinositol 3-Kinase $\hat{3}$ Is a Critical Mediator of Myocardial Ischemic and Adenosine-Mediated Preconditioning. <i>Circulation Research</i> , 2008, 103, 643-653.	2.0	64
149	Metastasis and AKT activation. <i>Cell Cycle</i> , 2008, 7, 2991-2996.	1.3	207
150	Human Cytomegalovirus Latent Infection of Myeloid Cells Directs Monocyte Migration by Up-Regulating Monocyte Chemotactic Protein-1. <i>Journal of Immunology</i> , 2008, 180, 6577-6585.	0.4	30
151	Down-Regulation of Class II Phosphoinositide 3-Kinase $\hat{2}$ Expression below a Critical Threshold Induces Apoptotic Cell Death. <i>Molecular Cancer Research</i> , 2008, 6, 614-623.	1.5	49
152	PTEN Represses RNA Polymerase III-Dependent Transcription by Targeting the TFIIIB Complex. <i>Molecular and Cellular Biology</i> , 2008, 28, 4204-4214.	1.1	93
153	Mitogen-Activated Protein (MAP) Kinase/MAP Kinase Phosphatase Regulation: Roles in Cell Growth, Death, and Cancer. <i>Pharmacological Reviews</i> , 2008, 60, 261-310.	7.1	515
154	Association between Phosphatidylinositol 3-Kinase Regulatory Subunit p85 $\hat{2}$ Met326Ile Genetic Polymorphism and Colon Cancer Risk. <i>Clinical Cancer Research</i> , 2008, 14, 633-637.	3.2	42
155	Do unsaturated phosphoinositides mix with ordered phosphadidylcholine model membranes?. <i>Journal of Lipid Research</i> , 2008, 49, 1918-1925.	2.0	20
156	Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging. <i>Cancer Research</i> , 2008, 68, 6598-6607.	0.4	173
157	Transforming Growth Factor $\hat{2}$ Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab. <i>Molecular and Cellular Biology</i> , 2008, 28, 5605-5620.	1.1	153
158	PIK3CA Mutations and Copy Number Gains in Human Lung Cancers. <i>Cancer Research</i> , 2008, 68, 6913-6921.	0.4	399
159	Organ size determination and the limits of regulation. <i>Cell Cycle</i> , 2008, 7, 318-324.	1.3	55
160	The challenge of selecting protein kinase assays for lead discovery optimization. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 607-621.	2.5	171
161	Phosphoinositide 3-Kinase p110 $\hat{2}$ Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development. <i>Science Signaling</i> , 2008, 1, ra3.	1.6	219
162	Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 223-238.	1.5	56
163	Regulation of microtubule nucleation from membranes by complexes of membrane-bound $\hat{3}$ -tubulin with Fyn kinase and phosphoinositide 3-kinase. <i>Biochemical Journal</i> , 2008, 416, 421-430.	1.7	48
164	Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). <i>Molecular Medicine Reports</i> , 0, , .	1.1	3

#	ARTICLE	IF	CITATIONS
165	Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases. <i>Current Signal Transduction Therapy</i> , 2008, 3, 138-151.	0.3	5
166	Isoform Selective Phosphoinositide 3-Kinase γ and δ Inhibitors and Their Therapeutic Potential. <i>Recent Patents on Inflammation and Allergy Drug Discovery</i> , 2008, 2, 1-10.	3.9	15
167	Signal Transduction by Growth Factor Receptors. , 2008, , 155-168.		0
168	Multiple roles and therapeutic implications of Akt signaling in cancer. <i>OncoTargets and Therapy</i> , 2009, 2, 135.	1.0	14
169	The Fathers of Italian Histology. <i>European Journal of Histochemistry</i> , 2009, 51, 1.	0.6	5
170	Expression of Activated PIK3CA in Ovarian Surface Epithelium Results in Hyperplasia but Not Tumor Formation. <i>PLoS ONE</i> , 2009, 4, e4295.	1.1	30
171	Advances in preclinical small molecules for the treatment of NSCLC. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 731-751.	2.4	12
172	PDK1 signaling in oocytes controls reproductive aging and lifespan by manipulating the survival of primordial follicles. <i>Human Molecular Genetics</i> , 2009, 18, 2813-2824.	1.4	219
173	Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 274-279.	3.3	130
174	PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5049-5059.	3.2	338
175	Molecular Mechanisms Underlying the Activation of Mammalian Primordial Follicles. <i>Endocrine Reviews</i> , 2009, 30, 438-464.	8.9	351
176	Akt/Protein Kinase B and Glycogen Synthase Kinase-3 β Signaling Pathway Regulates Cell Migration through the NFAT1 Transcription Factor. <i>Molecular Cancer Research</i> , 2009, 7, 425-432.	1.5	65
177	Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110 α and are disrupted in oncogenic p85 mutants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20258-20263.	3.3	79
178	Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 4799-4805.	3.2	324
179	The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. <i>British Journal of Cancer</i> , 2009, 101, 145-148.	2.9	141
180	Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. <i>Future Medicinal Chemistry</i> , 2009, 1, 137-155.	1.1	28
181	A Cohort Study of STMN1 Expression in Colorectal Cancer: Body Mass Index and Prognosis. <i>American Journal of Gastroenterology</i> , 2009, 104, 2047-2056.	0.2	49
182	Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors. <i>Molecular Cancer Research</i> , 2009, 7, 601-613.	1.5	105

#	ARTICLE	IF	CITATIONS
183	Ambient Air Pollution Exaggerates Adipose Inflammation and Insulin Resistance in a Mouse Model of Diet-Induced Obesity. <i>Circulation</i> , 2009, 119, 538-546.	1.6	608
184	High Dietary Inorganic Phosphate Increases Lung Tumorigenesis and Alters Akt Signaling. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 59-68.	2.5	120
185	Striking the balance between PTEN and PDK1: it all depends on the cell context. <i>Genes and Development</i> , 2009, 23, 1699-1704.	2.7	19
186	PI3K-dependent cross-talk interactions converge with Ras as quantifiable inputs integrated by Erk. <i>Molecular Systems Biology</i> , 2009, 5, 246.	3.2	69
187	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 18351-18356.	3.3	251
188	RhoG Promotes Neural Progenitor Cell Proliferation in Mouse Cerebral Cortex. <i>Molecular Biology of the Cell</i> , 2009, 20, 4941-4950.	0.9	25
189	Loss of <i>p110</i> Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer. <i>Cancer Research</i> , 2009, 69, 4192-4201.	0.4	164
190	Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 3029-3036.	3.2	59
191	Zinc Finger Protein Zbtb20 Is Essential for Postnatal Survival and Glucose Homeostasis. <i>Molecular and Cellular Biology</i> , 2009, 29, 2804-2815.	1.1	77
192	<i>PIK3CA</i> Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1477-1484.	0.8	303
193	PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects. <i>Cell Cycle</i> , 2009, 8, 403-413.	1.3	85
194	Clozapine Interaction with Phosphatidylinositol 3-Kinase (PI3K)/Insulin-Signaling Pathway in <i>Caenorhabditis elegans</i> . <i>Neuropsychopharmacology</i> , 2009, 34, 1968-1978.	2.8	33
195	New trends in epidermal growth factor receptor-directed monoclonal antibodies. <i>Immunotherapy</i> , 2009, 1, 965-982.	1.0	10
196	PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?. <i>Current Medicinal Chemistry</i> , 2009, 16, 916-930.	1.2	38
197	Activation of the Lutropin/Choriogonadotropin Receptor Inhibits Apoptosis of Immature Leydig Cells in Primary Culture. <i>Endocrinology</i> , 2009, 150, 3766-3773.	1.4	85
198	The PTEN/PI3 Kinase Pathway in Human Glioma. , 2009, , 315-357.		3
199	Platinum Complexes. , 2008, , 2358-2363.		0
200	cAMP-GEF cytoprotection by Src tyrosine kinase activation of phosphoinositide-3-kinase p110 in rat hepatocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G764-G774.	1.6	23

#	ARTICLE	IF	CITATIONS
201	Spontaneous phosphoinositide 3-kinase signaling dynamics drive spreading and random migration of fibroblasts. <i>Journal of Cell Science</i> , 2009, 122, 313-323.	1.2	76
202	Cell type specificity of PI3K signaling in Pdk1- and Pten-deficient brains. <i>Genes and Development</i> , 2009, 23, 1619-1624.	2.7	66
203	Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations. <i>Cancer Research</i> , 2009, 69, 7644-7652.	0.4	138
204	Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 7466-7472.	0.4	73
205	Differential Enhancement of Breast Cancer Cell Motility and Metastasis by Helical and Kinase Domain Mutations of Class IA Phosphoinositide 3-Kinase. <i>Cancer Research</i> , 2009, 69, 8868-8876.	0.4	73
206	Is Akt the "Warburg kinase"? Akt-energy metabolism interactions and oncogenesis. <i>Seminars in Cancer Biology</i> , 2009, 19, 25-31.	4.3	497
207	The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1795, 37-52.	3.3	116
208	EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt. <i>Cancer Cell</i> , 2009, 16, 9-20.	7.7	436
209	AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer. <i>Cancer Cell</i> , 2009, 16, 21-32.	7.7	472
210	Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling. <i>Cancer Cell</i> , 2009, 16, 115-125.	7.7	411
211	A Molecular Link between AKT Regulation and Chemotherapeutic Response. <i>Cancer Cell</i> , 2009, 16, 178-180.	7.7	26
212	Somatic Mutations in p85 Promote Tumorigenesis through Class IA PI3K Activation. <i>Cancer Cell</i> , 2009, 16, 463-474.	7.7	291
213	Should individual PI3 kinase isoforms be targeted in cancer?. <i>Current Opinion in Cell Biology</i> , 2009, 21, 199-208.	2.6	106
214	First came the link between phosphoinositides and Ca ²⁺ signalling, and then a deluge of other phosphoinositide functions. <i>Cell Calcium</i> , 2009, 45, 521-526.	1.1	14
215	Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. <i>Cellular Signalling</i> , 2009, 21, 470-476.	1.7	226
216	Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. <i>Cellular Signalling</i> , 2009, 21, 1717-1726.	1.7	111
217	The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. <i>International Journal of Cancer</i> , 2009, 125, 932-941.	2.3	40
218	Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene targeting of the PI3K regulatory isoforms p85, p55, and p50. <i>Developmental Dynamics</i> , 2009, 238, 2670-2679.	0.8	54

#	ARTICLE	IF	CITATIONS
219	AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF1/Akt signaling in C2C12 myotubes. <i>Journal of Cellular Biochemistry</i> , 2009, 108, 458-468.	1.2	87
220	Low-power laser irradiation promotes cell proliferation by activating PI3K/Akt pathway. <i>Journal of Cellular Physiology</i> , 2009, 219, 553-562.	2.0	101
221	PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells. <i>Molecular Carcinogenesis</i> , 2009, 48, 1149-1158.	1.3	61
222	Non-Redundancy within the RAS Oncogene Family: Insights into Mutational Disparities in Cancer. <i>Molecules and Cells</i> , 2009, 28, 315-320.	1.0	42
223	Interferon- γ -induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway. <i>Journal of Gastroenterology</i> , 2009, 44, 856-863.	2.3	27
224	This month in APR. <i>Archives of Pharmacal Research</i> , 2009, 32, 463-464.	2.7	0
225	Oltipraz promotion of liver regeneration after partial hepatectomy: The role of PI3-kinase-dependent C/EBP β and cyclin E regulation. <i>Archives of Pharmacal Research</i> , 2009, 32, 625-635.	2.7	6
226	The glycerophosphoinositols: cellular metabolism and biological functions. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 3449-3467.	2.4	32
227	PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations. <i>Proteins: Structure, Function and Bioinformatics</i> , 2009, 75, 499-508.	1.5	21
228	cMyc increases cell number through uncoupling of cell division from cell size in CHO cells. <i>BMC Biotechnology</i> , 2009, 9, 76.	1.7	27
229	Regulation of PI(3)K/Akt signalling and cellular transformation by inositol polyphosphate 4-phosphatase. <i>EMBO Reports</i> , 2009, 10, 487-493.	2.0	79
230	The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. <i>Leukemia</i> , 2009, 23, 1029-1038.	3.3	114
231	Tumours with PI3K activation are resistant to dietary restriction. <i>Nature</i> , 2009, 458, 725-731.	18.7	416
232	Cancer's insatiable appetite. <i>Nature Biotechnology</i> , 2009, 27, 916-917.	9.4	44
233	Introducing the acetylome. <i>Nature Biotechnology</i> , 2009, 27, 917-919.	9.4	90
234	Inhibitor hijacking of Akt activation. <i>Nature Chemical Biology</i> , 2009, 5, 484-493.	3.9	272
235	The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF- κ B and activate T cells. <i>Nature Immunology</i> , 2009, 10, 158-166.	7.0	119
236	Beyond chemotherapy: targeted therapies in ovarian cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 167-181.	12.8	452

#	ARTICLE	IF	CITATIONS
237	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. <i>Nature Reviews Cancer</i> , 2009, 9, 463-475.	12.8	993
238	Targeting PI3K signalling in cancer: opportunities, challenges and limitations. <i>Nature Reviews Cancer</i> , 2009, 9, 550-562.	12.8	2,156
239	Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 709-723.	21.5	285
240	Targeting the phosphoinositide 3-kinase pathway in cancer. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 627-644.	21.5	2,218
241	Naive T cell homeostasis: from awareness of space to a sense of place. <i>Nature Reviews Immunology</i> , 2009, 9, 823-832.	10.6	332
242	Toll-like receptor signaling in the lysosomal pathways. <i>Immunological Reviews</i> , 2009, 227, 203-220.	2.8	145
243	Fine tuning the immune response with PI3K. <i>Immunological Reviews</i> , 2009, 228, 253-272.	2.8	191
244	The novel molecule 2-[[5-(2-chloroethyl)-2-acetoxybenzyl]-4-(2-chloroethyl)phenyl acetate inhibits phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells. <i>FEBS Journal</i> , 2009, 276, 4037-4050.	2.2	6
245	Identification of Allosteric PIF-Pocket Ligands for PDK1 using NMR-Based Fragment Screening and ¹⁵ N TROSY Experiments. <i>Chemical Biology and Drug Design</i> , 2009, 73, 179-188.	1.5	55
246	PI3K Signaling in Glioma—Animal Models and Therapeutic Challenges. <i>Brain Pathology</i> , 2009, 19, 112-120.	2.1	110
247	Inhibition of the phosphatase PTEN protects mice against oleic acid-induced acute lung injury. <i>British Journal of Pharmacology</i> , 2009, 156, 189-200.	2.7	45
248	Local effects of the sphingosine 1-phosphate on prostaglandin F ₂ α-induced luteolysis in the pregnant rat. <i>Molecular Reproduction and Development</i> , 2009, 76, 1153-1164.	1.0	19
249	Rethinking phosphatidylinositol 3-monophosphate. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 1795-1803.	1.9	44
250	Chapter 17 Emerging Therapies Based on Inhibitors of Phosphatidylinositol-3-Kinases. <i>Annual Reports in Medicinal Chemistry</i> , 2009, 44, 339-356.	0.5	19
251	Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis. <i>Advances in Cancer Research</i> , 2009, 102, 19-65.	1.9	469
252	Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer. <i>Cancer Letters</i> , 2009, 283, 203-211.	3.2	58
253	Wortmannin potentiates roscovitine-induced growth inhibition in human solid tumor cells by repressing PI3K/Akt pathway. <i>Cancer Letters</i> , 2009, 286, 232-239.	3.2	21
254	A Role of DNA-PK for the Metabolic Gene Regulation in Response to Insulin. <i>Cell</i> , 2009, 136, 1056-1072.	13.5	221

#	ARTICLE	IF	CITATIONS
255	PI3 Kinase Signals BCR-Dependent Mature B Cell Survival. <i>Cell</i> , 2009, 139, 573-586.	13.5	564
256	Phosphatidylinositol β and related-kinases: A genome-wide survey of classes and subtypes in the <i>Schistosoma mansoni</i> genome for designing subtype-specific inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2009, 380, 525-530.	1.0	12
257	Functional links between diacylglycerol and phosphatidylinositol signaling systems in human leukocyte-derived cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2009, 390, 1395-1401.	1.0	9
258	PI 3-kinase and cancer: changing accents. <i>Current Opinion in Genetics and Development</i> , 2009, 19, 12-17.	1.5	78
259	ErbB2 and ErbB3 regulate amputation-induced proliferation and migration during vertebrate regeneration. <i>Developmental Biology</i> , 2009, 327, 177-190.	0.9	68
260	Egr-1 is involved in the inhibitory effect of leptin on PPAR β expression in hepatic stellate cell in vitro. <i>Life Sciences</i> , 2009, 84, 544-551.	2.0	18
261	Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination. <i>Molecular and Cellular Endocrinology</i> , 2009, 299, 89-100.	1.6	97
262	A complex interplay between Akt, TSC2 and the two mTOR complexes. <i>Biochemical Society Transactions</i> , 2009, 37, 217-222.	1.6	623
263	The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma. <i>Oncology</i> , 2009, 77, 69-74.	0.9	16
264	Novel inhibitors of the PI3K family. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1265-1277.	1.9	36
265	p16. , 2008, , 2221-2221.		0
266	Airway Smooth Muscle. , 2009, , 225-239.		0
267	Noncontractile Functions of Airway Smooth Muscle Cells in Asthma. <i>Annual Review of Physiology</i> , 2009, 71, 509-535.	5.6	82
268	Regulation of Tissue Growth through Nutrient Sensing. <i>Annual Review of Genetics</i> , 2009, 43, 389-410.	3.2	265
269	Chapter 11 Spatio-temporal Dynamics of Phosphatidylinositol β ,4,5-trisphosphate Signalling. <i>Vitamins and Hormones</i> , 2009, 80, 287-311.	0.7	4
270	PTEN and the PI3-Kinase Pathway in Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009, 4, 127-150.	9.6	992
271	Phosphatidylinositol 3-Kinase/AKT Pathway Regulates the Endoplasmic Reticulum to Golgi Traffic of Ceramide in Glioma Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 5088-5096.	1.6	36
272	Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab. <i>Clinical Cancer Research</i> , 2009, 15, 4147-4156.	3.2	125

#	ARTICLE	IF	CITATIONS
273	Investigation of PTEN mRNA and protein expression in human gliomas. , 2009, , .		0
274	Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMPá€9. Hepatology Research, 2009, 39, 177-186.	1.8	308
275	Akt regulates proliferation induced by low-power laser irradiation in COS-7 cells. , 2009, , .		0
276	Nuclear PTEN levels and G2 progression in melanoma cells. Melanoma Research, 2009, 19, 203-210.	0.6	13
277	Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. International Journal of Oncology, 2009, 34, 1749-57.	1.4	53
279	Environmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells. Oncology Reports, 2009, 23, .	1.2	22
280	Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica, 2009, 94, 1698-1707.	1.7	40
281	Epidermal growth factor stimulates translocation of the class II phosphoinositide 3-kinase PI3K-C2Î² to the nucleus. Biochemical Journal, 2009, 422, 53-60.	1.7	16
282	Form and flexibility in phosphoinositide 3-kinases. Biochemical Society Transactions, 2009, 37, 615-626.	1.6	66
283	A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinaseâ€“regulated mammalian target of rapamycin activation. Blood, 2009, 113, 5206-5216.	0.6	46
284	Bone morphogenetic proteins. Blood, 2009, 114, 2012-2013.	0.6	10
285	PI3KÎ² goes to the head of its class. Blood, 2009, 114, 2011-2012.	0.6	2
286	Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 787-791.	0.5	30
287	Mutations in Phosphoinositide Metabolizing Enzymes and Human Disease. Physiology, 2009, 24, 8-16.	1.6	152
288	Current Screens Based on the AlphaScreen™ Technology for Deciphering Cell Signalling Pathways. Current Genomics, 2009, 10, 93-101.	0.7	51
289	Mouse Models to Decipher the PI3K Signaling Network in Human Cancer. Current Molecular Medicine, 2009, 9, 612-625.	0.6	19
290	Low-power laser irradiation inhibits AÎ² 25-35 -induced cell apoptosis through Akt activation. , 2009, , .		0
291	Leptin-Induced Sympathetic Nerve Activation: Signaling Mechanisms and Cardiovascular Consequences in Obesity. Current Hypertension Reviews, 2010, 6, 104-109.	0.5	74

#	ARTICLE	IF	CITATIONS
292	Integration of Anti-Epidermal Growth Factor Receptor Therapies With Cytotoxic Chemotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 226-234.	1.0	5
293	PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs. <i>Current Pharmaceutical Design</i> , 2010, 16, 1410-1416.	0.9	121
294	Recent Progress in Phosphoinositide 3-Kinases: Oncogenic Properties and Prognostic and Therapeutic Implications. <i>Current Protein and Peptide Science</i> , 2010, 11, 425-435.	0.7	6
295	AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. <i>Blood</i> , 2010, 115, 4030-4038.	0.6	246
296	2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. <i>International Journal of Oncology</i> , 2010, 37, .	1.4	5
297	Palmitoylation of oncogenic NRAS is essential for leukemogenesis. <i>Blood</i> , 2010, 115, 3598-3605.	0.6	72
298	Extracellular signal-regulated kinase and phosphatidylinositol-3-kinase/AKT signalling pathways in the human carotid body and peripheral ganglia. <i>Acta Histochemica</i> , 2010, 112, 305-316.	0.9	5
299	Chronotherapy and the molecular clock: Clinical implications in oncology. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 979-1001.	6.6	139
300	Activation mechanisms of PIP5K isozymes by the small GTPase ARF6. <i>Advances in Enzyme Regulation</i> , 2010, 50, 72-80.	2.9	15
301	Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 39-43.	1.3	320
302	PIKING the right isoform: the emergent role of the p110 β subunit in breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 235-243.	1.4	37
303	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. <i>Angiogenesis</i> , 2010, 13, 1-14.	3.7	408
304	Emerging trends at the interface of chemistry and biology: Applications to the design of human therapeutics. <i>Journal of Chemical Sciences</i> , 2010, 122, 97-107.	0.7	0
305	Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer. <i>Current Oncology Reports</i> , 2010, 12, 87-94.	1.8	54
306	PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 45-53.	1.1	73
307	Subtypes of familial breast tumours revealed by expression and copy number profiling. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 661-677.	1.1	86
308	Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27kip1. <i>Journal of Neuro-Oncology</i> , 2010, 98, 57-69.	1.4	26
309	Transcriptional regulation of the insulin signaling pathway genes by starvation and 20-hydroxyecdysone in the <i>Bombyx</i> fat body. <i>Journal of Insect Physiology</i> , 2010, 56, 1436-1444.	0.9	61

#	ARTICLE	IF	CITATIONS
310	Origins and evolution of the mechanisms regulating translation initiation in eukaryotes. Trends in Biochemical Sciences, 2010, 35, 63-73.	3.7	57
311	Muscle transcriptomic profiles in pigs with divergent phenotypes for fatness traits. BMC Genomics, 2010, 11, 372.	1.2	103
312	Akt2 regulates expression of the actinâ€bundling protein palladin. FEBS Letters, 2010, 584, 4769-4774.	1.3	31
313	Nuclear inositide signaling in myelodysplastic syndromes. Journal of Cellular Biochemistry, 2010, 109, 1065-1071.	1.2	25
314	Fibroblast growth factor 2 and plateletâ€derived growth factor, but not platelet lysate, induce proliferationâ€dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis and Rheumatism, 2010, 62, 3815-3825.	6.7	78
315	Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 653-656.	1.0	28
316	Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3897-3902.	1.0	27
317	PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5869-5873.	1.0	58
318	4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6096-6099.	1.0	31
319	Enhancement of P53-Mutant Human Colorectal Cancer Cells Radiosensitivity by Flavonoid Fisetin. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1527-1535.	0.4	29
320	Mammalian Target of Rapamycin Controls Dendritic Cell Development Downstream of Flt3 Ligand Signaling. Immunity, 2010, 33, 597-606.	6.6	142
321	A Flt3L Encounter: mTOR Signaling in Dendritic Cells. Immunity, 2010, 33, 580-582.	6.6	9
322	Isoformâ€selective phosphoinositide 3â€kinase inhibitors induce apoptosis in chronic lymphocytic leukaemia cells. British Journal of Haematology, 2010, 150, 108-110.	1.2	11
323	Post-translational modifications in signal integration. Nature Structural and Molecular Biology, 2010, 17, 666-672.	3.6	658
324	H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene, 2010, 29, 5193-5203.	2.6	93
325	Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO Journal, 2010, 29, 1091-1104.	3.5	267
326	Maternal phosphatidylinositol 3â€kinase signalling is crucial for embryonic genome activation and preimplantation embryogenesis. EMBO Reports, 2010, 11, 890-895.	2.0	27
327	Translation of the phosphoinositide code by PI effectors. Nature Chemical Biology, 2010, 6, 507-513.	3.9	217

#	ARTICLE	IF	CITATIONS
328	Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. <i>Nature Medicine</i> , 2010, 16, 205-213.	15.2	329
329	The regulatory subunits of PI3K, p85 [±] and p85 ^{Δ2} , interact with XBP-1 and increase its nuclear translocation. <i>Nature Medicine</i> , 2010, 16, 429-437.	15.2	267
330	Obesity: stressing about unfolded proteins. <i>Nature Medicine</i> , 2010, 16, 374-376.	15.2	15
331	An NGF-responsive element targets myo-inositol monophosphatase-1 mRNA to sympathetic neuron axons. <i>Nature Neuroscience</i> , 2010, 13, 291-301.	7.1	193
332	Phosphoinositide signalling in cancer: beyond PI3K and PTEN. <i>Nature Reviews Cancer</i> , 2010, 10, 342-352.	12.8	369
333	The engine driving the ship: metabolic steering of cell proliferation and death. <i>Nature Reviews Molecular Cell Biology</i> , 2010, 11, 715-727.	16.1	193
334	Transactivation of Genes Encoding for Phase II Enzymes and Phase III Transporters by Phytochemical Antioxidants. <i>Molecules</i> , 2010, 15, 6332-6348.	1.7	26
335	Chemotherapy and Experimental Medical Therapies for Meningiomas. , 2010, , 667-679.		1
336	Prospects for the Use of ATR Inhibitors to Treat Cancer. <i>Pharmaceuticals</i> , 2010, 3, 1311-1334.	1.7	50
337	Interactome Mapping of the Phosphatidylinositol 3-Kinase-Mammalian Target of Rapamycin Pathway Identifies Deformed Epidermal Autoregulatory Factor-1 as a New Glycogen Synthase Kinase-3 Interactor. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 1578-1593.	2.5	51
338	Role of PKB/Akt in Liver Diseases. , 2010, , 243-259.		6
339	Targeting a Common Collaborator in Cancer Development. <i>Science Translational Medicine</i> , 2010, 2, 48ps45.	5.8	29
340	The inositol 5-phosphatase SHIP2 regulates endocytic clathrin-coated pit dynamics. <i>Journal of Cell Biology</i> , 2010, 190, 307-315.	2.3	117
341	Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway. <i>Journal of General Virology</i> , 2010, 91, 1388-1395.	1.3	57
342	Functional Effects of <i>PTPN11</i> (SHP2) Mutations Causing LEOPARD Syndrome on Epidermal Growth Factor-Induced Phosphoinositide 3-Kinase/AKT/Glycogen Synthase Kinase 3 ^{Δ2} Signaling. <i>Molecular and Cellular Biology</i> , 2010, 30, 2498-2507.	1.1	85
343	La voie de la phosphatidylinositol-3-kinase. , 2010, , 59-69.		0
344	Essential Role of the p110 ^{Δ2} Subunit of Phosphoinositide 3-OH Kinase in Male Fertility. <i>Molecular Biology of the Cell</i> , 2010, 21, 704-711.	0.9	58
345	The Phosphoinositide 3-Kinase Regulatory Subunit p85 [±] Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling. <i>Cancer Research</i> , 2010, 70, 5305-5315.	0.4	140

#	ARTICLE	IF	CITATIONS
346	Phosphoinositide 3-kinase signaling in the vertebrate retina. <i>Journal of Lipid Research</i> , 2010, 51, 4-22.	2.0	36
347	Shaping Development of Autophagy Inhibitors with the Structure of the Lipid Kinase Vps34. <i>Science</i> , 2010, 327, 1638-1642.	6.0	222
348	Pathophysiology of bronchial smooth muscle remodelling in asthma. <i>European Respiratory Journal</i> , 2010, 36, 1174-1184.	3.1	139
349	Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors. <i>Science Translational Medicine</i> , 2010, 2, 43ra55.	5.8	141
350	Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status: <i>in silico</i> and Biological Evaluations. <i>Cancer Research</i> , 2010, 70, 4982-4994.	0.4	108
351	Inhibition of the PI3K Pathway: Hope We Can Believe in?. <i>Clinical Cancer Research</i> , 2010, 16, 3094-3099.	3.2	37
352	Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 976-984.	1.9	60
353	Targeting Epidermal Growth Factor Receptor-Associated Signaling Pathways in Non-Small Cell Lung Cancer Cells: Implication in Radiation Response. <i>Molecular Cancer Research</i> , 2010, 8, 1027-1036.	1.5	69
354	Vascular Endothelial Growth Factor Receptor 1 Contributes to <i>Escherichia coli</i> K1 Invasion of Human Brain Microvascular Endothelial Cells through the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway. <i>Infection and Immunity</i> , 2010, 78, 4809-4816.	1.0	29
355	Critical Role for the Host GTPase-Activating Protein ARAP2 in InB-Mediated Entry of <i>Listeria monocytogenes</i> . <i>Infection and Immunity</i> , 2010, 78, 4532-4541.	1.0	18
356	The Akt isoforms, their unique functions and potential as anticancer therapeutic targets. <i>Biomolecular Concepts</i> , 2010, 1, 389-401.	1.0	10
357	Target of Rapamycin Signaling in Leukemia and Lymphoma. <i>Clinical Cancer Research</i> , 2010, 16, 5374-5380.	3.2	44
358	Adducin- and Ouabain-Related Gene Variants Predict the Antihypertensive Activity of Rostafuroxin, Part 1: Experimental Studies. <i>Science Translational Medicine</i> , 2010, 2, 59ra86.	5.8	38
359	Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors. <i>Current Topics in Microbiology and Immunology</i> , 2010, 347, 189-208.	0.7	15
360	The class IA phosphatidylinositol 3-kinase p110 β subunit is a positive regulator of autophagy. <i>Journal of Cell Biology</i> , 2010, 191, 827-843.	2.3	82
361	Novel strategies for treating relapsed/refractory urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1917-1932.	1.1	16
362	A biochemical mechanism for the oncogenic potential of the p110 β catalytic subunit of phosphoinositide 3-kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 19897-19902.	3.3	51
363	Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1436-1442.	1.7	78

#	ARTICLE	IF	CITATIONS
364	Akt signaling in platelets and thrombosis. <i>Expert Review of Hematology</i> , 2010, 3, 81-91.	1.0	127
365	Efficient Synthesis of Key Intermediate Toward Liphagal Synthesis. <i>Synthetic Communications</i> , 2010, 41, 177-183.	1.1	11
366	Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s). <i>Genes and Cancer</i> , 2010, 1, 1124-1131.	0.6	206
367	Stress-induced Synthesis of Phosphatidylinositol 3-Phosphate in Mycobacteria. <i>Journal of Biological Chemistry</i> , 2010, 285, 16643-16650.	1.6	22
368	Potential role of PI3K inhibitors in the treatment of breast cancer. <i>Future Oncology</i> , 2010, 6, 1251-1263.	1.1	8
369	Weight Loss via Exercise with Controlled Dietary Intake May Affect Phospholipid Profile for Cancer Prevention in Murine Skin Tissues. <i>Cancer Prevention Research</i> , 2010, 3, 466-477.	0.7	19
370	Phosphoinositide 3-Kinase Pathway Activation in Phosphate and Tensin Homolog (PTEN)-deficient Prostate Cancer Cells Is Independent of Receptor Tyrosine Kinases and Mediated by the p110 β and p110 δ Catalytic Subunits. <i>Journal of Biological Chemistry</i> , 2010, 285, 14980-14989.	1.6	82
371	Akt pathway is hypoactivated by synergistic actions of diabetes mellitus and hypercholesterolemia resulting in advanced coronary artery disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 299, H699-H706.	1.5	37
372	Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2010, 4, 19-34.	1.0	43
373	PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. <i>Genes and Cancer</i> , 2010, 1, 1170-1177.	0.6	347
374	Simian Virus 40 Infection Triggers a Balanced Network That Includes Apoptotic, Survival, and Stress Pathways. <i>Journal of Virology</i> , 2010, 84, 3431-3442.	1.5	25
375	PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective ON Clinical Progress. <i>Current Medicinal Chemistry</i> , 2010, 17, 4326-4341.	1.2	89
376	SHIP2, a factor associated with diet-induced obesity and insulin sensitivity, attenuates FGF signaling in vivo. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 733-742.	1.2	21
377	The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase β Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy. <i>Cancer Research</i> , 2010, 70, 5507-5517.	0.4	58
378	Emerging role of FKBP51 in AKT kinase/protein kinase B signaling. <i>Cell Cycle</i> , 2010, 9, 6-7.	1.3	9
379	Prostaglandin F2 β Represses IGF-I-Stimulated IRS1/Phosphatidylinositol-3-Kinase/AKT Signaling in the Corpus Luteum: Role of ERK and P70 Ribosomal S6 Kinase. <i>Molecular Endocrinology</i> , 2010, 24, 632-643.	3.7	33
380	The regulation of organ size in <i>Drosophila</i> . <i>Organogenesis</i> , 2010, 6, 76-87.	0.4	71
381	Introduction. <i>Current Topics in Microbiology and Immunology</i> , 2010, 346, 1-7.	0.7	4

#	ARTICLE	IF	CITATIONS
382	The Regulation of Class IA PI 3-Kinases by Inter-Subunit Interactions. <i>Current Topics in Microbiology and Immunology</i> , 2010, 346, 87-114.	0.7	73
383	Faithfull Modeling of PTEN Loss Driven Diseases in the Mouse. <i>Current Topics in Microbiology and Immunology</i> , 2010, 347, 135-168.	0.7	29
384	PI3K/AKT/mTOR Inhibitors In Ovarian Cancer. <i>Current Medicinal Chemistry</i> , 2010, 17, 4433-4447.	1.2	41
385	ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma. <i>Current Cancer Drug Targets</i> , 2010, 10, 611-622.	0.8	12
386	Phosphatidylinositol 3-Kinase: The Oncoprotein. <i>Current Topics in Microbiology and Immunology</i> , 2010, 347, 79-104.	0.7	94
387	Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy. <i>Future Oncology</i> , 2010, 6, 587-603.	1.1	16
388	Genetic inactivation of <i>AKT1</i> , <i>AKT2</i> , and <i>PDPK1</i> in human colorectal cancer cells clarifies their roles in tumor growth regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2598-2603.	3.3	113
389	Comparing the Roles of the p110 ^α and p110 ^β Isoforms of PI3K in Signaling and Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2010, 347, 55-77.	0.7	16
390	Autophagic pathways as new targets for cancer drug development. <i>Acta Pharmacologica Sinica</i> , 2010, 31, 1154-1164.	2.8	101
391	Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations. <i>Leukemia and Lymphoma</i> , 2010, 51, 1968-2005.	0.6	53
392	Modulation in Activation and Expression of Phosphatase and Tensin Homolog on Chromosome Ten, Akt1, and 3-Phosphoinositide-Dependent Kinase 1: Further Evidence Demonstrating Altered Phosphoinositide 3-Kinase Signaling in Postmortem Brain of Suicide Subjects. <i>Biological Psychiatry</i> , 2010, 67, 1017-1025.	0.7	46
393	HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches. <i>Pharmacological Research</i> , 2010, 62, 150-165.	3.1	63
394	Approaches and Applications of Quantitative LC-MS for Proteomics and Activitomics. <i>Methods in Molecular Biology</i> , 2010, 658, 3-17.	0.4	10
395	Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?. <i>Breast Cancer Research</i> , 2010, 12, 315.	2.2	3
396	The Role of Phosphoinositide 3-Kinase in Breast Cancer: An Overview. <i>Clinical Breast Cancer</i> , 2010, 10, S56-S58.	1.1	1
397	The Hormone Receptor GUCY2C Suppresses Intestinal Tumor Formation by Inhibiting AKT Signaling. <i>Gastroenterology</i> , 2010, 138, 241-254.	0.6	102
398	Phosphoinositide 3-Kinase Signaling Mediates β -Catenin Activation in Intestinal Epithelial Stem and Progenitor Cells in Colitis. <i>Gastroenterology</i> , 2010, 139, 869-881.e9.	0.6	135
399	Inositol polyphosphates, diphosphoinositol polyphosphates and phosphatidylinositol polyphosphate lipids: Structure, synthesis, and development of probes for studying biological activity. <i>Natural Product Reports</i> , 2010, 27, 1403.	5.2	87

#	ARTICLE	IF	CITATIONS
400	mTOR signaling in glioblastoma: lessons learned from bench to bedside. <i>Neuro-Oncology</i> , 2010, 12, 882-889.	0.6	159
401	Protective Effect of Quercetin against Arsenite-Induced COX-2 Expression by Targeting PI3K in Rat Liver Epithelial Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 5815-5820.	2.4	99
402	Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. <i>MedChemComm</i> , 2010, 1, 139.	3.5	68
403	The Actin-Bundling Protein Palladin Is an Akt1-Specific Substrate that Regulates Breast Cancer Cell Migration. <i>Molecular Cell</i> , 2010, 38, 333-344.	4.5	155
404	mTORC1 Signaling under Hypoxic Conditions Is Controlled by ATM-Dependent Phosphorylation of HIF-1 α . <i>Molecular Cell</i> , 2010, 40, 509-520.	4.5	244
405	The molecular therapy of colorectal cancer. <i>Molecular Aspects of Medicine</i> , 2010, 31, 171-178.	2.7	52
406	The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. <i>Molecular and Cellular Endocrinology</i> , 2010, 321, 20-28.	1.6	162
407	Targeting the PI3K signaling pathway in cancer. <i>Current Opinion in Genetics and Development</i> , 2010, 20, 87-90.	1.5	494
408	MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: Synergistic action with LY294002, an inhibitor of phosphatidylinositol 3 α -kinase. <i>Cancer Letters</i> , 2010, 291, 167-176.	3.2	23
409	Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. <i>Cancer Letters</i> , 2010, 297, 117-125.	3.2	28
410	Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 774-779.	1.0	24
411	Overexpression of phosphoinositide-3-kinase class II alpha enhances mesenchymal stem cell survival in infarcted myocardium. <i>Biochemical and Biophysical Research Communications</i> , 2010, 402, 272-279.	1.0	26
412	The ER UDPase ENTPD5 Promotes Protein N-Glycosylation, the Warburg Effect, and Proliferation in the PTEN Pathway. <i>Cell</i> , 2010, 143, 711-724.	13.5	184
413	Specific Roles of the p110 α Isoform of Phosphatidylinositol 3-Kinase in Hepatic Insulin Signaling and Metabolic Regulation. <i>Cell Metabolism</i> , 2010, 11, 220-230.	7.2	119
414	Class IA Phosphatidylinositol 3-Kinase in Pancreatic β Cells Controls Insulin Secretion by Multiple Mechanisms. <i>Cell Metabolism</i> , 2010, 12, 619-632.	7.2	101
415	Mechanisms maintaining the dormancy and survival of mammalian primordial follicles. <i>Trends in Endocrinology and Metabolism</i> , 2010, 21, 96-103.	3.1	201
416	Are we on the brink of nonsurgical treatment for ameloblastoma?. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2010, 110, 68-78.	1.6	35
417	Dual Role of 3-Methyladenine in Modulation of Autophagy via Different Temporal Patterns of Inhibition on Class I and III Phosphoinositide 3-Kinase. <i>Journal of Biological Chemistry</i> , 2010, 285, 10850-10861.	1.6	942

#	ARTICLE	IF	CITATIONS
418	Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 6029-6039.	3.2	77
419	Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5â€²-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2636-2645.	2.9	182
420	PI3K Signaling in Neutrophils. <i>Current Topics in Microbiology and Immunology</i> , 2010, 346, 183-202.	0.7	84
421	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. <i>Cancer Treatment Reviews</i> , 2010, 36, S21-S29.	3.4	128
422	A constitutively activated form of the p110Î² isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11002-11007.	3.3	57
423	Ligand-Macromolecular Interactions in Drug Discovery. <i>Methods in Molecular Biology</i> , 2010, , .	0.4	7
424	Toll-like receptorâ€“induced changes in glycolytic metabolism regulate dendritic cell activation. <i>Blood</i> , 2010, 115, 4742-4749.	0.6	998
425	AKT Signaling in Physiology and Disease. <i>Current Topics in Microbiology and Immunology</i> , 2010, 347, 105-133.	0.7	99
428	PTEN. , 2010, , 849-854.		0
429	Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts. <i>Breast Cancer Research</i> , 2010, 12, 202.	2.2	81
430	Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. <i>Breast Cancer Research</i> , 2010, 12, R20.	2.2	42
432	The PI3K Pathway As Drug Target in Human Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1075-1083.	0.8	1,114
433	Status of PI3K inhibition and biomarker development in cancer therapeutics. <i>Annals of Oncology</i> , 2010, 21, 683-691.	0.6	139
434	The Neurodevelopmental Implications of PI3K Signaling. <i>Current Topics in Microbiology and Immunology</i> , 2010, 346, 245-265.	0.7	55
435	Second AKT: The rise of SGK in cancer signalling. <i>Growth Factors</i> , 2010, 28, 394-408.	0.5	127
436	EGFR and KRAS in Colorectal Cancer. <i>Advances in Clinical Chemistry</i> , 2010, 51, 71-119.	1.8	103
437	Single-cell analysis of phosphoinositide 3-kinase and phosphatase and tensin homolog activation. <i>Faraday Discussions</i> , 2011, 149, 187-200.	1.6	18
438	Myocardial AKT: The Omnipresent Nexus. <i>Physiological Reviews</i> , 2011, 91, 1023-1070.	13.1	196

#	ARTICLE	IF	CITATIONS
439	Gab2, via PI-3K, Regulates ARF1 in Fc μ R1-Mediated Granule Translocation and Mast Cell Degranulation. <i>Journal of Immunology</i> , 2011, 187, 932-941.	0.4	40
440	Structure-Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5174-5184.	2.9	40
441	Phosphatidylinositol 3,4,5-Trisphosphate Activity Probes for the Labeling and Proteomic Characterization of Protein Binding Partners. <i>Biochemistry</i> , 2011, 50, 11143-11161.	1.2	45
442	An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway. <i>Cancer Discovery</i> , 2011, 1, 442-456.	7.7	346
443	Effects of Intermittent and Chronic Calorie Restriction on Mammalian Target of Rapamycin (mTOR) and IGF-I Signaling Pathways in Mammary Fat Pad Tissues and Mammary Tumors. <i>Nutrition and Cancer</i> , 2011, 63, 389-401.	0.9	40
444	Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 19024-19029.	3.3	91
445	Targeting PI3K Signaling as a Therapeutic Approach for Colorectal Cancer. <i>Gastroenterology</i> , 2011, 141, 50-61.	0.6	102
446	Molecular Biology of Lung Cancer: Clinical Implications. <i>Clinics in Chest Medicine</i> , 2011, 32, 703-740.	0.8	194
447	Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 809-813.	1.3	29
448	Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. <i>Xenobiotica</i> , 2011, 41, 1088-1099.	0.5	22
449	The Interplay between Protein L-Isoaspartyl Methyltransferase Activity and Insulin-Like Signaling to Extend Lifespan in <i>Caenorhabditis elegans</i> . <i>PLoS ONE</i> , 2011, 6, e20850.	1.1	17
450	Development of a Peptide-Drug Conjugate for Prostate Cancer Therapy. <i>Molecular Pharmaceutics</i> , 2011, 8, 901-912.	2.3	83
451	Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression. <i>Gastroenterology</i> , 2011, 140, 2084-2094.	0.6	26
452	Platinum resistance in breast and ovarian cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 91.	3.5	97
453	Phosphoinositide 3-kinase in Health and Disease. <i>Current Topics in Microbiology and Immunology</i> , 2011, , .	0.7	1
454	Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 34-38.	1.3	27
456	Activation of the PI3K/Akt signaling pathway through P2Y2 receptors by extracellular ATP is involved in osteoblastic cell proliferation. <i>Archives of Biochemistry and Biophysics</i> , 2011, 513, 144-152.	1.4	48
457	Anaplastic Lymphoma Kinase Spares Organ Growth during Nutrient Restriction in <i>Drosophila</i> . <i>Cell</i> , 2011, 146, 435-447.	13.5	211

#	ARTICLE	IF	CITATIONS
458	The Lin28/let-7 Axis Regulates Glucose Metabolism. <i>Cell</i> , 2011, 147, 81-94.	13.5	812
459	FKBP51 regulation of AKT/protein kinase B phosphorylation. <i>Current Opinion in Pharmacology</i> , 2011, 11, 360-364.	1.7	41
460	Does metformin influence the insulin-, IGF I- and IGF II-receptor gene expression and Akt phosphorylation in human decidualized endometrial stromal cells?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 158, 248-253.	0.5	10
461	NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 1200-1210.	0.6	31
462	Inflammation-Associated Autophagy-Related Programmed Necrotic Death of Human Neutrophils Characterized by Organelle Fusion Events. <i>Journal of Immunology</i> , 2011, 186, 6532-6542.	0.4	94
463	Structure of Lipid Kinase p110 ² /p85 ² Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism. <i>Molecular Cell</i> , 2011, 41, 567-578.	4.5	161
464	Involvement of PI3K/Akt signaling in PTH-stimulated ecdysteroidogenesis by prothoracic glands of the silkworm, <i>Bombyx mori</i> . <i>Insect Biochemistry and Molecular Biology</i> , 2011, 41, 197-202.	1.2	64
465	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. <i>Journal of Hepatology</i> , 2011, 55, 1400-1408.	1.8	57
466	arouser Reveals a Role for Synapse Number in the Regulation of Ethanol Sensitivity. <i>Neuron</i> , 2011, 70, 979-990.	3.8	54
467	Integrating Physiological Regulation with Stem Cell and Tissue Homeostasis. <i>Neuron</i> , 2011, 70, 703-718.	3.8	67
468	Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1789-1811.	2.9	103
469	New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 803-815.	1.5	1
470	Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. <i>Future Oncology</i> , 2011, 7, 1149-1167.	1.1	191
471	Quinoline as a Privileged Scaffold in Cancer Drug Discovery. <i>Current Medicinal Chemistry</i> , 2011, 18, 1488-1508.	1.2	488
472	Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases. <i>Science Signaling</i> , 2011, 4, re2.	1.6	249
473	Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure-Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4735-4751.	2.9	54
474	PI3K ² Plays a Critical Role in Neutrophil Activation by Immune Complexes. <i>Science Signaling</i> , 2011, 4, ra23.	1.6	130
475	Will PI3K pathway inhibitors be effective as single agents in patients with cancer?. <i>Oncotarget</i> , 2011, 2, 1314-1321.	0.8	49

#	ARTICLE	IF	CITATIONS
476	Insulin stimulation of Akt/PKB phosphorylation in the placenta of preeclampsia patients. Sao Paulo Medical Journal, 2011, 129, 387-391.	0.4	2
477	Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy. Current Signal Transduction Therapy, 2011, 6, 44-54.	0.3	0
478	Contribution of PKB/AKT signaling to thyroid cancer. Frontiers in Bioscience - Landmark, 2011, 16, 1461.	3.0	26
479	New Molecular Targets for the Systemic Therapy of Melanoma. , 0, , .		2
480	Molecular Biology of Thyroid Cancer. , 2011, , .		0
481	Role of Signaling Pathways and Epigenetic Factors in Lineage Determination During Human Embryonic Stem Cell Differentiation. , 2011, , .		2
482	Signaling Pathways in Mouse Embryo Stem Cell Self-Renewal. , 2011, , .		0
483	The Novel Role of Yin Yang 1 in the Regulation of Epithelial to Mesenchymal Transition in Cancer Via the Dysregulated NF- κ B/Snail/YY1/RKIP/PTEN Circuitry. Critical Reviews in Oncogenesis, 2011, 16, 211-226.	0.2	75
484	Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer. Journal of Signal Transduction, 2011, 2011, 1-11.	2.0	21
485	The Ras-PI3K Signaling Pathway Is Involved in Clathrin-Independent Endocytosis and the Internalization of Influenza Viruses. PLoS ONE, 2011, 6, e16324.	1.1	62
486	Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR. PLoS ONE, 2011, 6, e22862.	1.1	88
487	The Molecular Mechanisms of Glucocorticoids-Mediated Neutrophil Survival. Current Drug Targets, 2011, 12, 556-562.	1.0	129
488	Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets. Current Drug Targets, 2011, 12, 1056-1081.	1.0	38
489	Adipose Triglyceride Lipase: A New Target in the Regulation of Lipolysis by Insulin. Current Diabetes Reviews, 2011, 7, 270-277.	0.6	27
490	Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670 augments the efficacy of granulocyte transfusion in a clinically relevant mouse model. Blood, 2011, 117, 6702-6713.	0.6	63
491	Inhibition of Akt (ser473) Phosphorylation and Rapamycin-Resistant Cell Growth by Knockdown of Mammalian Target of Rapamycin with Small Interfering RNA in Vascular Endothelial Growth Factor Receptor-1-Targeting Vector. Biological and Pharmaceutical Bulletin, 2011, 34, 602-608.	0.6	26
492	Bag3 promotes resistance to apoptosis through Bcl-2 family members in non-small cell lung cancer. Oncology Reports, 2012, 27, 109-13.	1.2	28
493	New therapeutic targets and drugs in non-Hodgkin's lymphoma. Current Opinion in Hematology, 2011, 18, 1.	1.2	17

#	ARTICLE	IF	CITATIONS
494	Immunohistochemical biomarkers for bladder cancer prognosis. <i>International Journal of Urology</i> , 2011, 18, 616-629.	0.5	51
495	Hypoxia-inducible factors "regulation, role and comparative aspects in tumorigenesis. <i>Veterinary and Comparative Oncology</i> , 2011, 9, 16-37.	0.8	17
496	PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. <i>Oncogene</i> , 2011, 30, 3222-3233.	2.6	170
497	Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. <i>British Journal of Cancer</i> , 2011, 104, 1116-1125.	2.9	43
498	Myricetin is a potent chemopreventive phytochemical in skin carcinogenesis. <i>Annals of the New York Academy of Sciences</i> , 2011, 1229, 124-132.	1.8	71
499	Checkpoints of B cell differentiation: visualizing Ig-centric processes. <i>Annals of the New York Academy of Sciences</i> , 2011, 1246, 11-25.	1.8	23
500	Inhibition of phosphatidylinositol-3 kinase β reduces pruriceptive, inflammatory, and nociceptive responses induced by trypsin in mice. <i>Pain</i> , 2011, 152, 2861-2869.	2.0	20
501	Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. , 2011, 130, 310-324.		139
502	Interaction of the human cytomegalovirus particle with the host cell induces hypoxia-inducible factor 1 alpha. <i>Virology</i> , 2011, 414, 83-90.	1.1	34
503	The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. <i>Gynecologic Oncology</i> , 2011, 123, 411-420.	0.6	23
504	Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. <i>Drug Discovery Today</i> , 2011, 16, 325-331.	3.2	170
505	Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl)quinoxalines as PI3K inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 5540-5548.	2.6	31
506	Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. <i>Free Radical Biology and Medicine</i> , 2011, 51, 1164-1174.	1.3	89
507	Thrombin activation of PI3K/PDK1/Akt signaling promotes cyclin D1 upregulation and RPE cell proliferation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011, 1813, 1758-1766.	1.9	31
508	Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011, 1813, 2108-2117.	1.9	51
509	c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma. <i>Cancer Cell</i> , 2011, 19, 652-663.	7.7	260
510	PI3K β Mediates Kaposi's Sarcoma-Associated Herpesvirus vGPCR-Induced Sarcomagenesis. <i>Cancer Cell</i> , 2011, 19, 805-813.	7.7	62
511	mTOR signaling in disease. <i>Current Opinion in Cell Biology</i> , 2011, 23, 744-755.	2.6	409

#	ARTICLE	IF	CITATIONS
512	The catalytic class IA PI3K isoforms play divergent roles in breast cancer cell migration. <i>Cellular Signalling</i> , 2011, 23, 529-541.	1.7	10
513	Autism and cancer risk. <i>Autism Research</i> , 2011, 4, 302-310.	2.1	53
514	PI3K and STAT3: A New Alliance. <i>Cancer Discovery</i> , 2011, 1, 481-486.	7.7	103
515	PI3K Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic. <i>Cancer Discovery</i> , 2011, 1, 562-572.	7.7	126
517	Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 774-779.	1.3	223
518	Is prenatal myoinositol deficiency a mechanism of CNS injury in galactosemia?. <i>Journal of Inherited Metabolic Disease</i> , 2011, 34, 345-355.	1.7	46
519	PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 635-643.	1.1	49
520	Over-expression of LYRM1 inhibits glucose transport in rat skeletal muscles via attenuated phosphorylation of PI3K (p85) and Akt. <i>Molecular and Cellular Biochemistry</i> , 2011, 348, 149-154.	1.4	15
521	PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. <i>Molecular Biology Reports</i> , 2011, 38, 1347-1351.	1.0	14
522	PI3Kinase signaling in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 103, 417-427.	1.4	66
523	PI3K/Akt pathway mediates high glucose-induced lipogenesis and extracellular matrix accumulation in HKC cells through regulation of SREBP-1 and TGF- β 1. <i>Histochemistry and Cell Biology</i> , 2011, 135, 173-181.	0.8	47
524	Evolution of the TOR Pathway. <i>Journal of Molecular Evolution</i> , 2011, 73, 209-220.	0.8	118
525	PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 523-531.	2.1	36
526	Evolution of the VEGF-Regulated Vascular Network from a Neural Guidance System. <i>Molecular Neurobiology</i> , 2011, 43, 192-206.	1.9	16
527	Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. <i>Targeted Oncology</i> , 2011, 6, 69-94.	1.7	38
528	Predictive and Prognostic Markers in Colorectal Cancer. <i>Current Oncology Reports</i> , 2011, 13, 206-215.	1.8	48
529	PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. <i>BMC Cancer</i> , 2011, 11, 248.	1.1	135
530	The secret life of kinases: functions beyond catalysis. <i>Cell Communication and Signaling</i> , 2011, 9, 23.	2.7	154

#	ARTICLE	IF	CITATIONS
531	Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. <i>Journal of Translational Medicine</i> , 2011, 9, 133.	1.8	49
532	Genetic Enhancement of Behavioral Itch Responses in Mice Lacking Phosphoinositide 3-Kinase- β (PI3K β). <i>Molecular Pain</i> , 2011, 7, 1744-8069-7-96.	1.0	7
533	Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. <i>Radiation Oncology</i> , 2011, 6, 114.	1.2	26
534	Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery. <i>BMC Evolutionary Biology</i> , 2011, 11, 4.	3.2	91
535	Genetically informed lung cancer medicine. <i>Journal of Pathology</i> , 2011, 223, 231-241.	2.1	59
536	Phosphatase and Tensin Homolog Regulates the Pluripotent State and Lineage Fate Choice in Human Embryonic Stem Cells. <i>Stem Cells</i> , 2011, 29, 1952-1962.	1.4	38
537	Cutaneous melanoma: A model to study cancer metastasis. <i>Journal of Surgical Oncology</i> , 2011, 103, 538-549.	0.8	38
538	Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. <i>Medicinal Research Reviews</i> , 2011, 31, 924-954.	5.0	124
539	Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas. <i>Molecular Carcinogenesis</i> , 2011, 50, 301-309.	1.3	48
540	Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. <i>Molecular Carcinogenesis</i> , 2011, 50, 264-279.	1.3	62
541	Regulation of PIP5K activity by Arf6 and its physiological significance. <i>Journal of Cellular Physiology</i> , 2011, 226, 888-895.	2.0	57
542	A class IA PI3K controls inflammatory cytokine production in human neutrophils. <i>European Journal of Immunology</i> , 2011, 41, 1709-1719.	1.6	49
543	Metabolic surgery and cancer. <i>Cancer</i> , 2011, 117, 1788-1799.	2.0	134
544	Suppression of the PI3K subunit p85 β delays embryoid body development and inhibits cell adhesion. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 3573-3581.	1.2	6
546	The Catalytic Enantioselective Total Synthesis of (+)-Lipagal. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 6814-6818.	7.2	71
547	Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1270-1274.	1.0	32
548	16-Hydroxycyclohexa-3,13-dien-15,16-olide deregulates PI3K and Aurora B activities that involve in cancer cell apoptosis. <i>Toxicology</i> , 2011, 285, 72-80.	2.0	21
549	Small-molecule inhibitors of the PI3K signaling network. <i>Future Medicinal Chemistry</i> , 2011, 3, 549-565.	1.1	96

#	ARTICLE	IF	CITATIONS
550	PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2189-2199.	1.9	150
551	The Phosphoinositide 3-Kinase Signaling Pathway as a Therapeutic Target in Grade IV Brain Tumors. <i>Current Cancer Drug Targets</i> , 2011, 11, 894-918.	0.8	30
552	Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85± Src homology-2 domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14157-14162.	3.3	68
553	Ral's engagement with the exocyst: Breaking up is hard to do. <i>Cell Cycle</i> , 2011, 10, 2299-2304.	1.3	10
554	Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4452-4461.	0.8	346
555	New phosphatidylinositol 3-kinase inhibitors for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 507-518.	1.9	52
556	RAS Interaction with PI3K: More Than Just Another Effector Pathway. <i>Genes and Cancer</i> , 2011, 2, 261-274.	0.6	580
557	Emerging Theme: Cellular PDZ Proteins as Common Targets of Pathogenic Viruses. <i>Journal of Virology</i> , 2011, 85, 11544-11556.	1.5	175
558	Tannerella forsythia invasion in oral epithelial cells requires phosphoinositide 3-kinase activation and clathrin-mediated endocytosis. <i>Microbiology (United Kingdom)</i> , 2011, 157, 2382-2391.	0.7	21
559	Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor. <i>Clinical Cancer Research</i> , 2011, 17, 3193-3203.	3.2	146
560	Differential Expression of S6K2 Dictates Tissue-Specific Requirement for S6K1 in Mediating Aberrant mTORC1 Signaling and Tumorigenesis. <i>Cancer Research</i> , 2011, 71, 3669-3675.	0.4	19
561	p85± Regulates Osteoblast Differentiation by Cross-talking with the MAPK Pathway. <i>Journal of Biological Chemistry</i> , 2011, 286, 13512-13521.	1.6	20
562	Metabolic benefits of resistance training and fast glycolytic skeletal muscle. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E3-E10.	1.8	90
563	ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis. <i>Cancer Research</i> , 2011, 71, 3941-3951.	0.4	69
564	A Rit GTPase-p38 Mitogen-Activated Protein Kinase Survival Pathway Confers Resistance to Cellular Stress. <i>Molecular and Cellular Biology</i> , 2011, 31, 1938-1948.	1.1	28
565	Phosphoinositide 3-kinase signaling pathway mediated by p110± regulates invadopodia formation. <i>Journal of Cell Biology</i> , 2011, 193, 1275-1288.	2.3	114
566	Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors. <i>Cancer Research</i> , 2011, 71, 4344-4351.	0.4	109
567	Protein Kinases and Phosphatases in the Control of Cell Fate. <i>Enzyme Research</i> , 2011, 2011, 1-26.	1.8	229

#	ARTICLE	IF	CITATIONS
568	Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors. <i>Clinical Cancer Research</i> , 2011, 17, 4378-4388.	3.2	92
569	Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16217-16222.	3.3	36
570	An evolutionarily conserved Rho GTPase-p38 MAPK signaling pathway mediates oxidative stress resistance. <i>Molecular Biology of the Cell</i> , 2011, 22, 3231-3241.	0.9	61
571	Hyperinsulinemia leads to uncoupled insulin regulation of the GLUT4 glucose transporter and the FoxO1 transcription factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 10162-10167.	3.3	86
572	Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review). <i>International Journal of Oncology</i> , 2012, 40, 639-44.	1.4	81
573	Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer. <i>Cancer Research</i> , 2011, 71, 5965-5975.	0.4	15
574	The E-box Binding Factors Max/Mnt, MITF, and USF1 Act Coordinately with FoxO to Regulate Expression of Proapoptotic and Cell Cycle Control Genes by Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3 Signaling. <i>Journal of Biological Chemistry</i> , 2011, 286, 36215-36227.	1.6	36
575	Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 6486-6491.	3.3	62
576	Epithelial Phosphatidylinositol-3-Kinase Signaling Is Required for β -Catenin Activation and Host Defense against <i>Citrobacter rodentium</i> Infection. <i>Infection and Immunity</i> , 2011, 79, 1863-1872.	1.0	41
577	PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E699-708.	3.3	190
578	Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. <i>Oncogene</i> , 2011, 30, 4567-4577.	2.6	61
579	The Class III Kinase Vps34 Promotes T Lymphocyte Survival through Regulating IL-7R α Surface Expression. <i>Journal of Immunology</i> , 2011, 187, 5051-5061.	0.4	78
580	Therapeutic Strategies for Targeting Ras Proteins. <i>Genes and Cancer</i> , 2011, 2, 359-372.	0.6	282
581	The emerging role of maternal phosphatidylinositol 3 kinase (PI3K) signaling in manipulating mammalian preimplantation embryogenesis. <i>Cell Cycle</i> , 2011, 10, 178-179.	1.3	6
582	Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 6433-6448.	1.6	56
583	Phosphoinositide [PI(3,5)P ₂] lipid-dependent regulation of the general transcriptional regulator Tup1. <i>Genes and Development</i> , 2011, 25, 984-995.	2.7	51
584	MAPK/ERK Signaling Regulates Insulin Sensitivity to Control Glucose Metabolism in <i>Drosophila</i> . <i>PLoS Genetics</i> , 2011, 7, e1002429.	1.5	114
585	mTOR Inhibitors in Cancer Treatment. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
586	Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2350-2362.	1.9	219
587	Akt isoform-specific signaling in breast cancer. <i>Cell Adhesion and Migration</i> , 2011, 5, 211-214.	1.1	79
588	The Phosphatidylinositol 3-Kinase/mTor Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration. <i>Pharmaceuticals</i> , 2011, 4, 1070-1087.	1.7	20
589	Insights into Primary Ovarian Insufficiency through Genetically Engineered Mouse Models. <i>Seminars in Reproductive Medicine</i> , 2011, 29, 283-298.	0.5	34
590	FOSL1 Is Integral to Establishing the Maternal-Fetal Interface. <i>Molecular and Cellular Biology</i> , 2011, 31, 4801-4813.	1.1	68
591	Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 109.	1.3	72
592	The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas. <i>Neurology Research International</i> , 2012, 2012, 1-13.	0.5	3
593	Akt and mTOR in B Cell Activation and Differentiation. <i>Frontiers in Immunology</i> , 2012, 3, 228.	2.2	165
594	P2X ₇ -mediated calcium influx triggers a sustained, PI3K-dependent increase in metabolic acid production by osteoblast-like cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 302, E561-E575.	1.8	36
595	Pten coordinates retinal neurogenesis by regulating Notch signalling. <i>EMBO Journal</i> , 2012, 31, 817-828.	3.5	37
596	Regulation of T Cell Homeostasis and Responses by Pten. <i>Frontiers in Immunology</i> , 2012, 3, 151.	2.2	37
597	Role of autophagy in angiogenesis in aortic endothelial cells. <i>American Journal of Physiology - Cell Physiology</i> , 2012, 302, C383-C391.	2.1	151
598	New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 3002-3007.	3.2	32
599	Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007 – present). <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 1263-1287.	2.4	15
600	Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1315-1326.	0.5	175
601	Hepatitis C Virus Upregulates Beclin1 for Induction of Autophagy and Activates mTOR Signaling. <i>Journal of Virology</i> , 2012, 86, 8705-8712.	1.5	145
602	New promising molecular targets in head and neck squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2012, 24, 235-242.	1.1	31
603	Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition. <i>Current Opinion in Oncology</i> , 2012, 24, 623-634.	1.1	44

#	ARTICLE	IF	CITATIONS
604	Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235. <i>Molecular Pharmacology</i> , 2012, 82, 1230-1240.	1.0	78
605	An Introduction to Phosphoinositides. <i>Current Topics in Microbiology and Immunology</i> , 2012, 362, 1-42.	0.7	17
606	Uncoupling of PI3K from ErbB3 Impairs Mammary Gland Development but Does Not Impact on ErbB2-Induced Mammary Tumorigenesis. <i>Cancer Research</i> , 2012, 72, 3080-3090.	0.4	23
607	Molecular Cloning and Characterization of PI3K-p85 [±] Gene from Inner Mongolia Cashmere Goat (<i>Capra hircus</i>). <i>Advanced Materials Research</i> , 2012, 554-556, 1705-1708.	0.3	0
608	Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions. <i>Modern Pathology</i> , 2012, 25, 930-937.	2.9	39
609	A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia. <i>Current Medicinal Chemistry</i> , 2012, 19, 5294-5318.	1.2	22
610	Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110 ² as a Potential Anticancer Agent. <i>Cancer Discovery</i> , 2012, 2, 425-433.	7.7	152
611	Personalized medicine in colorectal cancer: the evidence so far. <i>Clinical Investigation</i> , 2012, 2, 1013-1021.	0.0	0
612	Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1 [±] expression by blocking protein translation and increases cell death under hypoxia. <i>Cancer Biology and Therapy</i> , 2012, 13, 1102-1111.	1.5	33
613	B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 267-272.	3.3	73
614	Optical imaging of metabolism in HER2 overexpressing breast cancer cells. <i>Biomedical Optics Express</i> , 2012, 3, 75.	1.5	70
615	AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. <i>Cell Cycle</i> , 2012, 11, 895-908.	1.3	23
616	Targeting the PI3K pathway for cancer therapy. <i>Future Medicinal Chemistry</i> , 2012, 4, 1153-1169.	1.1	53
617	Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2003-2008.	3.3	327
618	Regulation of mRNA Translation by Signaling Pathways. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a012252-a012252.	2.3	146
619	Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation. <i>Cell Death and Differentiation</i> , 2012, 19, 1561-1570.	5.0	205
620	Inhibition of Chemokine (CXC Motif) Ligand 12/Chemokine (CXC Motif) Receptor 4 Axis (CXCL12/CXCR4)-mediated Cell Migration by Targeting Mammalian Target of Rapamycin (mTOR) Pathway in Human Gastric Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 12132-12141.	1.6	81
621	Pten deletion causes mTorc1-dependent ectopic neuroblast differentiation without causing uniform migration defects. <i>Development (Cambridge)</i> , 2012, 139, 3422-3431.	1.2	37

#	ARTICLE	IF	CITATIONS
622	Identification of Components of the Host Type IA Phosphoinositide 3-Kinase Pathway That Promote Internalization of <i>Listeria monocytogenes</i> . <i>Infection and Immunity</i> , 2012, 80, 1252-1266.	1.0	33
623	The Maternally Expressed Gene <i>Tssc3</i> Regulates the Expression of MASH2 Transcription Factor in Mouse Trophoblast Stem Cells through the AKT-Sp1 Signaling Pathway. <i>Journal of Biological Chemistry</i> , 2012, 287, 42685-42694.	1.6	35
624	PERK Utilizes Intrinsic Lipid Kinase Activity To Generate Phosphatidic Acid, Mediate Akt Activation, and Promote Adipocyte Differentiation. <i>Molecular and Cellular Biology</i> , 2012, 32, 2268-2278.	1.1	97
625	PI3Ks as Drug Targets in Inflammation and Cancer. <i>Sub-Cellular Biochemistry</i> , 2012, 58, 111-181.	1.0	9
626	Targeting the PI3K Pathway in the Brain: Efficacy of a PI3K Inhibitor Optimized to Cross the Blood-Brain Barrier. <i>Clinical Cancer Research</i> , 2012, 18, 6239-6248.	3.2	59
627	The Biological Role of PI3K Pathway in Lung Cancer. <i>Pharmaceuticals</i> , 2012, 5, 1236-1264.	1.7	89
628	The Role of Phosphoinositide 3-Kinase Signaling in Intestinal Inflammation. <i>Journal of Signal Transduction</i> , 2012, 2012, 1-13.	2.0	20
629	Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer. <i>Biochemistry Research International</i> , 2012, 2012, 1-18.	1.5	42
630	Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2718-2723.	3.3	313
631	Protein kinase N1, a cell inhibitor of Akt kinase, has a central role in quality control of germinal center formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 21022-21027.	3.3	26
632	The p110 α and p110 β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. <i>Genes and Development</i> , 2012, 26, 1573-1586.	2.7	116
633	<i>Drosophila poly</i> suggests a novel role for the Elongator complex in insulin receptor target of rapamycin signalling. <i>Open Biology</i> , 2012, 2, 110031.	1.5	14
634	Bladder Cancer: A Simple Model Becomes Complex. <i>Current Genomics</i> , 2012, 13, 395-415.	0.7	29
635	Recent Developments in Targeted Therapies of the RAF-MEK and PI3K/AKT Pathways in Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2012, 8, 205-217.	0.2	0
636	Phosphatidylinositol-3-Kinase Pathway. <i>Journal of Thoracic Oncology</i> , 2012, 7, S383-S384.	0.5	2
637	Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin Pathway in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, S379-S382.	0.5	4
638	Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 69-95.	0.2	204
639	Synergism between altered cortical polarity and the PI3K/TOR pathway in the suppression of tumour growth. <i>EMBO Reports</i> , 2012, 13, 157-162.	2.0	12

#	ARTICLE	IF	CITATIONS
640	Akt signaling-associated metabolic effects of dietary gold nanoparticles in <i>Drosophila</i> . <i>Scientific Reports</i> , 2012, 2, 563.	1.6	51
641	PI3K inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 1897-1900.	0.6	143
642	A novel mechanism of sustained platelet α IIb β 3 activation via PEAR1. <i>Blood</i> , 2012, 119, 4056-4065.	0.6	75
643	Peripheral T-cell lymphoma: pharmacotherapy overview. <i>Clinical Investigation</i> , 2012, 2, 403-416.	0.0	0
644	Global Profiling Strategies for Mapping Dysregulated Metabolic Pathways in Cancer. <i>Cell Metabolism</i> , 2012, 16, 565-577.	7.2	103
645	Epigenetics advancing personalized nanomedicine in cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1532-1543.	6.6	35
646	Positive feedback regulation of Akt \rightarrow FMRP pathway protects neurons from cell death. <i>Journal of Neurochemistry</i> , 2012, 123, 226-238.	2.1	19
647	Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2012, 23, 2399-2408.	0.6	125
648	PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. <i>Biochemical Journal</i> , 2012, 442, 465-481.	1.7	196
649	Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1747-1757.	1.9	110
650	Glioblastoma Multiforme. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 825-853.	0.9	125
651	Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. <i>Cell Death and Disease</i> , 2012, 3, e440-e440.	2.7	10
652	Akt-Mediated Regulation of Autophagy and Tumorigenesis Through Beclin 1 Phosphorylation. <i>Science</i> , 2012, 338, 956-959.	6.0	630
653	Oncogenes in Cell Survival and Cell Death. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a009829-a009829.	2.3	99
654	Molecular Analysis of Protein \rightarrow Phosphoinositide Interactions. <i>Current Topics in Microbiology and Immunology</i> , 2012, 362, 111-126.	0.7	9
655	Modular evolution of phosphorylation-based signalling systems. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2012, 367, 2540-2555.	1.8	138
656	Class IA phosphatidylinositol 3-kinase regulates osteoclastic bone resorption through protein kinase B \rightarrow mediated vesicle transport. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2464-2475.	3.1	35
657	Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 205-216.	1.0	77

#	ARTICLE	IF	CITATIONS
658	Plausible role of naringenin against cerebrally implanted C6 glioma cells in rats. <i>Molecular and Cellular Biochemistry</i> , 2013, 375, 171-8.	1.4	11
659	JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer. <i>Cancer Cell</i> , 2012, 22, 796-811.	7.7	213
660	Essential roles of PIKfyve and PTEN on phagosomal phosphatidylinositol 3-phosphate dynamics. <i>FEBS Letters</i> , 2012, 586, 4010-4015.	1.3	24
661	mTOR pathway inhibition in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 356-361.	0.8	8
662	Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual PI3K/mTOR Inhibitor NVP-BEZ235. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S127.	0.4	1
663	Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase β inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7534-7538.	1.0	24
664	Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies. <i>Pharmacological Reviews</i> , 2012, 64, 1027-1054.	7.1	107
665	p37 β is a new isoform of PI3K p110 β that increases cell proliferation and is overexpressed in tumors. <i>Oncogene</i> , 2012, 31, 3277-3286.	2.6	21
666	Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 319-337.	1.4	24
667	Augmentation of ADAMTS9 gene expression by IL-1 β is reversed by NF- κ B and MAPK inhibitors, but not PI3 kinase inhibitors. <i>Cell Biochemistry and Function</i> , 2013, 31, 539-544.	1.4	18
668	Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7796-7816.	2.9	42
669	The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 823-842.	2.7	59
670	Agammaglobulinemia and absent B lineage cells in a patient lacking the p85 α subunit of PI3K. <i>Journal of Experimental Medicine</i> , 2012, 209, 463-470.	4.2	200
671	The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. <i>Leukemia</i> , 2012, 26, 1195-1202.	3.3	138
672	Retroviral oncogenes: a historical primer. <i>Nature Reviews Cancer</i> , 2012, 12, 639-648.	12.8	108
673	Leptin revisited: its mechanism of action and potential for treating diabetes. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 692-708.	21.5	232
674	Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 2048-2055.	3.2	50
675	Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1785-1796.	1.7	36

#	ARTICLE	IF	CITATIONS
676	Endothelial PI3K-C2 β , a class II PI3K, has an essential role in angiogenesis and vascular barrier function. <i>Nature Medicine</i> , 2012, 18, 1560-1569.	15.2	174
677	Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. <i>Advances in Biological Regulation</i> , 2012, 52, 205-213.	1.4	30
678	Achieving specificity in Akt signaling in cancer. <i>Advances in Biological Regulation</i> , 2012, 52, 78-87.	1.4	59
679	PTEN regulates retinal interneuron morphogenesis and synaptic layer formation. <i>Molecular and Cellular Neurosciences</i> , 2012, 49, 171-183.	1.0	24
680	p85 β SH2 Domain Phosphorylation by IKK Promotes Feedback Inhibition of PI3K and Akt in Response to Cellular Starvation. <i>Molecular Cell</i> , 2012, 45, 719-730.	4.5	63
681	Cooperative Activation of PI3K by Ras and Rho Family Small GTPases. <i>Molecular Cell</i> , 2012, 47, 281-290.	4.5	146
682	Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 901, 9-17.	1.2	6
683	Apo- and holo-lactoferrin stimulate proliferation of mouse crypt cells but through different cellular signaling pathways. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 91-100.	1.2	39
684	Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5114-5117.	1.0	36
685	Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State. <i>Cell</i> , 2012, 149, 49-62.	13.5	339
686	Oncogenic PI3K Mutations Lead to NF- κ B-Dependent Cytokine Expression following Growth Factor Deprivation. <i>Cancer Research</i> , 2012, 72, 3260-3269.	0.4	74
687	The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5856-5864.	3.2	325
688	The Chemical Biology of Phosphoinositide 3-kinases. <i>ChemBioChem</i> , 2012, 13, 2022-2035.	1.3	35
689	Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration. <i>Journal of Physiology</i> , 2012, 590, 777-792.	1.3	82
690	Gene expression analysis of mammary tissue during fetal bud formation and growth in two pig breeds – indications of prenatal initiation of postnatal phenotypic differences. <i>BMC Developmental Biology</i> , 2012, 12, 13.	2.1	5
691	Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2012, 12, 481.	1.1	43
692	Comprehensive predictions of target proteins based on protein-chemical interaction using virtual screening and experimental verifications. <i>BMC Chemical Biology</i> , 2012, 12, 2.	1.6	7
693	Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells. <i>Cardiovascular Diabetology</i> , 2012, 11, 27.	2.7	18

#	ARTICLE	IF	CITATIONS
694	CC chemokine ligand 2 upregulates the current density and expression of TRPV1 channels and Nav1.8 sodium channels in dorsal root ganglion neurons. <i>Journal of Neuroinflammation</i> , 2012, 9, 189.	3.1	78
695	Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library. <i>BMC Medical Genomics</i> , 2012, 5, 34.	0.7	41
696	Host cell kinases, β 5 and β 21 integrins, and Rac1 signalling on the microtubule cytoskeleton are important for non-typable <i>Haemophilus influenzae</i> invasion of respiratory epithelial cells. <i>Microbiology (United Kingdom)</i> 156(10):1071-1081, 2012.	0.0	0
697	Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance. <i>Cancer Science</i> , 2012, 103, 1955-1960.	1.7	17
698	Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 213-220.	1.1	23
699	Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer. <i>Cancer Discovery</i> , 2012, 2, 1048-1063.	7.7	384
700	Quercetin suppresses NF- κ B and MCP-1 expression in a high glucose-induced human mesangial cell proliferation model. <i>International Journal of Molecular Medicine</i> , 2012, 30, 119-25.	1.8	26
701	The promise of mTOR inhibitors in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1775-1788.	1.9	26
702	PrP. , 2012, , 1488-1488.		0
703	A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer. <i>Cancer Letters</i> , 2012, 324, 210-220.	3.2	21
704	The consequences of enhanced cell-autonomous glucose metabolism. <i>Trends in Endocrinology and Metabolism</i> , 2012, 23, 545-551.	3.1	17
705	Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 449-455.	4.0	36
706	Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2012, 77, 192-198.	0.9	64
707	Phosphoinositide 3-Kinases—A Historical Perspective. <i>Sub-Cellular Biochemistry</i> , 2012, 58, 95-110.	1.0	18
708	The Role of the Insulin-like Growth Factor-1 Receptor (IGF-1R), Phosphatase and Tensin Homolog (PTEN), c-Met, and the PI3-Kinase Pathway in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 243-253.	1.0	0
709	Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. <i>Translational Oncology</i> , 2012, 5, 422-429.	1.7	26
710	Phosphoinositides and Disease. <i>Current Topics in Microbiology and Immunology</i> , 2012, , .	0.7	2
711	Heat Shock Protein 90B1 Plays an Oncogenic Role and is a Target of microRNA-223 in Human Osteosarcoma. <i>Cellular Physiology and Biochemistry</i> , 2012, 30, 1481-1490.	1.1	83

#	ARTICLE	IF	CITATIONS
712	The mTOR Signalling Pathway in Human Cancer. <i>International Journal of Molecular Sciences</i> , 2012, 13, 1886-1918.	1.8	662
713	EMP-1 promotes tumorigenesis of NSCLC through PI3K/AKT pathway. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 834-838.	1.0	26
714	Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies. <i>Paediatric Drugs</i> , 2012, 14, 299-316.	1.3	31
715	Gene of the month: PTEN. <i>Journal of Clinical Pathology</i> , 2012, 65, 601-603.	1.0	15
716	Phosphoinositides I: Enzymes of Synthesis and Degradation. <i>Sub-Cellular Biochemistry</i> , 2012, , .	1.0	6
717	Insulin-like Growth Factors and Cancer. , 2012, , .		16
718	An RGS4-Mediated Phenotypic Switch of Bronchial Smooth Muscle Cells Promotes Fixed Airway Obstruction in Asthma. <i>PLoS ONE</i> , 2012, 7, e28504.	1.1	30
719	Ubiquitin-Specific Protease 4 Inhibits Mono-Ubiquitination of the Master Growth Factor Signaling Kinase PDK1. <i>PLoS ONE</i> , 2012, 7, e31003.	1.1	20
720	Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e31331.	1.1	55
721	The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion. <i>PLoS ONE</i> , 2012, 7, e40378.	1.1	176
722	Phosphoinositide 3-Kinase C2 ¹ 2 Regulates RhoA and the Actin Cytoskeleton through an Interaction with Dbl. <i>PLoS ONE</i> , 2012, 7, e44945.	1.1	15
723	Multiple Metabolic Alterations Exist in Mutant PI3K Cancers, but Only Glucose Is Essential as a Nutrient Source. <i>PLoS ONE</i> , 2012, 7, e45061.	1.1	14
724	Estrogen-Dependent Uterine Secretion of Osteopontin Activates Blastocyst Adhesion Competence. <i>PLoS ONE</i> , 2012, 7, e48933.	1.1	35
725	Fucoidan from Seaweed <i>Fucus vesiculosus</i> Inhibits Migration and Invasion of Human Lung Cancer Cell via PI3K-Akt-mTOR Pathways. <i>PLoS ONE</i> , 2012, 7, e50624.	1.1	150
726	PI3K Pathway in NSCLC. <i>Frontiers in Oncology</i> , 2012, 1, 55.	1.3	7
727	PI3KÁAKTÁmTOR inhibitors for the systemic treatment of endometrial cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2012, 7, 421-430.	0.4	1
728	Akt1 and insulin-like growth factor 2 (Igf2) regulate placentation and fetal/postnatal development. <i>International Journal of Developmental Biology</i> , 2012, 56, 255-261.	0.3	33
729	Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies. <i>Paediatric Drugs</i> , 2012, 14, 299-316.	1.3	86

#	ARTICLE	IF	CITATIONS
730	Role of Phosphatidylinositol-3-Kinase Pathway in Head and Neck Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2012, 2012, 1-12.	0.6	29
731	Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. <i>World Journal of Virology</i> , 2012, 1, 154.	1.3	66
732	Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. <i>OncoTargets and Therapy</i> , 2012, 5, 21.	1.0	15
733	Regulation and cellular functions of class II phosphoinositide 3-kinases. <i>Biochemical Journal</i> , 2012, 443, 587-601.	1.7	141
734	The functions and regulation of the PTEN tumour suppressor. <i>Nature Reviews Molecular Cell Biology</i> , 2012, 13, 283-296.	16.1	1,638
735	Discovery of novel morpholinoquinoxalines as PI3K inhibitors by pharmacophore-based screening. <i>MedChemComm</i> , 2012, 3, 659.	3.5	16
736	Small molecules targeting phosphoinositide 3-kinases. <i>MedChemComm</i> , 2012, 3, 1337.	3.5	54
737	Hepatitis C Virus Activates the mTOR/S6K1 Signaling Pathway in Inhibiting IRS-1 Function for Insulin Resistance. <i>Journal of Virology</i> , 2012, 86, 6315-6322.	1.5	104
738	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S17-S27.	1.5	580
739	Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 282-290.	0.8	635
740	Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2012, 18, 4013-4018.	3.2	44
741	Emerging insights into the molecular and cellular basis of glioblastoma. <i>Genes and Development</i> , 2012, 26, 756-784.	2.7	463
742	PI3K: A potential therapeutic target for cancer. <i>Journal of Cellular Physiology</i> , 2012, 227, 2818-2821.	2.0	49
743	PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 130, 2505-2513.	2.3	36
744	Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110 inhibition as a potential therapeutic strategy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12165-12170.	3.3	127
745	Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5188-5219.	2.9	43
746	De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. <i>Nature Genetics</i> , 2012, 44, 934-940.	9.4	621
747	Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 409-423.	1.9	5

#	ARTICLE	IF	CITATIONS
748	Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. <i>Journal of Molecular Medicine</i> , 2012, 90, 695-706.	1.7	50
749	SGK3 is associated with estrogen receptor expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 531-541.	1.1	22
750	Testosterone improves the transition of primary oocytes in artificial maturation eels (<i>Anguilla</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 662	0.9	6
751	Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1601-1615.	1.1	70
752	Microarray analysis of Akt PH domain binding employing synthetic biotinylated analogs of all seven phosphoinositide headgroup isomers. <i>Chemistry and Physics of Lipids</i> , 2012, 165, 207-215.	1.5	11
753	Ubiquitination and phosphorylation of Beclin 1 and its binding partners: Tuning class III phosphatidylinositol 3-kinase activity and tumor suppression. <i>FEBS Letters</i> , 2012, 586, 1584-1591.	1.3	77
754	Synthesis, molecular docking and biological evaluation of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 1373-1379.	1.4	17
755	Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase \pm (PI3K \pm) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2837-2844.	1.4	16
756	Synthesis, biological evaluation and molecular docking studies of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 3359-3367.	1.4	17
757	Normal and cancer cell metabolism: lymphocytes and lymphoma. <i>FEBS Journal</i> , 2012, 279, 2598-2609.	2.2	53
758	Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. <i>Leukemia Research</i> , 2012, 36, 342-349.	0.4	44
759	Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary. <i>Molecular and Cellular Endocrinology</i> , 2012, 356, 24-30.	1.6	132
760	Oogenesis: Transcriptional regulators and mouse models. <i>Molecular and Cellular Endocrinology</i> , 2012, 356, 31-39.	1.6	97
761	Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder. <i>Pediatric Transplantation</i> , 2012, 16, 220-229.	0.5	20
762	Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. <i>NMR in Biomedicine</i> , 2012, 25, 379-388.	1.6	23
763	InCl ₃ -mediated intramolecular Friedel-Crafts-type cyclization and its application to construct the [6-7-5-6] tetracyclic scaffold of liphagal. <i>Science China Chemistry</i> , 2012, 55, 36-42.	4.2	6
764	Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 29-39.	1.1	83
765	MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 106, 217-224.	1.4	36

#	ARTICLE	IF	CITATIONS
766	AKT activation by N-cadherin regulates beta-catenin signaling and neuronal differentiation during cortical development. <i>Neural Development</i> , 2013, 8, 7.	1.1	96
767	The PI(3)P interactome from a colon cancer cell. <i>Journal of Proteomics</i> , 2013, 82, 35-51.	1.2	27
768	<i>Cancer Genomics.</i> , 2013, , .		4
769	Improved synthesis of 17 β -hydroxy-16 α -iodo-wortmannin, 17 β -hydroxy-16 α -iodoPX866, and the [131I] analogue as useful PET tracers for PI3-kinase. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 5182-5187.	1.4	4
770	Investigating New Therapeutic Strategies Targeting Hyperinsulinemia's Mitogenic Effects in a Female Mouse Breast Cancer Model. <i>Endocrinology</i> , 2013, 154, 1701-1710.	1.4	30
771	Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells. <i>Frontiers in Oncology</i> , 2013, 3, 85.	1.3	96
772	Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in <i>vitro</i> and in <i>vivo</i> . <i>European Journal of Medicinal Chemistry</i> , 2013, 67, 243-251.	2.6	44
773	Phosphatidylinositol 3,4,5-trisphosphate: Tool of choice for class I PI3-kinases. <i>BioEssays</i> , 2013, 35, 602-611.	1.2	38
774	BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies. <i>International Reviews of Immunology</i> , 2013, 32, 358-376.	1.5	42
775	Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling. <i>BMC Cancer</i> , 2013, 13, 227.	1.1	13
776	AEG-1/MTDH/LYRIC. <i>Advances in Cancer Research</i> , 2013, 120, 75-111.	1.9	87
777	Network nonlinearities in drug treatment. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2013, 5, 85-94.	2.2	7
778	<i>Diagnostic Pathology of Pleuropulmonary Neoplasia.</i> , 2013, , .		8
779	LPS-Stimulating Astrocyte-Conditioned Medium Causes Neuronal Apoptosis Via Increasing CDK1p58 Expression in PC12 Cells Through Downregulating AKT Pathway. <i>Cellular and Molecular Neurobiology</i> , 2013, 33, 779-787.	1.7	9
780	Mitochondrial fission-fusion as an emerging key regulator of cell proliferation and differentiation. <i>BioEssays</i> , 2013, 35, 955-964.	1.2	126
781	PTEN/PI3K and MAPK signaling in protection and pathology following CNS injuries. <i>Frontiers in Biology</i> , 2013, 8, 421-433.	0.7	35
782	<i>Immune Homeostasis.</i> <i>Methods in Molecular Biology</i> , 2013, , .	0.4	2
783	Role of Phosphatidylinositol 3,4,5-Trisphosphate in Cell Signaling. <i>Advances in Experimental Medicine and Biology</i> , 2013, 991, 105-139.	0.8	36

#	ARTICLE	IF	CITATIONS
784	Lipid-mediated Protein Signaling. <i>Advances in Experimental Medicine and Biology</i> , 2013, , .	0.8	11
785	Abnormal expression of PI3K isoforms in patients with tobacco-related oral squamous cell carcinoma. <i>Clinica Chimica Acta</i> , 2013, 416, 100-106.	0.5	10
786	PIK3R1 Mutations Cause Syndromic Insulin Resistance with Lipoatrophy. <i>American Journal of Human Genetics</i> , 2013, 93, 141-149.	2.6	162
787	Germline PIK3CA and AKT1 Mutations in Cowden and Cowden-like Syndromes. <i>American Journal of Human Genetics</i> , 2013, 92, 76-80.	2.6	174
788	Phospho-mTOR: A novel target in regulation of renal lipid metabolism abnormality of diabetes. <i>Experimental Cell Research</i> , 2013, 319, 2296-2306.	1.2	37
789	The mTOR pathway negatively controls ATM by up-regulating miRNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11869-11874.	3.3	43
790	Discovery of N-[5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl]acetamide (TASPO415914) as an orally potent phosphoinositide 3-kinase β inhibitor for the treatment of inflammatory diseases. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7578-7583.	1.4	20
791	Supramolecular Nanoparticles That Target Phosphoinositide-3-Kinase Overcome Insulin Resistance and Exert Pronounced Antitumor Efficacy. <i>Cancer Research</i> , 2013, 73, 6987-6997.	0.4	17
792	Novel approaches to inhibitor design for the p110 β phosphoinositide 3-kinase. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 149-153.	4.0	11
793	Activation of PDK-1 maintains mouse embryonic stem cell self-renewal in a PKB-dependent manner. <i>Oncogene</i> , 2013, 32, 5397-5408.	2.6	17
795	Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19426-19431.	3.3	51
796	3D-QSAR and docking studies of 3-Pyridine heterocyclic derivatives as potent PI3K/mTOR inhibitors. <i>Journal of Molecular Structure</i> , 2013, 1054-1055, 107-116.	1.8	8
797	NADPH oxidase subunit p22 phox-mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 3375-3385.	1.9	39
798	mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 β Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer. <i>Science Translational Medicine</i> , 2013, 5, 196ra99.	5.8	251
799	Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. <i>Journal of Hematology and Oncology</i> , 2013, 6, 88.	6.9	211
801	Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases. <i>SpringerPlus</i> , 2013, 2, 464.	1.2	12
802	Histone acetyltransferase PCAF Up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating AKT signaling. <i>Molecular Cancer</i> , 2013, 12, 96.	7.9	41
803	Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2013, 33, 845-851.	1.0	4

#	ARTICLE	IF	CITATIONS
804	Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma. Biomarker Research, 2013, 1, 30.	2.8	11
805	PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Letters, 2013, 335, 1-8.	3.2	65
806	Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treatment Reviews, 2013, 39, 313-320.	3.4	81
807	Biomarkers in Oncology. , 2013, , .		1
808	Ammonia-induced Na,K-ATPase/ouabain-mediated EGF receptor transactivation, MAPK/ERK and PI3K/AKT signaling and ROS formation cause astrocyte swelling. Neurochemistry International, 2013, 63, 610-625.	1.9	54
810	Correlation of Breast Cancer Axillary Lymph Node Metastases With Stem Cell Mutations. JAMA Surgery, 2013, 148, 873.	2.2	17
811	The novel phosphoinositide 3-kinase mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. International Journal of Cancer, 2013, 133, 505-513.	2.3	28
812	PI3Ks and small GTPases in neutrophil migration: Two sides of the same coin. Molecular Immunology, 2013, 55, 83-86.	1.0	23
813	Suppression of Inflammatory Responses during Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis Is Regulated by AKT3 Signaling. Journal of Immunology, 2013, 190, 1528-1539.	0.4	39
814	Initial testing (stage 1) of the phosphatidylinositol 3 kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 791-798.	0.8	19
815	Molecular Pathology of Lung Cancer. , 2013, , 443-459.		0
816	Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy. Cancer Research, 2013, 73, 1621-1634.	0.4	88
817	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nature Reviews Clinical Oncology, 2013, 10, 14-26.	12.5	281
818	The PI3K, Metabolic, and Autophagy Networks: Interactive Partners in Cellular Health and Disease. Annual Review of Pharmacology and Toxicology, 2013, 53, 89-106.	4.2	112
819	Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Medicinal Chemistry Letters, 2013, 4, 91-97.	1.3	54
820	Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology, 2013, 10, 143-153.	12.5	694
821	Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?. Drug Resistance Updates, 2013, 16, 68-72.	6.5	20
822	Neferine induces reactive oxygen species mediated intrinsic pathway of apoptosis in HepG2 cells. Food Chemistry, 2013, 136, 659-667.	4.2	81

#	ARTICLE	IF	CITATIONS
823	PTEN Deficiency Contributes to the Development and Progression of Head and Neck Cancer. <i>Neoplasia</i> , 2013, 15, 461-471.	2.3	111
824	Major signaling pathways in intestinal stem cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 2410-2426.	1.1	53
825	Characterization of fragmented 3-phosphoinositide-dependent protein kinase-1 (PDK1) by phosphosite-specific antibodies. <i>Life Sciences</i> , 2013, 93, 700-706.	2.0	7
826	The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma. <i>Experimental and Molecular Pathology</i> , 2013, 95, 270-275.	0.9	17
827	Phospho-GSK-3 β is involved in the high-glucose-mediated lipid deposition in renal tubular cells in diabetes. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 2066-2075.	1.2	23
828	Methanol extract from the stem of <i>Cotinus coggygia</i> Scop., and its major bioactive phytochemical constituent myricetin modulate pyrogallol-induced DNA damage and liver injury. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2013, 755, 81-89.	0.9	49
829	The mechanisms responsible for exercise intolerance in early-stage breast cancer: What role does chemotherapy play?. <i>Hong Kong Physiotherapy Journal</i> , 2013, 31, 2-11.	0.3	5
830	Dietary supplementation with resveratrol and/or docosahexaenoic acid alters hippocampal gene expression in adult C57Bl/6 mice. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 1735-1740.	1.9	16
831	Lead optimization of a dihydropyrrlopyrimidine inhibitor against phosphoinositide 3-kinase (PI3K) to improve the phenol glucuronic acid conjugation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 673-678.	1.0	16
832	Activation of the mTOR pathway by the amino acid l-leucine in the 5q- syndrome and other ribosomopathies. <i>Advances in Biological Regulation</i> , 2013, 53, 8-17.	1.4	33
833	Head and neck cancer: from anatomy to biology. <i>International Journal of Cancer</i> , 2013, 133, 2013-2023.	2.3	130
834	Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells. <i>Annual Review of Immunology</i> , 2013, 31, 675-704.	9.5	349
835	Epigenetic methylations and their connections with metabolism. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 1495-1508.	2.4	30
836	Class IA PI3K p110 β Subunit Promotes Autophagy through Rab5 Small GTPase in Response to Growth Factor Limitation. <i>Molecular Cell</i> , 2013, 50, 29-42.	4.5	112
837	Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. <i>International Journal of Molecular Sciences</i> , 2013, 14, 3874-3900.	1.8	40
838	Real-Time Quantitative (RQ-)PCR Approach to Quantify the Contribution of Proliferation to B Lymphocyte Homeostasis. <i>Methods in Molecular Biology</i> , 2013, 979, 133-145.	0.4	3
839	Biology of Renal Cell Carcinoma (Vascular Endothelial Growth Factor, Mammalian Target of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102 T		
840	Signaling pathways that control mRNA turnover. <i>Cellular Signalling</i> , 2013, 25, 1699-1710.	1.7	27

#	ARTICLE	IF	CITATIONS
841	Design, synthesis and biological evaluation of novel aliphatic amido/sulfonamido-quaternary ammonium salts as antitumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 788-794.	1.4	6
842	Cross-talk between GPER and growth factor signaling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 137, 50-56.	1.2	73
843	Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2787-2792.	1.0	22
844	Cell survival and metastasis regulation by Akt signaling in colorectal cancer. <i>Cellular Signalling</i> , 2013, 25, 1711-1719.	1.7	137
845	Wnt4 inhibits cell motility induced by oncogenic Ras. <i>Oncogene</i> , 2013, 32, 4110-4119.	2.6	17
846	RACK1 promotes the proliferation, migration and invasion capacity of mouse hepatocellular carcinoma cell line in vitro probably by PI3K/Rac1 signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 313-319.	2.5	39
847	c-MYC overexpression overrides TAK1 dependency in efficient tumorigenicity of AKT-transformed cells. <i>Cancer Letters</i> , 2013, 336, 290-298.	3.2	3
848	Redox regulation of protein kinases. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2013, 48, 332-356.	2.3	132
849	Inhibition of 72 kDa inositol polyphosphate 5-phosphatase E improves insulin signal transduction in diet-induced obesity. <i>Journal of Endocrinology</i> , 2013, 217, 131-140.	1.2	8
850	YB-1: oncoprotein, prognostic marker and therapeutic target?. <i>Biochemical Journal</i> , 2013, 449, 11-23.	1.7	180
851	SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway. <i>Cancer Science</i> , 2013, 104, 810-816.	1.7	67
852	Resolution of inflammation: Mechanisms and opportunity for drug development. , 2013, 139, 189-212.		183
853	mVps34 Deletion in Podocytes Causes Glomerulosclerosis by Disrupting Intracellular Vesicle Trafficking. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 198-207.	3.0	72
854	Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1023-1040.	1.9	32
855	Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. <i>Biochemical Journal</i> , 2013, 452, 499-508.	1.7	141
856	Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4652-4656.	1.0	7
857	Insulin receptor substrate-1 (IRS-1) forms a ribonucleoprotein complex associated with polysomes. <i>FEBS Letters</i> , 2013, 587, 2319-2324.	1.3	11
858	Molecular Mechanisms of Childhood Overgrowth. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2013, 163, 71-75.	0.7	43

#	ARTICLE	IF	CITATIONS
859	SHORT Syndrome with Partial Lipodystrophy Due to Impaired Phosphatidylinositol 3 Kinase Signaling. <i>American Journal of Human Genetics</i> , 2013, 93, 150-157.	2.6	117
860	Lysophosphatidic acid: Chemical signature of neuropathic pain. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013, 1831, 61-73.	1.2	81
861	HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. <i>Cancer Letters</i> , 2013, 328, 152-159.	3.2	42
862	Current Development of Acupuncture Research in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2013, 111, 141-158.	0.9	25
863	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 921-936.	1.5	15
864	Targeted inhibition of phosphatidylinositol 3-kinase p110 β , but not p110 α , enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 509-520.	2.2	25
865	Divergent Modification of Low-Dose 56Fe-Particle and Proton Radiation on Skeletal Muscle. <i>Radiation Research</i> , 2013, 180, 455.	0.7	8
866	NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 665-673.	0.7	21
867	Dissecting Pin1 and phospho ϵ pRb regulation. <i>Journal of Cellular Physiology</i> , 2013, 228, 73-77.	2.0	19
868	PAQR3 Modulates Insulin Signaling by Shunting Phosphoinositide 3-Kinase p110 β to the Golgi Apparatus. <i>Diabetes</i> , 2013, 62, 444-456.	0.3	52
869	Thioredoxin and Thioredoxin Target Proteins: From Molecular Mechanisms to Functional Significance. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 1165-1207.	2.5	311
870	Flotillins as regulators of ErbB2 levels in breast cancer. <i>Oncogene</i> , 2013, 32, 3443-3451.	2.6	63
872	Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: Correlation with clinicopathological criteria. <i>Oncology Reports</i> , 2013, 29, 1043-1052.	1.2	33
874	Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients. <i>Cancer Biology and Therapy</i> , 2013, 14, 888-896.	1.5	23
875	Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models. <i>Journal of Neurosurgery</i> , 2013, 118, 838-845.	0.9	5
876	Antitumor Effect of Everolimus in a Patient with Type 3 Gastric Neuroendocrine Tumor. <i>Onkologie</i> , 2013, 36, 1-1.	1.1	3
877	Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2688-2698.	3.2	76
878	Signal transduction mechanisms for autocrine/paracrine regulation of somatotactin-1 β secretion and synthesis in carp pituitary cells by somatotactin-1 α and -1 β . <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E176-E186.	1.8	30

#	ARTICLE	IF	CITATIONS
879	AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV. <i>Frontiers in Immunology</i> , 2012, 3, 401.	2.2	104
880	The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 8213-8227.	1.8	153
881	p55PIK Transcriptionally Activated by MZF1 Promotes Colorectal Cancer Cell Proliferation. <i>BioMed Research International</i> , 2013, 2013, 1-10.	0.9	38
882	p110 β PI3 kinase pathway: emerging roles in cancer. <i>Frontiers in Oncology</i> , 2013, 3, 40.	1.3	52
883	Mechanisms of Omega-3 Polyunsaturated Fatty Acids in Prostate Cancer Prevention. <i>BioMed Research International</i> , 2013, 2013, 1-10.	0.9	75
884	Two-Tiered Control of Epithelial Growth and Autophagy by the Insulin Receptor and the Ret-Like Receptor, Stitche. <i>PLoS Biology</i> , 2013, 11, e1001612.	2.6	22
885	Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. <i>Prostate Cancer</i> , 2013, 2013, 1-23.	0.4	48
886	Radioresistant Cancer Cells Can Be Conditioned to Enter Senescence by mTOR Inhibition. <i>Cancer Research</i> , 2013, 73, 4267-4277.	0.4	55
887	Conditional Loss of ErbB3 Delays Mammary Gland Hyperplasia Induced by Mutant <i>PIK3CA</i> without Affecting Mammary Tumor Latency, Gene Expression, or Signaling. <i>Cancer Research</i> , 2013, 73, 4075-4085.	0.4	22
888	TREM-2 Promotes Host Resistance Against <i>Pseudomonas aeruginosa</i> Infection by Suppressing Corneal Inflammation via a PI3K/Akt Signaling Pathway. , 2013, 54, 3451.		59
889	PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival. <i>Clinical Cancer Research</i> , 2013, 19, 6450-6460.	3.2	17
890	<i>Pten</i> -Null Tumors Cohabiting the Same Lung Display Differential AKT Activation and Sensitivity to Dietary Restriction. <i>Cancer Discovery</i> , 2013, 3, 908-921.	7.7	36
891	Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. <i>Experimental Biology and Medicine</i> , 2013, 238, 1082-1094.	1.1	23
892	Biomarkers in precision therapy in colorectal cancer. <i>Gastroenterology Report</i> , 2013, 1, 166-183.	0.6	86
893	Major Signaling Pathways Involved in Breast Cancer. , 2013, , 47-64.		3
894	PKB/Akt-Dependent Regulation of Cell Motility. <i>Journal of the National Cancer Institute</i> , 2013, 105, 393-404.	3.0	220
895	Insulin and the Lung: Connecting Asthma and Metabolic Syndrome. <i>Journal of Allergy</i> , 2013, 2013, 1-8.	0.7	62
896	<i>PIK3CA</i> Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 2451-2459.	3.2	83

#	ARTICLE	IF	CITATIONS
897	Effects of Zileuton on Airway Smooth Muscle Remodeling after Repeated Allergen Challenge in Brown Norway Rats. <i>Respiration</i> , 2013, 86, 421-429.	1.2	11
898	Pertuzumab: new hope for patients with HER2-positive breast cancer. <i>Annals of Oncology</i> , 2013, 24, 273-282.	0.6	128
899	Megalencephaly Syndromes and Activating Mutations in the PI3K/ÅAKT Pathway: MPPH and MCAP. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2013, 163, 122-130.	0.7	139
900	CoÅtargeting the PI3K/ÅmTOR/Å and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1385-1396.	1.6	96
901	Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1410-1414.	1.6	5
902	LongÅterm p110Å PI3K inactivation exerts a beneficial effect onÅ metabolism. <i>EMBO Molecular Medicine</i> , 2013, 5, 563-571.	3.3	84
903	BioactiveÅrich extracts of persimmon, but not nettle, Å <i>Sideritis</i> Å, dill or kale, increase Åscp>eNOS/Å activation and Åscp>NO/Å bioavailability and decrease endothelinÅ1 secretion by human vascular endothelial cells. <i>Journal of the Science of Food and Agriculture</i> , 2013, 93, 3574-3580.	1.7	11
904	Intracellular signalling during female gametogenesis. <i>Molecular Human Reproduction</i> , 2013, 19, 265-278.	1.3	56
905	Perifosine Å“ a new option in treatment of acute myeloid leukemia?. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1315-1327.	1.9	13
906	Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2569-2574.	3.3	290
907	New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR PathwayÅ“The Devil Is in the Details. <i>Clinical Cancer Research</i> , 2013, 19, 5264-5274.	3.2	51
908	Transition from Heterotypic to Homotypic PDK1 Homodimerization Is Essential for TCR-Mediated NF-ÅB Activation. <i>Journal of Immunology</i> , 2013, 190, 4508-4515.	0.4	16
909	Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. <i>Cell Cycle</i> , 2013, 12, 1058-1070.	1.3	36
910	Phosphatidylinositol 5-phosphate 4-kinase (PIP4K) regulates TOR signaling and cell growth during Å <i>Drosophila</i> Å development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5963-5968.	3.3	66
911	Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2013, 27, 586-594.	3.3	92
912	FBXL2- and PTPL1-mediated degradation of p110-free p85Å2 regulatory subunit controls the PI(3)K signallingÅcascade. <i>Nature Cell Biology</i> , 2013, 15, 472-480.	4.6	98
913	An Orthosteric Inhibitor of the RASÅ“SOS Interaction. <i>The Enzymes</i> , 2013, 34 Pt. B, 25-39.	0.7	15
914	Putting the Rit in cellular resistance. <i>Communicative and Integrative Biology</i> , 2013, 6, e22297.	0.6	3

#	ARTICLE	IF	CITATIONS
915	Transcriptional regulation of lipogenesis and its contribution to hepatosteatosis. <i>Clinical Lipidology</i> , 2013, 8, 165-168.	0.4	2
916	Loss of Phosphoinositide 3-Kinase p110 β is Protective in the Acute Phase but Detrimental in the Resolution Phase of Hapten-Induced Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 489-500.	0.9	3
917	FKBP5 genetic variation. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 156-166.	0.7	54
918	Four MicroRNAs Promote Prostate Cell Proliferation with Regulation of PTEN and Its Downstream Signals In Vitro. <i>PLoS ONE</i> , 2013, 8, e75885.	1.1	93
919	Stage-dependent expression of PI3K/Akt-pathway genes in neuroblastoma. <i>International Journal of Oncology</i> , 2013, 42, 609-616.	1.4	19
920	Analgesic-antitumor peptide induces apoptosis and inhibits the proliferation of SW480 human colon cancer cells. <i>Oncology Letters</i> , 2013, 5, 483-488.	0.8	31
921	Imidacloprid, a neonicotinoid insecticide, induces insulin resistance. <i>Journal of Toxicological Sciences</i> , 2013, 38, 655-660.	0.7	39
922	AKT-independent PI3-K signaling in cancer – emerging role for SGK3. <i>Cancer Management and Research</i> , 2013, 5, 281.	0.9	73
923	The genetics and biology of KRAS in lung cancer. <i>Chinese Journal of Cancer</i> , 2013, 32, 63-70.	4.9	76
924	Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.8	14
925	Prostate Cancer Progression to Androgen Independent Disease: The Role of the PI3K/AKT Pathway. , 0, , .		0
926	ERG Transcriptional Networks in Primary Acute Leukemia Cells Implicate a Role for ERG in Deregulated Kinase Signaling. <i>PLoS ONE</i> , 2013, 8, e52872.	1.1	13
927	Conditional Deletion of Pten Leads to Defects in Nerve Innervation and Neuronal Survival in Inner Ear Development. <i>PLoS ONE</i> , 2013, 8, e55609.	1.1	14
928	In Silico Modeling of Itk Activation Kinetics in Thymocytes Suggests Competing Positive and Negative IP4 Mediated Feedbacks Increase Robustness. <i>PLoS ONE</i> , 2013, 8, e73937.	1.1	8
929	Genome-Wide Analysis of the Phosphoinositide Kinome from Two Ciliates Reveals Novel Evolutionary Links for Phosphoinositide Kinases in Eukaryotic Cells. <i>PLoS ONE</i> , 2013, 8, e78848.	1.1	10
930	Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data. <i>PLoS ONE</i> , 2013, 8, e67980.	1.1	27
931	HIV-1 Tat Promotes Kaposi's Sarcoma-Associated Herpesvirus (KSHV) vIL-6-Induced Angiogenesis and Tumorigenesis by Regulating PI3K/PTEN/AKT/GSK-3 β Signaling Pathway. <i>PLoS ONE</i> , 2013, 8, e53145.	1.1	93
932	Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus. <i>Anais Brasileiros De Dermatologia</i> , 2013, 88, 36-38.	0.5	9

#	ARTICLE	IF	CITATIONS
933	Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells. <i>Current Medicinal Chemistry</i> , 2013, 20, 1923-1945.	1.2	86
934	The normal human ovary part I: reproductive and endocrine functions. , 0, , 1-36.		1
935	Targeting the PI3K-AKT-mTOR signaling network in cancer. <i>Chinese Journal of Cancer</i> , 2013, 32, 253-265.	4.9	173
936	PI3K. , 0, , 218-230.		0
938	Apoptosis and Clearance of the Secretory Mammary Epithelium. , 0, , .		1
939	Glutamate Signaling in Human Cancers. , 0, , .		0
940	Anticancer Compound Plumbagin and Its Molecular Targets: A Structural Insight into the Inhibitory Mechanisms Using Computational Approaches. <i>PLoS ONE</i> , 2014, 9, e87309.	1.1	56
941	PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup. <i>PLoS ONE</i> , 2014, 9, e88291.	1.1	126
942	Phosphoinositide-3 Kinase Inhibition Modulates Responses to Rhinovirus by Mechanisms that Are Predominantly Independent of Autophagy. <i>PLoS ONE</i> , 2014, 9, e116055.	1.1	6
943	Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer. <i>Scientific World Journal</i> , The, 2014, 2014, 1-9.	0.8	56
944	Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance. <i>Molecules</i> , 2014, 19, 14304-14315.	1.7	66
945	PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Theranostics</i> , 2014, 4, 336-365.	4.6	78
946	Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents. <i>Recent Patents on CNS Drug Discovery</i> , 2014, 9, 2-12.	0.9	12
948	The PI3k inhibitors: new hopes in the battle against advanced NSCLC. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 259.	3.0	6
949	FKBP5 (FK506 binding protein 5). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2014, , .	0.1	0
950	PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. <i>Asian Journal of Andrology</i> , 2014, 16, 378.	0.8	217
951	Classes of phosphoinositide 3-kinases at a glance. <i>Journal of Cell Science</i> , 2014, 127, 923-928.	1.2	278
952	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. <i>Cancer Research</i> , 2014, 74, 4458-4469.	0.4	63

#	ARTICLE	IF	CITATIONS
953	Role of class III phosphatidylinositol 3-kinase during programmed nuclear death of <i>Tetrahymena thermophila</i> . <i>Autophagy</i> , 2014, 10, 209-225.	4.3	16
954	Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 489-500.	1.9	3
955	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. <i>Pharmacogenomics</i> , 2014, 15, 1701-1715.	0.6	4
956	Selective and potent small-molecule inhibitors of PI3Ks. <i>Future Medicinal Chemistry</i> , 2014, 6, 737-756.	1.1	12
957	Exploring the role of two interacting phosphoinositide 3-kinases of <i>Haemonchus contortus</i> . <i>Parasites and Vectors</i> , 2014, 7, 498.	1.0	13
958	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 233-245.	3.2	142
959	Phosphorylated AKT inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular carcinoma by preventing the translocation of DRAM to mitochondria. <i>Cell Death and Disease</i> , 2014, 5, e1078-e1078.	2.7	34
960	A phosphatase-independent gain-of-function mutation in PTEN triggers aberrant cell growth in astrocytes through an autocrine IGF-1 loop. <i>Oncogene</i> , 2014, 33, 4114-4122.	2.6	12
961	Exploring Developmental and Physiological Functions of Fatty Acid and Lipid Variants Through Worm and Fly Genetics. <i>Annual Review of Genetics</i> , 2014, 48, 119-148.	3.2	24
962	Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells. <i>Bioscience Reports</i> , 2014, 34, .	1.1	1
963	The Inhibitory Effect of PIK-75 on Inflammatory Mediator Response Induced by Hydrogen Peroxide in Feline Esophageal Epithelial Cells. <i>Mediators of Inflammation</i> , 2014, 2014, 1-9.	1.4	1
964	Functions and Regulation of the PTEN Gene in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 326.	1.3	88
965	Acupuncture Mechanism and Redox Equilibrium. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-7.	0.5	16
966	Inpp5e increases the Rab5 association and phosphatidylinositol 3-phosphate accumulation at the phagosome through an interaction with Rab20. <i>Biochemical Journal</i> , 2014, 464, 365-375.	1.7	19
967	“Druggable” alterations detected by Ion Torrent in metastatic colorectal cancer patients. <i>Oncology Letters</i> , 2014, 7, 1761-1766.	0.8	10
968	Switching Off Key Signaling Survival Molecules to Switch On the Resolution of Inflammation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	1.4	25
969	Role of miRNA <i>Let-7</i> and Its Major Targets in Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	45
970	Insulin Receptor Substrate-1 Associates with Small Nucleolar RNA Which Contributes to Ribosome Biogenesis. <i>Frontiers in Endocrinology</i> , 2014, 5, 24.	1.5	11

#	ARTICLE	IF	CITATIONS
971	MDA-9/syntenin is a key regulator of glioma pathogenesis. <i>Neuro-Oncology</i> , 2014, 16, 50-61.	0.6	51
972	Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. <i>Breast Cancer Research</i> , 2014, 16, 434.	2.2	157
973	A Rapid Cytoplasmic Mechanism for PI3 Kinase Regulation by the Nuclear Thyroid Hormone Receptor, TR β , and Genetic Evidence for Its Role in the Maturation of Mouse Hippocampal Synapses In Vivo. <i>Endocrinology</i> , 2014, 155, 3713-3724.	1.4	73
974	Analysis, Regulation, and Roles of Endosomal Phosphoinositides. <i>Methods in Enzymology</i> , 2014, 535, 75-91.	0.4	3
975	Role of the Mammalian Target of Rapamycin (mTOR) Complexes in Pancreatic β -Cell Mass Regulation. <i>Vitamins and Hormones</i> , 2014, 95, 425-469.	0.7	16
976	What is the potential of using PI3K inhibitors in the management of breast cancer in the clinic?. <i>Breast Cancer Management</i> , 2014, 3, 345-357.	0.2	0
977	Simultaneous chemical and electrical stimulation on lung cancer cells using a multichannel-dual-electric-field chip. <i>Biomicrofluidics</i> , 2014, 8, 052007.	1.2	14
978	Targeting the PI3K/Akt/mTOR Pathway in Ocular Neovascularization. <i>Advances in Experimental Medicine and Biology</i> , 2014, 801, 805-811.	0.8	35
979	The activation of the adaptive immune system: Cross-talk between antigen-presenting cells, T cells and B cells. <i>Immunology Letters</i> , 2014, 162, 103-112.	1.1	110
980	Akt Signaling Leads to Stem Cell Activation and Promotes Tumor Development in Epidermis. <i>Stem Cells</i> , 2014, 32, 1917-1928.	1.4	30
981	Smarter drugs emerging in pancreatic cancer therapy. <i>Annals of Oncology</i> , 2014, 25, 1260-1270.	0.6	72
982	Phosphoinositide-3-kinase inhibitors: Evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5630-5634.	1.0	4
983	Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 543-555.	1.1	27
984	Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2014, 105, 347-353.	1.7	81
985	Bmi-1-shRNA Inhibits the Proliferation of Lung Adenocarcinoma Cells by Blocking the G1/S Phase Through Decreasing Cyclin D1 and Increasing p21/p27 Levels. <i>Nucleic Acid Therapeutics</i> , 2014, 24, 210-216.	2.0	20
986	The PTEN inhibitor bisperoxovanadium enhances myelination by amplifying IGF1 signaling in rat and human oligodendrocyte progenitors. <i>Glia</i> , 2014, 62, 64-77.	2.5	40
987	The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 154-166.	1.4	378
988	In Vivo Modeling of Malignant Glioma. <i>Advances in Cancer Research</i> , 2014, 121, 261-330.	1.9	21

#	ARTICLE	IF	CITATIONS
989	Ganitumab (AMG 479) Inhibits IGF-IIâ€œDependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 2947-2958.	3.2	41
990	Modification of Sialylation Mediates the Invasive Properties and Chemosensitivity of Human Hepatocellular Carcinoma. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 520-536.	2.5	61
991	PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 1067-1078.	0.8	189
992	Phosphoinositide 3-kinase inhibitors in lymphoma. <i>Current Opinion in Oncology</i> , 2014, 26, 469-475.	1.1	34
993	Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, 316-323.	0.5	44
994	HER2 Expression and PI3K-Akt Pathway Alterations in Gastric Cancer. <i>Digestion</i> , 2014, 89, 12-17.	1.2	62
995	Advances in subunits of PI3K class I in cancer. <i>Pathology</i> , 2014, 46, 169-176.	0.3	15
996	Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2014, 20, 1656-1665.	3.2	58
997	AKT as a therapeutic target in multiple myeloma. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 897-915.	1.5	44
998	A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition. <i>Cancer Research</i> , 2014, 74, 15-23.	0.4	57
999	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5908-5917.	3.2	38
1000	Signaling pathways influencing tumor microenvironment and their exploitation for targeted drug delivery. <i>Nanotechnology Reviews</i> , 2014, 3, .	2.6	14
1001	Metabolic Influences That Regulate Dendritic Cell Function in Tumors. <i>Frontiers in Immunology</i> , 2014, 5, 24.	2.2	67
1002	PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. <i>Breast Cancer Research</i> , 2014, 16, 201.	2.2	94
1003	PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 6395-6400.	3.3	66
1004	The Phosphatidylinositol 3-Kinase (PI3K) Isoform Dependence of Tumor Formation Is Determined by the Genetic Mode of PI3K Pathway Activation Rather than by Tissue Type. <i>Journal of Virology</i> , 2014, 88, 10673-10679.	1.5	10
1005	Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2014, 191, 227-234.	0.2	60
1006	Combination of 2-methoxy-3-phenylsulfonfylaminobenzamide and 2-aminobenzothiazole to discover novel anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 3739-3748.	1.4	26

#	ARTICLE	IF	CITATIONS
1007	Rigosertib Is a More Effective Radiosensitizer Than Cisplatin in Concurrent Chemoradiation Treatment of Cervical Carcinoma, In Vitro and In Vivo. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1180-1187.	0.4	24
1008	Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treatment Reviews, 2014, 40, 109-117.	3.4	152
1009	PKD1 controls upstream PI3K expression and PIP3 generation. Oncogene, 2014, 33, 3043-3053.	2.6	30
1010	Discovery of Selective Small Molecule Type III Phosphatidylinositol 4-Kinase Alpha (PI4KIII α) Inhibitors as Anti Hepatitis C (HCV) Agents. Journal of Medicinal Chemistry, 2014, 57, 2091-2106.	2.9	56
1011	Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma. Journal of Translational Medicine, 2014, 12, 10.	1.8	40
1012	Activation of PI3K α by physiological effectors and by oncogenic mutations: structural and dynamic effects. Biophysical Reviews, 2014, 6, 89-95.	1.5	29
1013	Cellular and molecular interactions of phosphoinositides and peripheral proteins. Chemistry and Physics of Lipids, 2014, 182, 3-18.	1.5	95
1014	Novel insights into G protein and G protein-coupled receptor signaling in cancer. Current Opinion in Cell Biology, 2014, 27, 126-135.	2.6	252
1015	The relationship between mTOR signalling pathway and recombinant antibody productivity in CHO cell lines. BMC Biotechnology, 2014, 14, 15.	1.7	19
1016	Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook. BioDrugs, 2014, 28, 373-381.	2.2	14
1017	Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. BMC Medical Genomics, 2014, 7, 4.	0.7	59
1018	Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 525-538.	1.1	31
1019	Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. Journal of Experimental and Clinical Cancer Research, 2014, 33, 15.	3.5	33
1021	Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 δ , for relapsed/refractory chronic lymphocytic leukemia. Blood, 2014, 123, 3390-3397.	0.6	562
1022	Direction pathway analysis of large-scale proteomics data reveals novel features of the insulin action pathway. Bioinformatics, 2014, 30, 808-814.	1.8	29
1023	Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 790-793.	1.0	7
1024	Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors. Molecular Cancer Therapeutics, 2014, 13, 1021-1031.	1.9	375
1025	Imidazo[1,2-a]pyrazine inhibitors of phosphoinositide 3-kinase alpha (PI3K α): 3D-QSAR analysis utilizing the Hybrid Monte Carlo algorithm to refine receptor-ligand complexes for molecular alignment. SAR and QSAR in Environmental Research, 2014, 25, 221-247.	1.0	2

#	ARTICLE	IF	CITATIONS
1026	Signaling pathways involved in MDSC regulation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 55-65.	3.3	152
1027	CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition. <i>Biochimie</i> , 2014, 103, 118-125.	1.3	13
1028	NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2014, 19, 895-904.	2.2	30
1029	PTEN action in leukaemia dictated by the tissue microenvironment. <i>Nature</i> , 2014, 510, 402-406.	13.7	40
1030	The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. <i>British Journal of Cancer</i> , 2014, 110, 2887-2895.	2.9	80
1031	The Hippo-YAP signaling pathway and contact inhibition of growth. <i>Journal of Cell Science</i> , 2014, 127, 709-717.	1.2	279
1032	PTEN is a protein tyrosine phosphatase for IRS1. <i>Nature Structural and Molecular Biology</i> , 2014, 21, 522-527.	3.6	116
1033	Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. <i>Trends in Biochemical Sciences</i> , 2014, 39, 268-276.	3.7	206
1034	Long-Term Effects of Nanoparticles on Nutrition and Metabolism. <i>Small</i> , 2014, 10, 3603-3611.	5.2	60
1035	Targeting Akt3 Signaling in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2014, 74, 964-973.	0.4	124
1036	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, 142, 164-175.		648
1037	Regulation of matrix metalloproteinase-1, -3, and -9 in Mycobacterium tuberculosis-dependent respiratory networks by the rapamycin-sensitive PI3K/p70 S6K cascade. <i>FASEB Journal</i> , 2014, 28, 85-93.	0.2	27
1038	New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: Targeted therapy of β -secretase inhibitor resistant T-cell acute lymphoblastic leukemia. <i>Cellular Signalling</i> , 2014, 26, 149-161.	1.7	166
1039	Chemical modulation of glycerolipid signaling and metabolic pathways. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014, 1841, 1060-1084.	1.2	27
1040	PI3K and cancer: lessons, challenges and opportunities. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 140-156.	21.5	1,398
1041	Ndfip1 Is Required for the Development of Pyramidal Neuron Dendrites and Spines in the Neocortex. <i>Cerebral Cortex</i> , 2014, 24, 3289-3300.	1.6	8
1042	SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer. <i>Molecular Cell</i> , 2014, 56, 595-607.	4.5	133
1043	Macrophage PTEN Regulates Expression and Secretion of Arginase I Modulating Innate and Adaptive Immune Responses. <i>Journal of Immunology</i> , 2014, 193, 1717-1727.	0.4	117

#	ARTICLE	IF	CITATIONS
1044	mTOR signaling in tumorigenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 638-654.	3.3	113
1045	<i>Dictyostelium</i> uses ether-linked inositol phospholipids for intracellular signalling. <i>EMBO Journal</i> , 2014, 33, 2188-2200.	3.5	53
1046	Inhibition of pan-class I phosphatidylinositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 425-434.	0.6	41
1047	Metabolomics in cell culture—A strategy to study crucial metabolic pathways in cancer development and the response to treatment. <i>Archives of Biochemistry and Biophysics</i> , 2014, 564, 100-109.	1.4	67
1048	Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3K: 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 9157-9165.	1.5	14
1049	The role of targeted therapy for gastrointestinal tumors. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 875-885.	1.4	27
1050	Nras in melanoma: Targeting the undruggable target. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 107-122.	2.0	67
1051	MicroRNA and signaling pathways in gastric cancer. <i>Cancer Gene Therapy</i> , 2014, 21, 305-316.	2.2	51
1052	Daily Exposure to Di(2-ethylhexyl) Phthalate Alters Estrous Cyclicity and Accelerates Primordial Follicle Recruitment Potentially Via Dysregulation of the Phosphatidylinositol 3-Kinase Signaling Pathway in Adult Mice. <i>Biology of Reproduction</i> , 2014, 90, 136.	1.2	142
1053	Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression. <i>Carcinogenesis</i> , 2014, 35, 2778-2786.	1.3	103
1054	Modulation of autophagy for the treatment of liver diseases. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 965-977.	1.9	30
1055	Vaccine therapies for patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 119, 531-546.	1.4	32
1056	Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1935-1945.	3.2	121
1057	Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K/mTOR Dual Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 613-631.	2.9	71
1058	Inhibition of Akt Phosphorylation Diminishes Mitochondrial Biogenesis Regulators, Tricarboxylic Acid Cycle Activity and Exacerbates Recognition Memory Deficit in Rat Model of Alzheimer's Disease. <i>Cellular and Molecular Neurobiology</i> , 2014, 34, 1223-1233.	1.7	29
1059	CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors. <i>Cancer Cell</i> , 2014, 26, 136-149.	7.7	375
1060	PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. <i>Advances in Biological Regulation</i> , 2014, 56, 66-80.	1.4	77
1061	PTEN. <i>Annual Review of Biochemistry</i> , 2014, 83, 641-669.	5.0	427

#	ARTICLE	IF	CITATIONS
1062	miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. <i>Nature Communications</i> , 2014, 5, 4620.	5.8	57
1063	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. <i>Clinical Cancer Research</i> , 2014, 20, 3133-3145.	3.2	29
1064	Molecular Approaches Toward Targeted Cancer Prevention with Some Food Plants and Their Products: Inflammatory and Other Signal Pathways. <i>Nutrition and Cancer</i> , 2014, 66, 194-205.	0.9	72
1065	Regulation of the pentose phosphate pathway in cancer. <i>Protein and Cell</i> , 2014, 5, 592-602.	4.8	363
1066	Constitutive AKT activation in follicular lymphoma. <i>BMC Cancer</i> , 2014, 14, 565.	1.1	19
1067	Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer. <i>Pharmacological Reviews</i> , 2014, 66, 1033-1079.	7.1	209
1068	Definition of the binding mode of phosphoinositide 3-kinase $\hat{\pm}$ -selective inhibitor A-66S through molecular dynamics simulation. <i>Journal of Molecular Modeling</i> , 2014, 20, 2166.	0.8	7
1069	From Inducing Autophagy to Programmed Cell Death? The PI3K Functional Domain Study of Protein Latcripin-1 from <i>Lentinula edodes</i> C91-3. <i>International Journal of Peptide Research and Therapeutics</i> , 2014, 20, 341-352.	0.9	1
1070	The NS1 Protein: A Multitasking Virulence Factor. <i>Current Topics in Microbiology and Immunology</i> , 2014, 386, 73-107.	0.7	115
1071	Therapeutic targeting of the mTOR signalling pathway in cancer: benefits and limitations. <i>British Journal of Pharmacology</i> , 2014, 171, 3801-3813.	2.7	92
1072	The novel PI3 kinase inhibitor, BAY 806946, impairs melanoma growth <i>in vivo</i> and <i>in vitro</i> . <i>Experimental Dermatology</i> , 2014, 23, 579-584.	1.4	13
1073	Akt Phosphorylation and Regulation of Transketolase Is a Nodal Point for Amino Acid Control of Purine Synthesis. <i>Molecular Cell</i> , 2014, 55, 264-276.	4.5	70
1074	Glucose and glutamine metabolism control by APC and SCF during the G1-to-S phase transition of the cell cycle. <i>Journal of Physiology and Biochemistry</i> , 2014, 70, 569-581.	1.3	22
1075	Exome sequencing identifies a novel mutation in PIK3R1 as the cause of SHORT syndrome. <i>BMC Medical Genetics</i> , 2014, 15, 51.	2.1	34
1076	Towards the clinical implementation of pharmacogenetics in bipolar disorder. <i>BMC Medicine</i> , 2014, 12, 90.	2.3	23
1077	Inhibition of Akt kinase activity suppresses entry and replication of influenza virus. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 891-898.	1.0	65
1078	The links between AKT and two intracellular proteolytic cascades: Ubiquitination and autophagy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 342-352.	3.3	58
1079	Discovery and Optimization of Pyrimidone Indoline Amide PI3K ¹² Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 903-920.	2.9	75

#	ARTICLE	IF	CITATIONS
1080	ST6GalNAcII mediates the invasive properties of breast carcinoma through PI3K/Akt/NF- κ B signaling pathway. <i>IUBMB Life</i> , 2014, 66, 300-308.	1.5	34
1081	The PI3K pathway acting on alternative HIV-1 pre-mRNA splicing. <i>Journal of General Virology</i> , 2014, 95, 1809-1815.	1.3	4
1082	Gene of the month: Interleukin 6 (IL-6). <i>Journal of Clinical Pathology</i> , 2014, 67, 932-937.	1.0	106
1083	Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4538-4541.	1.0	17
1084	Inducible Metabolic Adaptation Promotes Mesenchymal Stem Cell Therapy for Ischemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 870-876.	1.1	50
1085	The role of SDF-1-ECM crosstalk in determining neural stem cell fate. <i>Biomaterials</i> , 2014, 35, 3263-3272.	5.7	27
1086	Hc-daf-2 encodes an insulin-like receptor kinase in the barber's pole worm, <i>Haemonchus contortus</i> , and restores partial dauer regulation. <i>International Journal for Parasitology</i> , 2014, 44, 485-496.	1.3	25
1087	The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 232-247.	3.3	29
1088	Lymphatic vessel abnormalities arising from disorders of Ras signal transduction. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 121-127.	2.3	28
1089	PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[1,4]indene Derivative in Lung Cancer Cells. <i>Translational Oncology</i> , 2014, 7, 256-266.e5.	1.7	1
1090	Dietary resveratrol supplementation normalizes gene expression in the hippocampus of streptozotocin-induced diabetic C57Bl/6 mice. <i>Journal of Nutritional Biochemistry</i> , 2014, 25, 313-318.	1.9	30
1091	SAMP8 mice have altered hippocampal gene expression in long term potentiation, phosphatidylinositol signaling, and endocytosis pathways. <i>Neurobiology of Aging</i> , 2014, 35, 159-168.	1.5	22
1092	Regulation of Cancer Metabolism by Oncogenes and Tumor Suppressors. <i>Methods in Enzymology</i> , 2014, 542, 59-80.	0.4	89
1093	PI3K/AKT signaling pathway and cancer: an updated review. <i>Annals of Medicine</i> , 2014, 46, 372-383.	1.5	887
1094	Recent and current Phase II clinical trials in endometrial cancer: review of the state of art. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 773-792.	1.9	14
1095	Steering tumor progression through the transcriptional response to growth factors and stroma. <i>FEBS Letters</i> , 2014, 588, 2407-2414.	1.3	7
1096	Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition. <i>Cancer Discovery</i> , 2014, 4, 896-904.	7.7	88
1097	Anti-tumor effect of paeonol via regulating NF- κ B, AKT and MAPKs activation: A quick review. <i>Biomedicine and Preventive Nutrition</i> , 2014, 4, 9-14.	0.9	10

#	ARTICLE	IF	CITATIONS
1098	Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene. <i>Oncogene</i> , 2014, 33, 2405-2412.	2.6	20
1099	A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway. <i>International Journal of Oncology</i> , 2014, 45, 771-781.	1.4	12
1100	mTORC2 Phosphorylation of Akt1: A Possible Mechanism for Hydrogen Sulfide-Induced Cardioprotection. <i>PLoS ONE</i> , 2014, 9, e99665.	1.1	31
1102	Significance of AKT in gastric cancer (Review). <i>International Journal of Oncology</i> , 2014, 45, 2187-2192.	1.4	48
1103	Activation of EGFR-PI3K-AKT signaling is required for <i>Mycoplasma hyorhinis</i> -promoted gastric cancer cell migration. <i>Cancer Cell International</i> , 2014, 14, 135.	1.8	37
1104	Anti-apoptotic and apoptotic pathway analysis of arsenic trioxide-induced apoptosis in human gastric cancer SGC-7901 cells. <i>Oncology Reports</i> , 2014, 32, 973-978.	1.2	4
1105	The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer. <i>Clinical Investigation</i> , 2014, 4, 1123-1138.	0.0	0
1106	Design and Synthesis of Novel Quinazoline Derivatives and Their Evaluation as PI3Ks Inhibitors. <i>Chemical and Pharmaceutical Bulletin</i> , 2014, 62, 1166-1172.	0.6	1
1107	Potential role of ATM in hepatocyte endocytosis of ApoE-deficient, ApoB48-containing lipoprotein in ApoE-deficient mice. <i>International Journal of Molecular Medicine</i> , 2014, 33, 462-468.	1.8	5
1108	Behavioral effects of social challenges and genomic mechanisms of social priming: What's testosterone got to do with it?. <i>Environmental Epigenetics</i> , 2014, 60, 791-803.	0.9	15
1109	MEK and PI3K inhibition in solid tumors: rationale and evidence to date. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 170-180.	1.4	105
1110	Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474. <i>Cancer Science</i> , 2015, 106, 171-178.	1.7	12
1111	Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 505-512.	1.4	12
1112	Leptin induced GRP78 expression through the PI3K-mTOR pathway in neuronal cells. <i>Scientific Reports</i> , 2014, 4, 7096.	1.6	42
1113	Myristoylated p110 α Causes Embryonic Death Due to Developmental and Vascular Defects. <i>Open Life Sciences</i> , 2015, 10, 461-478.	0.6	5
1115	A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 2686-2694.	0.6	224
1117	The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells. <i>Cell Death Discovery</i> , 2015, 1, 15044.	2.0	10
1119	Genetic variation in insulin-induced kinase signaling. <i>Molecular Systems Biology</i> , 2015, 11, 820.	3.2	14

#	ARTICLE	IF	CITATIONS
1120	PTEN regulates lung endodermal morphogenesis through MEK/ERK pathway. <i>Developmental Biology</i> , 2015, 408, 56-65.	0.9	9
1121	Metabolic signatures differentiate ovarian from colon cancer cell lines. <i>Journal of Translational Medicine</i> , 2015, 13, 223.	1.8	34
1122	Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 3298-3306.	2.0	32
1123	Evolutionary history of phosphatidylinositol-3-kinases: ancestral origin in eukaryotes and complex duplication patterns. <i>BMC Evolutionary Biology</i> , 2015, 15, 226.	3.2	16
1124	Centipeda minima (Ebushicao) extract inhibits PI3K-Akt-mTOR signaling in nasopharyngeal carcinoma CNE-1 cells. <i>Chinese Medicine</i> , 2015, 10, 26.	1.6	26
1125	Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 1837-1847.	1.2	22
1126	Biology and oncogenicity of the Kaposi sarcoma herpesvirus K1 protein. <i>Reviews in Medical Virology</i> , 2015, 25, 273-285.	3.9	8
1127	MicroRNA-200 promotes lung cancer cell growth through FOG2-independent AKT activation. <i>IUBMB Life</i> , 2015, 67, 720-725.	1.5	26
1128	Follicle Online: an integrated database of follicle assembly, development and ovulation. <i>Database: the Journal of Biological Databases and Curation</i> , 2015, 2015, bav036-bav036.	1.4	11
1130	YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERK and PI3K/Akt Pathways. <i>Journal of Cancer</i> , 2015, 6, 319-326.	1.2	11
1131	A Systematic Review on Antitumor Agents with 1, 3, 5-triazines. , 2015, 5, .		27
1132	MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. <i>Oncotarget</i> , 2015, 6, 3211-3224.	0.8	145
1133	Fat Body Development and its Function in Energy Storage and Nutrient Sensing in <i>Drosophila melanogaster</i> . <i>Journal of Tissue Science & Engineering</i> , 2015, 06, .	0.2	16
1134	Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study. <i>Journal of Breast Cancer</i> , 2015, 18, 378.	0.8	25
1135	Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. <i>Oncotarget</i> , 2015, 6, 24750-24779.	0.8	115
1136	PI3K and AKT: Unfaithful Partners in Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 21138-21152.	1.8	208
1137	Mesenchymal Stem Cell-Mediated Effects of Tumor Support or Suppression. <i>International Journal of Molecular Sciences</i> , 2015, 16, 30015-30033.	1.8	159
1138	The Guareschi Pyridine Scaffold as a Valuable Platform for the Identification of Selective PI3K Inhibitors. <i>Molecules</i> , 2015, 20, 17275-17287.	1.7	5

#	ARTICLE	IF	CITATIONS
1139	Focus on PTEN regulation. <i>Frontiers in Oncology</i> , 2015, 5, 166.	1.3	107
1140	The Expression of CD9 and PIK3CD is Associated with Prognosis of Follicular Lymphoma. <i>Journal of Cancer</i> , 2015, 6, 1222-1229.	1.2	18
1141	Role of Cbl-PI3K Interaction during Skeletal Remodeling in a Murine Model of Bone Repair. <i>PLoS ONE</i> , 2015, 10, e0138194.	1.1	8
1142	Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. <i>PLoS ONE</i> , 2015, 10, e0140479.	1.1	93
1143	The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β -Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt. <i>PLoS ONE</i> , 2015, 10, e0141753.	1.1	22
1144	Identification of Major Signaling Pathways in Prion Disease Progression Using Network Analysis. <i>PLoS ONE</i> , 2015, 10, e0144389.	1.1	7
1145	Variation in the Phosphoinositide 3-Kinase Gamma Gene Affects Plasma HDL-Cholesterol without Modification of Metabolic or Inflammatory Markers. <i>PLoS ONE</i> , 2015, 10, e0144494.	1.1	22
1147	Cross Talks Between Oncoprotein Signaling Networks and Tumor Suppressor p53 in Breast Cancer. <i>Current Cancer Therapy Reviews</i> , 2015, 11, 59-71.	0.2	0
1148	Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma. <i>Current Molecular Medicine</i> , 2015, 15, 82-93.	0.6	62
1149	Protective Effects of the Mushroom <i>Lactarius deterrimus</i> Extract on Systemic Oxidative Stress and Pancreatic Islets in Streptozotocin-Induced Diabetic Rats. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-10.	1.0	22
1150	PTEN Plays an Important Role in Thrombin-Mediated Lung Cancer Cell Functions. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	4
1151	Targeting the PI3K/AKT/mTOR Pathway in Cancer Cells. , 0, , .		7
1153	The Genome-Wide Expression Profile of <i>Saussurea lappa</i> Extract on House Dust Mite-Induced Atopic Dermatitis in Nc/Nga Mice. <i>Molecules and Cells</i> , 2015, 38, 765-772.	1.0	11
1154	Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110 β , for treating relapsed or refractory non-Hodgkin's lymphoma. <i>Oncotarget</i> , 2015, 6, 44049-44056.	0.8	3
1155	Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer. <i>Oncotarget</i> , 2015, 6, 2509-2523.	0.8	69
1156	Signal Transduction in Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a006098-a006098.	2.9	665
1157	Inhibition of 5-Lipoxygenase Selectively Triggers Disruption of c-Myc Signaling in Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2015, 290, 4994-5006.	1.6	50
1158	Identification of PI3K regulatory subunit p55 δ as a novel inhibitor of vascular smooth muscle cell proliferation and neointimal formation. <i>Cardiovascular Research</i> , 2015, 105, 75-85.	1.8	19

#	ARTICLE	IF	CITATIONS
1159	The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1 α Phosphorylation. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1928-1938.	1.9	54
1160	Fascaplysin Induces Caspase Mediated Crosstalk Between Apoptosis and Autophagy Through the Inhibition of PI3K/AKT/mTOR Signaling Cascade in Human Leukemia HL60 Cells. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 985-997.	1.2	54
1161	Design of selective PI3K α inhibitors starting from a promiscuous pan kinase scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2679-2685.	1.0	9
1162	Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015, 15, 395.	1.1	96
1163	Assaying PTEN catalysis in vitro. <i>Methods</i> , 2015, 77-78, 51-57.	1.9	9
1164	PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3 β /CTNNB1 signaling pathway. <i>Scientific Reports</i> , 2015, 5, 8997.	1.6	56
1165	GRPR/PI3K β : Partners in Central Transmission of Itch. <i>Journal of Neuroscience</i> , 2015, 35, 16272-16281.	1.7	23
1166	Regulation of FOXO3 subcellular localization by Kit ligand in the neonatal mouse ovary. <i>Journal of Assisted Reproduction and Genetics</i> , 2015, 32, 1741-1747.	1.2	14
1167	Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 993-1009.	0.9	2
1168	A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches. <i>Journal of Molecular Graphics and Modelling</i> , 2015, 62, 226-234.	1.3	20
1169	Keratoacanthoma of the Lip. <i>Medicine (United States)</i> , 2015, 94, e1552.	0.4	6
1170	Cadmium induces matrix metalloproteinase-9 expression via ROS-dependent EGFR, NF- κ B, and AP-1 pathways in human endothelial cells. <i>Toxicology</i> , 2015, 338, 104-116.	2.0	60
1171	Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7650-7660.	1.4	9
1172	TOR signalling in plants. <i>Biochemical Journal</i> , 2015, 470, 1-14.	1.7	95
1173	Sedanolid induces autophagy through the PI3K, p53 and NF- κ B signaling pathways in human liver cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 2240-2246.	1.4	22
1174	Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage. <i>International Journal of Oncology</i> , 2015, 47, 1103-1110.	1.4	14
1175	Energy metabolism determines the sensitivity of human hepatocellular carcinoma cells to mitochondrial inhibitors and biguanide drugs. <i>Oncology Reports</i> , 2015, 34, 1620-1628.	1.2	27
1177	Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer. <i>Cancer Letters</i> , 2015, 359, 47-56.	3.2	23

#	ARTICLE	IF	CITATIONS
1178	Transcriptional profiling of five isolated size-matched stages of human preantral follicles. <i>Molecular and Cellular Endocrinology</i> , 2015, 401, 189-201.	1.6	38
1179	MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 111.e17-111.e26.	0.8	11
1180	Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2015, 51, 291-298.	0.8	136
1181	Reconstruction of Canine Diffuse Large B-cell Lymphoma Gene Regulatory Network: Detection of Functional Modules and Hub Genes. <i>Journal of Comparative Pathology</i> , 2015, 152, 119-130.	0.1	15
1182	Anticancer Effects of Agents Derived from Fruits and Vegetables Against Stomach Cancer. , 2015, , 309-335.		2
1183	Role of phosphoinositide 3-kinase IA (PI3K-IA) activation in cardioprotection induced by ouabain preconditioning. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 80, 114-125.	0.9	22
1184	Leptin exerts proliferative and anti-apoptotic effects on goose granulosa cells through the PI3K/Akt/mTOR signaling pathway. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 149, 70-79.	1.2	39
1185	The role of the PI3K pathway in colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 18-30.	2.0	96
1186	Sevoflurane Postconditioning Protects Rat Hearts against Ischemia-Reperfusion Injury via the Activation of PI3K/AKT/mTOR Signaling. <i>Scientific Reports</i> , 2014, 4, 7317.	1.6	86
1187	PTEN deletion potentiates invasion of colorectal cancer spheroidal cells through 3D Matrigel. <i>Integrative Biology (United Kingdom)</i> , 2015, 7, 324-334.	0.6	15
1188	PI3-kinase activation is critical for host barrier permissiveness to <i>Listeria monocytogenes</i> . <i>Journal of Experimental Medicine</i> , 2015, 212, 165-183.	4.2	65
1189	Novel benzoxazines as inhibitors of angiogenesis. <i>Investigational New Drugs</i> , 2015, 33, 45-52.	1.2	8
1190	PI3K signalling in inflammation. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 882-897.	1.2	380
1191	The structure of phosphoinositide phosphatases: Insights into substrate specificity and catalysis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 698-710.	1.2	70
1192	Constitutive Activation of Epidermal Growth Factor Receptor Promotes Tumorigenesis of Cr(VI)-transformed Cells through Decreased Reactive Oxygen Species and Apoptosis Resistance Development. <i>Journal of Biological Chemistry</i> , 2015, 290, 2213-2224.	1.6	43
1193	Signaling Via PI3K/FOXO1A Pathway Modulates Formation and Survival of Human Embryonic Stem Cell-Derived Endothelial Cells. <i>Stem Cells and Development</i> , 2015, 24, 869-878.	1.1	18
1194	Development and application of PI3K assays for novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 171-186.	2.5	17
1195	6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine derivatives as selective inhibitors of PI3K. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1231-1240.	1.4	26

#	ARTICLE	IF	CITATIONS
1196	Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction. <i>Tumor Biology</i> , 2015, 36, 2993-2999.	0.8	7
1197	PTEN/PI3K/Akt/VEGF signaling and the cross talk to KRIT1, CCM2, and PDCD10 proteins in cerebral cavernous malformations. <i>Neurosurgical Review</i> , 2015, 38, 229-237.	1.2	30
1198	Attenuation of the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway by <i>Porphyromonas gingivalis</i> Gingipains RgpA, RgpB, and Kgp. <i>Journal of Biological Chemistry</i> , 2015, 290, 5190-5202.	1.6	53
1199	Textbook of Cell Signalling in Cancer. , 2015, , .		6
1200	The involvement of FAK-PI3K-AKT-Rac1 pathway in porcine reproductive and respiratory syndrome virus entry. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 392-398.	1.0	24
1201	Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 434-438.	1.3	34
1202	YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models. <i>Scientific Reports</i> , 2015, 4, 6031.	1.6	31
1203	Phosphatidylinositol 3-Kinase Pathway. , 2015, , 43-54.		0
1204	Phosphatidylinositol 3-Kinase Class II β -Isoform PI3K-C2 β Is Required for Transforming Growth Factor β 2-induced Smad Signaling in Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2015, 290, 6086-6105.	1.6	39
1205	Tumor and Stromal-Based Contributions to Head and Neck Squamous Cell Carcinoma Invasion. <i>Cancers</i> , 2015, 7, 382-406.	1.7	40
1206	Novel Candidate Key Drivers in the Integrative Network of Genes, MicroRNAs, Methylations, and Copy Number Variations in Squamous Cell Lung Carcinoma. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	31
1207	Turning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response. <i>Frontiers in Immunology</i> , 2015, 6, 19.	2.2	379
1208	Synthesis and evaluation of pyrrolotriazine based molecules as PI3 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3142-3146.	1.0	10
1209	Modification of N -(6-(2-methoxy-3-(4-fluorophenylsulfonamido)pyridin-5-yl)-[1,2,4]triazolo[1,5- a] Tj ETQq1 1 0.784314 rgBT /Overlooked. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5662-5671.	1.4	12
1210	Mono(2-Ethylhexyl) Phthalate Accelerates Early Folliculogenesis and Inhibits Steroidogenesis in Cultured Mouse Whole Ovaries and Antral Follicles1. <i>Biology of Reproduction</i> , 2015, 92, 120.	1.2	98
1211	Conformational Restriction and Steric Hindrance in Medicinal Chemistry. , 2015, , 279-299.		29
1212	Genetic variants in the inositol phosphate metabolism pathway and risk of different types of cancer. <i>Scientific Reports</i> , 2015, 5, 8473.	1.6	35
1213	The Metabolic Basis of Kidney Cancer. , 2015, , 89-102.		1

#	ARTICLE	IF	CITATIONS
1214	Molecular Biology of Urothelial Cancer. , 2015, , 563-590.		0
1215	The acetyl-CoA carboxylase enzyme: a target for cancer therapy?. Expert Review of Anticancer Therapy, 2015, 15, 667-676.	1.1	80
1216	Regulation of the Tumor-Suppressor Function of the Class III Phosphatidylinositol 3-Kinase Complex by Ubiquitin and SUMO. Cancers, 2015, 7, 1-29.	1.7	28
1217	Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration. Journal of Controlled Release, 2015, 213, 112-119.	4.8	21
1218	PIK3CA: a Target or a Marker in Breast Cancers. Current Breast Cancer Reports, 2015, 7, 161-169.	0.5	6
1219	Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation. Seminars in Cancer Biology, 2015, 35, 180-190.	4.3	140
1220	B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells, Molecules, and Diseases, 2015, 55, 255-265.	0.6	22
1221	Class I PI 3-kinases: Function and evolution. Advances in Biological Regulation, 2015, 59, 53-64.	1.4	66
1222	Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. Journal of the National Cancer Institute, 2015, 107, djv171-djv171.	3.0	78
1223	PTEN loss is a contextâ€dependent outcome determinant in obese and nonâ€obese endometrioid endometrial cancer patients. Molecular Oncology, 2015, 9, 1694-1703.	2.1	47
1224	The Cell. , 2015, , 11-42.		2
1225	Novel therapeutic strategies for multiple myeloma. Experimental Hematology, 2015, 43, 732-741.	0.2	98
1226	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8638-8643.	3.3	174
1227	The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. Oncologist, 2015, 20, 1058-1068.	1.9	56
1228	NVP-BE2235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/ mTOR phosphorylation. OncoTargets and Therapy, 2015, 8, 269.	1.0	22
1229	Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	91
1230	Sorghum polyphenol suppresses the growth as well as metastasis of colon cancer xenografts through co-targeting jak2/STAT3 and PI3K/Akt/mTOR pathways. Journal of Functional Foods, 2015, 15, 193-206.	1.6	23
1231	Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2015, 96, 382-395.	2.6	33

#	ARTICLE	IF	CITATIONS
1232	Berberine inhibits Smad and non-Smad signaling cascades and enhances autophagy against pulmonary fibrosis. <i>Journal of Molecular Medicine</i> , 2015, 93, 1015-1031.	1.7	83
1233	Utility of [¹⁸ F]FLT-PET to Assess Treatment Response in Trastuzumab-Resistant and Trastuzumab-Sensitive HER2-Overexpressing Human Breast Cancer Xenografts. <i>Molecular Imaging and Biology</i> , 2015, 17, 119-128.	1.3	12
1234	PTEN-Foxo1 signaling triggers HMGB1-mediated innate immune responses in acute lung injury. <i>Immunologic Research</i> , 2015, 62, 95-105.	1.3	24
1235	Transcriptomic profiling of peripheral blood CD4+ T-cells in asthmatics with and without depression. <i>Gene</i> , 2015, 565, 282-287.	1.0	13
1236	Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation. <i>Annals of Surgical Oncology</i> , 2015, 22, 3659-3665.	0.7	20
1237	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ra51.	5.8	276
1238	The PI3K/AKT/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. <i>Oral Diseases</i> , 2015, 21, 815-825.	1.5	132
1239	Buparlisib in breast cancer. <i>Future Oncology</i> , 2015, 11, 1463-1470.	1.1	17
1240	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1495-1503.	1.9	26
1242	Novel Insights into Myelofibrosis Pathophysiology and Treatment. , 2015, , .		0
1243	Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder. <i>Neurotherapeutics</i> , 2015, 12, 609-619.	2.1	67
1244	The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. <i>Leukemia</i> , 2015, 29, 1811-1822.	3.3	151
1245	PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging. <i>Clinical Cancer Research</i> , 2015, 21, 3602-3609.	3.2	25
1246	PTEN: Multiple Functions in Human Malignant Tumors. <i>Frontiers in Oncology</i> , 2015, 5, 24.	1.3	356
1247	New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 1-14.	0.7	43
1248	Design, synthesis and antiproliferative activity evaluation of m-(4-morpholinyl-1,3,5-triazin-2-yl)benzamides in vitro. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1730-1735.	1.0	14
1249	PTEN Functions by Recruitment to Cytoplasmic Vesicles. <i>Molecular Cell</i> , 2015, 58, 255-268.	4.5	89
1250	Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. <i>Molecular and Cellular Oncology</i> , 2015, 2, e1012976.	0.3	117

#	ARTICLE	IF	CITATIONS
1251	Akt suppresses DLK for maintaining self-renewal of mouse embryonic stem cells. <i>Cell Cycle</i> , 2015, 14, 1207-1217.	1.3	24
1252	p110 ^H Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110 ^H Kinase Activity. <i>Molecular and Cellular Biology</i> , 2015, 35, 3258-3273.	1.1	3
1253	Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1190-1194.	1.3	25
1254	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>in Vitro</i> and <i>in Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2519-2526.	1.9	30
1255	Biomarkers and novel agents in esophago-gastric cancer: are we making progress?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1103-1119.	1.1	6
1256	Autophagy protein 5 enhances the function of rat EPCs and promotes EPCs homing and thrombus recanalization via activating AKT. <i>Thrombosis Research</i> , 2015, 136, 642-651.	0.8	20
1257	Chimeric Nanoparticle: A Platform for Simultaneous Targeting of Phosphatidylinositol-3-Kinase Signaling and Damaging DNA in Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 18327-18335.	4.0	16
1258	The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4136-4142.	1.0	19
1259	Inhibition of Ras-mediated signaling pathways in CML stem cells. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 407-418.	2.1	16
1260	The effect of <i>LKB1</i> on the <i>PI3K/Akt</i> pathway activation in association with <i>PTEN</i> and <i>PIK3CA</i> in <i>HNC</i> . <i>Clinical Otolaryngology</i> , 2015, 40, 622-628.	0.6	2
1261	Effects of dietary supplementation with docosahexaenoic acid (DHA) on hippocampal gene expression in streptozotocin induced diabetic C57Bl/6 mice. <i>Journal of Nutrition & Intermediary Metabolism</i> , 2015, 2, 2-7.	1.7	1
1262	Analysis of an independent tumor suppressor locus telomeric to <i>Tp53</i> suggested <i>Inpp5k</i> and <i>Myo1c</i> as novel tumor suppressor gene candidates in this region. <i>BMC Genetics</i> , 2015, 16, 80.	2.7	28
1264	Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one, (AZD8835): A potent and selective inhibitor of PI3K ^H and PI3K ^I for the treatment of cancers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5155-5162.	1.0	29
1265	The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?. <i>Future Medicinal Chemistry</i> , 2015, 7, 1137-1147.	1.1	155
1266	Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase β for the Treatment of Respiratory Disease. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7381-7399.	2.9	118
1268	<i>De novo</i> resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer. <i>Pharmacogenomics</i> , 2015, 16, 1411-1426.	0.6	7
1269	Inhibition of Protein Kinases AKT and ERK1/2 Reduce the Carotid Body Chemoreceptor Response to Hypoxia in Adult Rats. <i>Advances in Experimental Medicine and Biology</i> , 2015, 860, 269-277.	0.8	3
1270	Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3227-3234.	0.8	125

#	ARTICLE	IF	CITATIONS
1271	Ligand-Selective Signal Transduction by Two Endogenous GnRH Isoforms Involves Biased Activation of the Class I PI3K Catalytic Subunits p110 ^β , p110 ^γ , and p110 ^δ in Pituitary Gonadotropes and Somatotropes. <i>Endocrinology</i> , 2015, 156, 218-230.	1.4	10
1272	Suppression of Nkx3.2 by phosphatidylinositol-3-kinase signaling regulates cartilage development by modulating chondrocyte hypertrophy. <i>Cellular Signalling</i> , 2015, 27, 2389-2400.	1.7	10
1273	Akt Phosphorylates Wnt Coactivator and Chromatin Effector Pygo2 at Serine 48 to Antagonize Its Ubiquitin/Proteasome-mediated Degradation. <i>Journal of Biological Chemistry</i> , 2015, 290, 21553-21567.	1.6	10
1274	High resolution mass spectrometry imaging of plant tissues: towards a plant metabolite atlas. <i>Analyst</i> , 2015, 140, 7696-7709.	1.7	91
1275	Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7765-7776.	1.4	19
1276	PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark Zones. <i>Immunity</i> , 2015, 43, 1075-1086.	6.6	206
1277	Complications of hyperglycaemia with PI3K/AKT/mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. <i>British Journal of Cancer</i> , 2015, 113, 1541-1547.	2.9	30
1278	PTEN and PI3K/AKT in non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2015, 16, 1843-1862.	0.6	180
1279	Sprouty gain of function disrupts lens cellular processes and growth by restricting RTK signaling. <i>Developmental Biology</i> , 2015, 406, 129-146.	0.9	16
1280	Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET. <i>Tumor Biology</i> , 2015, 36, 1511-1518.	0.8	16
1281	Axl as a downstream effector of TGF- β 1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma. <i>Tumor Biology</i> , 2015, 36, 1115-1127.	0.8	34
1282	The interplay of NR4A receptors and the oncogene/tumor suppressor networks in cancer. <i>Cellular Signalling</i> , 2015, 27, 257-266.	1.7	76
1283	ErbB2 signaling activates the Hedgehog pathway via PI3K/Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts. <i>Cellular Signalling</i> , 2015, 27, 373-381.	1.7	45
1284	PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. <i>Nature Reviews Cancer</i> , 2015, 15, 7-24.	12.8	1,083
1285	Insulin signaling pathway in the oriental fruit fly: The role of insulin receptor substrate in ovarian development. <i>General and Comparative Endocrinology</i> , 2015, 216, 125-133.	0.8	27
1286	Inositol Polyphosphate-5-Phosphatase F (INPP5F) inhibits STAT3 activity and suppresses gliomas tumorigenicity. <i>Scientific Reports</i> , 2015, 4, 7330.	1.6	28
1287	Digital gene expression analysis in hemocytes of the white shrimp <i>Litopenaeus vannamei</i> in response to low salinity stress. <i>Fish and Shellfish Immunology</i> , 2015, 42, 400-407.	1.6	54
1288	PI3K signaling in the pathogenesis of obesity: The cause and the cure. <i>Advances in Biological Regulation</i> , 2015, 58, 1-15.	1.4	26

#	ARTICLE	IF	CITATIONS
1289	The current and potential impact of genetics and genomics on neuropsychopharmacology. <i>European Neuropsychopharmacology</i> , 2015, 25, 671-681.	0.3	11
1290	Susceptibility of PTEN-positive metastatic tumors to small interfering RNA targeting the mammalian target of rapamycin. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 185-194.	1.7	15
1291	Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 41-71.	2.9	122
1293	Convergent loss of PTEN leads to clinical resistance to a PI(3)K inhibitor. <i>Nature</i> , 2015, 518, 240-244.	13.7	486
1294	Integrated analysis reveals that STAT3 is central to the crosstalk between HER/ErbB receptor signaling pathways in human mammary epithelial cells. <i>Molecular BioSystems</i> , 2015, 11, 146-158.	2.9	14
1295	Genetic variants in <i>AKT1</i> gene were associated with risk and survival of <i>OSCC</i> in Chinese Han Population. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 45-50.	1.4	29
1296	miR-23a-3p Causes Cellular Senescence by Targeting Hyaluronan Synthase 2: Possible Implication for Skin Aging. <i>Journal of Investigative Dermatology</i> , 2015, 135, 369-377.	0.3	61
1297	<i>PI3Kcb</i> Links Hippo-YAP and PI3K-AKT Signaling Pathways to Promote Cardiomyocyte Proliferation and Survival. <i>Circulation Research</i> , 2015, 116, 35-45.	2.0	237
1299	Targeting PI3 kinase in cancer. , 2015, 146, 53-60.		129
1300	Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use in the treatment of bladder cancers. , 2015, 145, 1-18.		75
1301	Oncogenes and Signal Transduction. , 2015, , 19-34.e3.		2
1302	Analysing Molecular Mechanism Related to Therapy- Resistance in In-vitro Models of Ovarian Cancer. , 2016, , .		0
1303	The Phosphoinositide 3-Kinase Catalytic Subunit <i>p110α</i> is Required for Normal Lens Growth. , 2016, 57, 3145.		14
1304	Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2016, 11, 283-296.	0.8	35
1305	Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2016, 16, 85.	0.9	13
1306	Comparative mRNA Expression of eEF1A Isoforms and a PI3K/Akt/mTOR Pathway in a Cellular Model of Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-11.	0.6	28
1307	The PI3K AKT pathway in the pathogenesis of prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2016, 21, 1084-1091.	3.0	191
1308	Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-17.	0.6	23

#	ARTICLE	IF	CITATIONS
1309	Andrographolide inhibits growth of human T-cell acute lymphoblastic leukemia Jurkat cells by downregulation of PI3K/AKT and upregulation of p38 MAPK pathways. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1389.	2.0	29
1310	The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo. <i>Oncology Reports</i> , 2016, 36, 356-364.	1.2	19
1311	Induction of Central Host Signaling Kinases during Pneumococcal Infection of Human THP-1 Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 2016, 6, 48.	1.8	7
1312	MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines. <i>Frontiers in Genetics</i> , 2016, 7, 197.	1.1	74
1313	Increased Urinary Phthalate Levels in Women with Uterine Leiomyoma: A Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 1247.	1.2	28
1314	A Comprehensive and System Review for the Pharmacological Mechanism of Action of Rhein, an Active Anthraquinone Ingredient. <i>Frontiers in Pharmacology</i> , 2016, 7, 247.	1.6	105
1315	The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer. <i>Frontiers in Physiology</i> , 2016, 7, 168.	1.3	11
1316	The Multifaceted Roles of PI3K β in Hypertension, Vascular Biology, and Inflammation. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1858.	1.8	14
1317	Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics. <i>Translational Oncogenomics</i> , 2016, Suppl. 1, 33-49.	1.7	25
1318	Human β -defensin 3 contains an oncolytic motif that binds PI(4,5)P2 to mediate tumour cell permeabilisation. <i>Oncotarget</i> , 2016, 7, 2054-2069.	0.8	44
1319	PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. <i>Oncotarget</i> , 2016, 7, 33440-33450.	0.8	400
1320	Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer. <i>Medical Science Monitor</i> , 2016, 22, 1435-1441.	0.5	53
1321	Negative regulation of TLR signaling in myeloid cells—implications for autoimmune diseases. <i>Immunological Reviews</i> , 2016, 269, 212-227.	2.8	86
1322	Dynamics of GFP-Fusion p110 α and p110 β Isoforms of PI3K Signaling Pathway in Normal and Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2864-2874.	1.2	8
1323	The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures. <i>Cancer Drug Discovery and Development</i> , 2016, , 109-124.	0.2	0
1324	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19,784 Diverse Solid Tumors. <i>JAMA Oncology</i> , 2016, 2, 1565.	3.4	195
1325	Detection and treatment of <i>Trypanosoma cruzi</i> : a patent review (2011-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 993-1015.	2.4	13
1326	Ligand-biased regulation of PtdIns(3,4,5)P3-dependent signal transduction in GPCR control of pituitary hormone release. <i>Endocrinology</i> , 2016, 158, en.2016-1552.	1.4	3

#	ARTICLE	IF	CITATIONS
1327	PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 515-524.	2.7	300
1328	Highly sensitive detection of the PIK3CA H1047R mutation in colorectal cancer using a novel PCR-RFLP method. <i>BMC Cancer</i> , 2016, 16, 454.	1.1	10
1329	Downregulation of fatty acid synthase complex suppresses cell migration by targeting phospho-AKT in bladder cancer. <i>Molecular Medicine Reports</i> , 2016, 13, 1845-1850.	1.1	15
1330	The PI3K/Akt/mTOR Pathway. , 2016, , 128-135.		2
1331	The PI3K Pathway: Background and Treatment Approaches. <i>Breast Care</i> , 2016, 11, 398-404.	0.8	28
1332	Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma. <i>Cancer Biomarkers</i> , 2016, 16, 377-383.	0.8	8
1333	Following the trail of lipids: Signals initiated by PI3K function at multiple cellular membranes. <i>Science Signaling</i> , 2016, 9, re4.	1.6	23
1334	DNA methylation mediates the effect of exposure to prenatal maternal stress on cytokine production in children at age 13½ years: Project Ice Storm. <i>Clinical Epigenetics</i> , 2016, 8, 54.	1.8	57
1335	Regulation of Insulin Resistance by Multiple MiRNAs via Targeting the GLUT4 Signalling Pathway. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 2063-2078.	1.1	83
1336	Sorting Motifs in the Cytoplasmic Tail of the Immunomodulatory E3/49K Protein of Species D Adenoviruses Modulate Cell Surface Expression and Ectodomain Shedding. <i>Journal of Biological Chemistry</i> , 2016, 291, 6796-6812.	1.6	11
1337	ST6GalNAcII mediates tumor invasion through PI3K/Akt/NF- κ B signaling pathway in follicular thyroid carcinoma. <i>Oncology Reports</i> , 2016, 35, 2131-2140.	1.2	18
1338	Effects of phoxim on nutrient metabolism and insulin signaling pathway in silkworm midgut. <i>Chemosphere</i> , 2016, 146, 478-485.	4.2	35
1339	Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation. <i>Gynecologic Oncology</i> , 2016, 141, 570-579.	0.6	3
1340	The Nuclear Zinc Finger Protein Zfat Maintains FoxO1 Protein Levels in Peripheral T Cells by Regulating the Activities of Autophagy and the Akt Signaling Pathway. <i>Journal of Biological Chemistry</i> , 2016, 291, 15282-15291.	1.6	14
1341	A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells. <i>Journal of Proteomics</i> , 2016, 145, 91-102.	1.2	21
1342	Gallium and its competing roles with iron in biological systems. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2044-2053.	1.9	173
1343	Concomitant Inhibition of PI3K \hat{I}^2 and BRAF or MEK in PTEN-Deficient/ <i>BRAF</i> -Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K \hat{I}^2 -Selective Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1460-1471.	1.9	18
1344	Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1248-1260.	1.9	30

#	ARTICLE	IF	CITATIONS
1345	KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review. <i>Medical Oncology</i> , 2016, 33, 32.	1.2	25
1346	Role of Host Type IA Phosphoinositide 3-Kinase Pathway Components in Invasin-Mediated Internalization of <i>Yersinia enterocolitica</i> . <i>Infection and Immunity</i> , 2016, 84, 1826-1841.	1.0	25
1347	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1412-1424.	1.9	16
1348	Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients. <i>Schizophrenia Research</i> , 2016, 177, 70-77.	1.1	22
1349	The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date. <i>Drugs</i> , 2016, 76, 639-646.	4.9	20
1350	Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs. <i>Cancer Cell</i> , 2016, 29, 429-431.	7.7	23
1351	Maternal vitamin D-restricted diet has consequences in the formation of pancreatic islet/insulin-signaling in the adult offspring of mice. <i>Endocrine</i> , 2016, 54, 60-69.	1.1	17
1352	TPX2 in human clear cell renal carcinoma: Expression, function and prognostic significance. <i>Oncology Letters</i> , 2016, 11, 3515-3521.	0.8	8
1353	Breast Cancer: A Molecular and Redox Snapshot. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 337-370.	2.5	16
1354	Genetics of Melanoma. , 2016, , .		3
1355	Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 83-90.	1.1	5
1356	Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review. <i>BMC Cancer</i> , 2016, 16, 400.	1.1	40
1357	<i>Pten</i> Regulates Retinal Amacrine Cell Number by Modulating Akt, <i>Tgfr2</i> , and Erk Signaling. <i>Journal of Neuroscience</i> , 2016, 36, 9454-9471.	1.7	21
1358	Targeting PI3-Kinases in Modulating Autophagy and Anti-cancer Therapy. <i>Current Cancer Research</i> , 2016, , 85-97.	0.2	0
1359	Mutation of the 3-Phosphoinositide-Dependent Protein Kinase 1 (PDK1) Substrate-Docking Site in the Developing Brain Causes Microcephaly with Abnormal Brain Morphogenesis Independently of Akt, Leading to Impaired Cognition and Disruptive Behaviors. <i>Molecular and Cellular Biology</i> , 2016, 36, 2967-2982.	1.1	27
1360	FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 462-469.	2.5	33
1361	High-fat diet feeding promotes stemness and precancerous changes in murine gastric mucosa mediated by leptin receptor signaling pathway. <i>Archives of Biochemistry and Biophysics</i> , 2016, 610, 16-24.	1.4	23
1362	Wedelolactone, an Anti-inflammatory Botanical, Interrupts c-Myc Oncogenic Signaling and Synergizes with Enzalutamide to Induce Apoptosis in Prostate Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2791-2801.	1.9	27

#	ARTICLE	IF	CITATIONS
1363	Protein Tyrosine Phosphatases in Cancer. , 2016, , .		4
1365	Unravelling the Mechanism of TrkA-Induced Cell Death by Macropinocytosis in Medulloblastoma Daoy Cells. <i>Molecular and Cellular Biology</i> , 2016, 36, 2596-2611.	1.1	13
1366	Experimental verification of a predicted novel microRNA located in human PIK3CA gene with a potential oncogenic function in colorectal cancer. <i>Tumor Biology</i> , 2016, 37, 14089-14101.	0.8	11
1367	GSK3 β -dependent dysregulation of neurodevelopment in SPG11 β -patient induced pluripotent stem cell model. <i>Annals of Neurology</i> , 2016, 79, 826-840.	2.8	40
1368	p110 α and p110 β isoforms of PI3K signaling: are they two sides of the same coin?. <i>FEBS Letters</i> , 2016, 590, 3071-3082.	1.3	20
1369	Metabolic scavenging by cancer cells: when the going gets tough, the tough keep eating. <i>British Journal of Cancer</i> , 2016, 115, 635-640.	2.9	43
1370	Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4408-4413.	1.0	24
1371	Clinical significance of T cell metabolic reprogramming in cancer. <i>Clinical and Translational Medicine</i> , 2016, 5, 29.	1.7	69
1372	MicroRNA-21 activation of Akt via PTEN is involved in the epithelial \rightarrow mesenchymal transition and malignant transformation of human keratinocytes induced by arsenite. <i>Toxicology Research</i> , 2016, 5, 1140-1147.	0.9	7
1373	Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non \rightarrow small-cell Lung Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e384.	2.3	22
1374	Ayurvedic Amalaki Rasayana promotes improved stress tolerance and thus has anti-aging effects in <i>Drosophila melanogaster</i> . <i>Journal of Biosciences</i> , 2016, 41, 697-711.	0.5	16
1375	The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 97.	3.5	36
1376	Addition of the p110 α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. <i>Tumor Biology</i> , 2016, 37, 14831-14839.	0.8	6
1377	Maternal and fetal genomes interplay through phosphoinositol 3-kinase(PI3K)-p110 α signaling to modify placental resource allocation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11255-11260.	3.3	62
1378	Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3803-3815.	0.8	336
1379	Discovery and in Vivo Evaluation of the Potent and Selective PI3K β Inhibitors 2-((1 <i>S</i>)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro- <i>N</i> -methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1 <i>S</i>)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro- <i>N</i> -methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7252-7267.	2.9	18
1380	Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7268-7274.	2.9	35
1381	Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E4338-47.	3.3	76

#	ARTICLE	IF	CITATIONS
1382	6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 731-743.	2.6	39
1383	Eupatilin inhibits EGF-induced JB6 cell transformation by targeting PI3K. <i>International Journal of Oncology</i> , 2016, 49, 1148-1154.	1.4	6
1384	The rise of genomic profiling in ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1337-1351.	1.5	18
1385	Neutrophil Necroptosis Is Triggered by Ligation of Adhesion Molecules following GM-CSF Priming. <i>Journal of Immunology</i> , 2016, 197, 4090-4100.	0.4	66
1386	Salinomycin causes migration and invasion of human fibrosarcoma cells by inducing MMP-2 expression via PI3-kinase, ERK-1/2 and p38 kinase pathways. <i>International Journal of Oncology</i> , 2016, 48, 2686-2692.	1.4	12
1387	Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX. <i>Translational Oncology</i> , 2016, 9, 458-465.	1.7	9
1388	Role of phosphatidylinositol-4,5-bisphosphate 3-kinase signaling in vesicular trafficking. <i>Life Sciences</i> , 2016, 167, 39-45.	2.0	17
1389	The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 861-886.	1.4	44
1390	miR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6. <i>Scientific Reports</i> , 2016, 6, 28968.	1.6	29
1391	Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer. <i>Oncology Letters</i> , 2016, 12, 2028-2032.	0.8	4
1392	Novel roles for class II Phosphoinositide 3-Kinase C2 ² in signalling pathways involved in prostate cancer cell invasion. <i>Scientific Reports</i> , 2016, 6, 23277.	1.6	22
1393	Past and future impact of next-generation sequencing in head and neck cancer. <i>Head and Neck</i> , 2016, 38, E2395-402.	0.9	6
1394	Control of the innate immune response by the mevalonate pathway. <i>Nature Immunology</i> , 2016, 17, 922-929.	7.0	159
1395	Determinants of hepcidin levels in sepsis-associated acute kidney injury: Impact on pAKT/PTEN pathways?. <i>Journal of Immunotoxicology</i> , 2016, 13, 751-757.	0.9	18
1396	Ras signaling through RASSF proteins. <i>Seminars in Cell and Developmental Biology</i> , 2016, 58, 86-95.	2.3	79
1397	Defining the Prognostic and Predictive Role of PIK3CA Mutations: Sifting Through the Conflicting Data. <i>Current Breast Cancer Reports</i> , 2016, 8, 73-79.	0.5	6
1398	Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 684-701.	2.6	15
1399	TW-01, a piperazinedione-derived compound, inhibits Ras-mediated cell proliferation and angioplasty-induced vascular restenosis. <i>Toxicology and Applied Pharmacology</i> , 2016, 305, 194-202.	1.3	1

#	ARTICLE	IF	CITATIONS
1400	The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 69-84.	1.1	23
1401	Activation of IGF1R/p110 ^β /AKT/mTOR confers resistance to $\hat{\pm}$ -specific PI3K inhibition. <i>Breast Cancer Research</i> , 2016, 18, 41.	2.2	74
1402	Reconstruction of the insulin-like signalling pathway of <i>Haemonchus contortus</i> . <i>Parasites and Vectors</i> , 2016, 9, 64.	1.0	12
1403	Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1964-1974.	1.9	47
1404	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. <i>Cell Reports</i> , 2016, 15, 2692-2704.	2.9	92
1405	Phosphatidylinositol 3-Kinase. <i>Pancreas</i> , 2016, 45, 21-31.	0.5	11
1407	Role and mechanism of insulin-like growth factor 2 on the proliferation of human trophoblasts <i>in vitro</i> . <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 44-51.	0.6	7
1408	Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. <i>Oncology Letters</i> , 2016, 12, 102-106.	0.8	25
1409	Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity. <i>Archiv Der Pharmazie</i> , 2016, 349, 309-326.	2.1	60
1410	Transcription factors and cognate signalling cascades in the regulation of autophagy. <i>Biological Reviews</i> , 2016, 91, 429-451.	4.7	20
1411	Oncogenic activation of the PI3-kinase p110 ^β isoform via the tumor-derived PIK3C ^Δ D1067V kinase domain mutation. <i>Oncogene</i> , 2016, 35, 1198-1205.	2.6	33
1412	Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with <i>in vivo</i> efficacies against hepatocellular carcinoma. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 957-966.	1.4	13
1413	Ras Conformational Ensembles, Allostery, and Signaling. <i>Chemical Reviews</i> , 2016, 116, 6607-6665.	23.0	290
1414	A headlight on liquid biopsies: a challenging tool for breast cancer management. <i>Tumor Biology</i> , 2016, 37, 4263-4273.	0.8	18
1415	Targeting therapeutic liabilities engendered by <i>PIK3R1</i> mutations for cancer treatment. <i>Pharmacogenomics</i> , 2016, 17, 297-307.	0.6	36
1416	PI3K ^γ promotes CD4 ⁺ T _H cell interactions with antigen-presenting cells by increasing LFA ¹ binding to ICAM ¹ . <i>Immunology and Cell Biology</i> , 2016, 94, 486-495.	1.0	19
1417	PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas. <i>International Journal of Oncology</i> , 2016, 48, 253-260.	1.4	13
1418	Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2874-2884.	3.2	103

#	ARTICLE	IF	CITATIONS
1419	Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3K β Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 431-447.	2.9	34
1420	Relationship between phosphoinositide-3-kinase genetic polymorphism and schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 272-275.	0.7	9
1421	Biophysical aspect of phosphatidylinositol 3-kinase and role of oncogenic mutants (E542K & Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	30
1422	PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 13-26.	1.6	66
1423	PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. <i>Oncogene</i> , 2016, 35, 2961-2970.	2.6	30
1424	Transcription factor 3 controls cell proliferation and migration in glioblastoma multiforme cell lines. <i>Biochemistry and Cell Biology</i> , 2016, 94, 247-255.	0.9	12
1425	miR-31 and miR-17-5p levels change during transformation of follicular lymphoma. <i>Human Pathology</i> , 2016, 50, 118-126.	1.1	23
1426	Endometrial cancerâ€”targeted therapies myth or reality? Review of current targeted treatments. <i>European Journal of Cancer</i> , 2016, 59, 99-108.	1.3	40
1427	Impact of transient down-regulation of DREAM in human embryonic stem cell pluripotency. <i>Stem Cell Research</i> , 2016, 16, 568-578.	0.3	6
1428	GPCR Signaling Mediates Tumor Metastasis via PI3K β . <i>Cancer Research</i> , 2016, 76, 2944-2953.	0.4	47
1429	Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 355-366.	2.0	13
1430	Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 112, 298-346.	2.6	55
1431	Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF β signaling. <i>Oncogene</i> , 2016, 35, 4641-4652.	2.6	65
1432	Phosphoinositide 3-kinase family in channel catfish and their regulated expression after bacterial infection. <i>Fish and Shellfish Immunology</i> , 2016, 49, 364-373.	1.6	11
1433	Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K α and PI3K β , Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 877-889.	1.9	38
1434	Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo. <i>Tumor Biology</i> , 2016, 37, 7615-7623.	0.8	19
1435	Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth. <i>Cancer Letters</i> , 2016, 374, 250-260.	3.2	29
1436	Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo. <i>Future Oncology</i> , 2016, 12, 515-524.	1.1	5

#	ARTICLE	IF	CITATIONS
1437	Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. <i>Tumor Biology</i> , 2016, 37, 7033-7045.	0.8	49
1438	Knockdown of Astrocyte Elevated Gene-1 Inhibits Activation of Hepatic Stellate Cells. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1961-1971.	1.1	6
1439	In Search of a Cure for Sepsis: Taming the Monster in Critical Care Medicine. <i>Journal of Innate Immunity</i> , 2016, 8, 156-170.	1.8	20
1440	Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 388-394.	1.2	16
1441	Prospective of curcumin, a pleiotropic signalling molecule from <i>Curcuma longa</i> in the treatment of Glioblastoma. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 23-35.	2.6	59
1442	First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2016, 22, 1932-1939.	3.2	78
1443	Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino- N -(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 644-654.	2.6	28
1444	Emerging strategies for targeting PI3K in gynecologic cancer. <i>Gynecologic Oncology</i> , 2016, 140, 333-344.	0.6	21
1445	Discovery of novel dual inhibitors of VEGFR and PI3K kinases containing 2-ureidothiazole scaffold. <i>Chinese Chemical Letters</i> , 2016, 27, 1-6.	4.8	13
1446	Analysis of <i>mTOR</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K/AKT/mTOR Pathway Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1018-1027.	3.2	69
1447	The PI3K/AKT Pathway as a Target for Cancer Treatment. <i>Annual Review of Medicine</i> , 2016, 67, 11-28.	5.0	631
1448	The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2016, 30, 337-345.	3.3	17
1449	Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt. <i>Journal of Gastroenterology</i> , 2016, 51, 230-240.	2.3	38
1450	Anti-tumour-promoting and thermal-induced protein denaturation inhibitory activities of Î²-sitosterol and lupeol isolated from <i>Diospyros lotus</i> L.. <i>Natural Product Research</i> , 2016, 30, 1205-1207.	1.0	21
1451	Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. <i>Oncogene</i> , 2016, 35, 2186-2196.	2.6	26
1452	The role of PTEN in regulation of hepatic macrophages activation and function in progression and reversal of liver fibrosis. <i>Toxicology and Applied Pharmacology</i> , 2017, 317, 51-62.	1.3	37
1453	Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 639-648.	1.2	7
1454	Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 271-279.	1.1	48

#	ARTICLE	IF	CITATIONS
1455	Starved epithelial cells uptake extracellular matrix for survival. <i>Nature Communications</i> , 2017, 8, 13989.	5.8	91
1456	Selective deletion of Pten in theca-interstitial cells leads to androgen excess and ovarian dysfunction in mice. <i>Molecular and Cellular Endocrinology</i> , 2017, 444, 26-37.	1.6	24
1457	Single nucleotide polymorphism markers for rapid detection of the Rsv4 locus for soybean mosaic virus resistance in diverse germplasm. <i>Molecular Breeding</i> , 2017, 37, 1.	1.0	8
1458	Over expression of proteins that alter the intracellular signaling pathways in the cytoplasm of the liver cells forming Mallory-Denk bodies. <i>Experimental and Molecular Pathology</i> , 2017, 102, 106-114.	0.9	12
1459	Neuroblast niche position is controlled by PI3-kinase dependent DE-Cadherin adhesion. <i>Development (Cambridge)</i> , 2017, 144, 820-829.	1.2	14
1460	Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity. <i>Scientific Reports</i> , 2017, 7, 42700.	1.6	32
1461	PDGFs and their receptors. <i>Gene</i> , 2017, 614, 1-7.	1.0	148
1462	Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. <i>Oncologist</i> , 2017, 22, 377-e37.	1.9	25
1463	Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. <i>Nature Communications</i> , 2017, 8, 14683.	5.8	88
1464	Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 13-30.	0.9	8
1465	PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. <i>International Journal of Oncology</i> , 2017, 50, 606-612.	1.4	66
1466	Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line. <i>Scientific Reports</i> , 2017, 7, 46079.	1.6	23
1467	RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro. <i>Anti-Cancer Drugs</i> , 2017, 28, 514-521.	0.7	20
1468	Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 41-54.	3.3	55
1469	Characterization and mechanism of phosphoinositide 3-kinases (PI3Ks) members in insulin-induced changes of protein metabolism in yellow catfish <i>Pelteobagrus fulvidraco</i> . <i>General and Comparative Endocrinology</i> , 2017, 247, 34-45.	0.8	16
1470	Therapeutic targeting and patient selection for cancers with homologous recombination defects. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 565-581.	2.5	32
1471	PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 236-241.	0.3	6
1472	COX-1/PGE2/EP4 alleviates mucosal injury by upregulating $\hat{2}$ -arr1-mediated Akt signaling in colitis. <i>Scientific Reports</i> , 2017, 7, 1055.	1.6	28

#	ARTICLE	IF	CITATIONS
1473	MicroRNA-155 promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. <i>Cancer Science</i> , 2017, 108, 620-631.	1.7	124
1474	AKT. , 2017, , 3-12.		0
1475	Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 487-497.	1.2	33
1476	An Anti-Cancer Drug Candidate OSI-027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 4558-4567.	1.2	29
1477	Genome-scale transcriptional analysis reveals key genes associated with the development of type II diabetes in mice. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 1044-1150.	0.8	6
1478	Discovery of a novel aminopyrazine series as selective PI3K inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3030-3035.	1.0	6
1479	EhRho1 regulates plasma membrane blebbing through PI3 kinase in <i>Entamoeba histolytica</i> . <i>Cellular Microbiology</i> , 2017, 19, e12751.	1.1	27
1480	Reduced Insulin Resistance Contributes to the Beneficial Effect of Protein Tyrosine Phosphatase-1B Deletion in a Mouse Model of Sepsis. <i>Shock</i> , 2017, 48, 355-363.	1.0	8
1481	^{125}I -NP63 is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E3964-E3973.	3.3	54
1482	New Genetic Diagnoses of Short Stature Provide Insights into Local Regulation of Childhood Growth. <i>Hormone Research in Paediatrics</i> , 2017, 88, 22-37.	0.8	29
1483	Negative regulation of ERK1/2 by PI3K is required for the protective effects of Pyropia yezoensis peptide against perfluorooctane sulfonate-induced endoplasmic reticulum stress. <i>Molecular Medicine Reports</i> , 2017, 15, 2583-2587.	1.1	6
1484	Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS. <i>Human Cell</i> , 2017, 30, 140-148.	1.2	3
1485	Expression quantitative trait loci for PI3K/AKT pathway. <i>Medicine (United States)</i> , 2017, 96, e5817.	0.4	11
1486	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. <i>Cancer Cell</i> , 2017, 31, 820-832.e3.	7.7	433
1488	Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction. <i>Journal of Experimental Medicine</i> , 2017, 214, 1877-1888.	4.2	30
1489	Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia. <i>Advances in Biological Regulation</i> , 2017, 65, 36-58.	1.4	33
1490	Comparative molecular profiling of HPV-induced squamous cell carcinomas. <i>Cancer Medicine</i> , 2017, 6, 1673-1685.	1.3	37
1491	Novel function of Porphyromonas gingivalis gingipains in the PI3K/Akt signaling pathway. <i>Journal of Oral Biosciences</i> , 2017, 59, 131-134.	0.8	1

#	ARTICLE	IF	CITATIONS
1492	Bmal1 interference impairs hormone synthesis and promotes apoptosis in porcine granulosa cells. <i>Theriogenology</i> , 2017, 99, 63-68.	0.9	28
1493	Role of Aspirin in Breast Cancer Survival. <i>Current Oncology Reports</i> , 2017, 19, 48.	1.8	62
1494	Hedgehog signaling contributes to basic fibroblast growth factor-regulated fibroblast migration. <i>Experimental Cell Research</i> , 2017, 355, 83-94.	1.2	18
1495	USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51- Akt signaling. <i>EMBO Journal</i> , 2017, 36, 1434-1446.	3.5	72
1496	Generation of tricyclic imidazo[1,2- <i>a</i>]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2536-2543.	1.0	10
1497	A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2017, 28, 557-564.	0.7	16
1498	Extracellular matrix in mammary gland development and breast cancer progression. <i>Frontiers in Laboratory Medicine</i> , 2017, 1, 36-39.	1.7	10
1499	A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study). <i>Clinical Colorectal Cancer</i> , 2017, 16, 410-415.e1.	1.0	7
1500	Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 359-375.	0.9	9
1501	Cancerous perturbations within the ERK, PI3K/Akt, and Wnt/ β -catenin signaling network constitutively activate inter-pathway positive feedback loops. <i>Molecular BioSystems</i> , 2017, 13, 830-840.	2.9	28
1502	Targeted radionuclide therapy for lung cancer with iodine-131-labeled peptide in a nude-mouse model. <i>Anti-Cancer Drugs</i> , 2017, 28, 480-488.	0.7	3
1503	A nomogram to predict 5-fluorouracil toxicity. <i>Anti-Cancer Drugs</i> , 2017, 28, 551-556.	0.7	10
1504	Protein kinase B. <i>Anti-Cancer Drugs</i> , 2017, 28, 569-580.	0.7	26
1505	Adriamycin in combination with dexamethasone and octreotide lacks activity on the treatment of a 4T1 metastatic breast cancer model. <i>Anti-Cancer Drugs</i> , 2017, 28, 489-502.	0.7	1
1506	PI3K- γ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells. <i>Anti-Cancer Drugs</i> , 2017, 28, 436-445.	0.7	22
1507	Duvelisib: a phosphoinositide-3 kinase γ/β inhibitor for chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 625-632.	1.9	60
1508	Homocysteine ameliorates the endothelium-independent hypoxic vasoconstriction via the suppression of phosphatidylinositol 3-kinase/Akt pathway in porcine coronary arteries. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 178-183.	1.0	4
1509	Nanocapsules of therapeutic proteins with enhanced stability and long blood circulation for hyperuricemia management. <i>Journal of Controlled Release</i> , 2017, 255, 54-61.	4.8	22

#	ARTICLE	IF	CITATIONS
1510	The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 123-131.	3.3	117
1511	Central Regulation of Glucose Homeostasis. , 2017, 7, 741-764.		52
1512	Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. <i>Lancet, The</i> , 2017, 389, 2403-2414.	6.3	168
1513	Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. <i>Mutation Research - Reviews in Mutation Research</i> , 2017, 771, 32-58.	2.4	30
1514	Mactosylceramide prevents glial cell overgrowth by inhibiting insulin and fibroblast growth factor receptor signaling. <i>Journal of Cellular Physiology</i> , 2017, 232, 3112-3127.	2.0	4
1515	Brain Development and Akt Signaling: the Crossroads of Signaling Pathway and Neurodevelopmental Diseases. <i>Journal of Molecular Neuroscience</i> , 2017, 61, 379-384.	1.1	131
1516	Transactivation of the epidermal growth factor receptor in responses to myocardial stress and cardioprotection. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 83, 97-110.	1.2	24
1517	Quantitative structural characterization of phosphatidylinositol phosphates from biological samples. <i>Journal of Lipid Research</i> , 2017, 58, 469-478.	2.0	16
1518	Identification of novel PI3K inhibitors through a scaffold hopping strategy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4794-4799.	1.0	5
1519	Exercise for Cardiovascular Disease Prevention and Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	3
1520	Upregulation of pAKT(Ser473) expression in progression of HPVâ€­positive oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 2397-2405.	0.9	14
1521	Use of nanoparticles for glioblastoma treatment: a new approach. <i>Nanomedicine</i> , 2017, 12, 2533-2554.	1.7	25
1522	Isoform Selective PI3K Inhibitors for Treating Cancer. <i>Topics in Medicinal Chemistry</i> , 2017, , 333-333.	0.4	2
1523	Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities. <i>Archiv Der Pharmazie</i> , 2017, 350, 1700242.	2.1	17
1524	miR-182 and miR-135b Mediate the Tumorigenesis and Invasiveness of Colorectal Cancer Cells via Targeting ST6GALNAC2 and PI3K/AKT Pathway. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3447-3459.	1.1	48
1525	PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K. <i>Molecular Cell</i> , 2017, 68, 566-580.e10.	4.5	149
1526	Mechanism of apoptosis involved in gastric mucosal lesions in Tibetans with high-altitude polycythemia. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 3780-3787.	0.8	7
1527	Endothelial SHIP2 Suppresses Nox2 NADPH Oxidaseâ€­Dependent Vascular Oxidative Stress, Endothelial Dysfunction, and Systemic Insulin Resistance. <i>Diabetes</i> , 2017, 66, 2808-2821.	0.3	23

#	ARTICLE	IF	CITATIONS
1528	B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. <i>Molecular Cancer Research</i> , 2017, 15, 1692-1703.	1.5	38
1529	Dual effects of the PI3K inhibitor ZSTK474 on multidrug efflux pumps in resistant cancer cells. <i>European Journal of Pharmacology</i> , 2017, 815, 127-137.	1.7	9
1530	Displacement and hybridization reactions in aptamer-functionalized hydrogels for biomimetic protein release and signal transduction. <i>Chemical Science</i> , 2017, 8, 7306-7311.	3.7	24
1531	Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. <i>Cancer Treatment Reviews</i> , 2017, 59, 93-101.	3.4	191
1532	Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 163, 250-254.	0.3	7
1533	Pharmacological, but not genetic, alteration of neural Epo modifies the CO ₂ /H ⁺ + central chemosensitivity in postnatal mice. <i>Respiratory Physiology and Neurobiology</i> , 2017, 242, 73-79.	0.7	4
1534	Target and Agent Prioritization for the Children's Oncology Group's National Cancer Institute Pediatric MATCH Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	85
1535	A vicious partnership between <sc>AKT</sc> and <sc>PHLDA</sc>3 to facilitate neuroendocrine tumors. <i>Cancer Science</i> , 2017, 108, 1101-1108.	1.7	20
1536	In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. <i>Anti-Cancer Drugs</i> , 2017, 28, 503-513.	0.7	21
1537	The PI3K Pathway in Human Disease. <i>Cell</i> , 2017, 170, 605-635.	13.5	1,702
1538	Lymphocyte Fate and Metabolism: A Clonal Balancing Act. <i>Trends in Cell Biology</i> , 2017, 27, 946-954.	3.6	11
1539	Surviving Stress: Modulation of ATF4-Mediated Stress Responses in Normal and Malignant Cells. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 794-806.	3.1	356
1540	miR-125a-3p/FUT5-FUT6 axis mediates colorectal cancer cell proliferation, migration, invasion and pathological angiogenesis via PI3K-Akt pathway. <i>Cell Death and Disease</i> , 2017, 8, e2968-e2968.	2.7	101
1541	Replication of JC Virus DNA in the G144 Oligodendrocyte Cell Line Is Dependent Upon Akt. <i>Journal of Virology</i> , 2017, 91, .	1.5	6
1542	ErbB2-positive mammary tumors can escape PI3K-p110 ^α loss through downregulation of the Pten tumor suppressor. <i>Oncogene</i> , 2017, 36, 6059-6066.	2.6	7
1544	Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs stimulate proliferation and post-irradiation cell survival of K-RAS-mutated cancer cells. <i>Cell Death Discovery</i> , 2017, 3, 17072.	2.0	35
1545	MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. <i>Science Signaling</i> , 2017, 10, .	1.6	41
1546	Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. <i>Genes and Development</i> , 2017, 31, 2067-2084.	2.7	57

#	ARTICLE	IF	CITATIONS
1547	Drosophila muscles regulate the immune response against wasp infection via carbohydrate metabolism. <i>Scientific Reports</i> , 2017, 7, 15713.	1.6	41
1548	New targets and therapies for gastrointestinal stromal tumors. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1117-1129.	1.1	18
1549	Modulation of telomere protection by the PI3K/AKT pathway. <i>Nature Communications</i> , 2017, 8, 1278.	5.8	47
1550	The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1000, 187-210.	0.8	74
1551	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5981-5992.	3.2	107
1552	AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway. <i>Oncology Letters</i> , 2017, 14, 981-986.	0.8	10
1553	Targeting the mTOR pathway in breast cancer. <i>Tumor Biology</i> , 2017, 39, 101042831771082.	0.8	20
1554	Global quantitative biology can illuminate ontological connections between diseases. <i>Quantitative Biology</i> , 2017, 5, 191-198.	0.3	3
1555	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017, 547, 109-113.	13.7	142
1556	Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 17.	2.3	41
1557	Somatic PI3K activity regulates transition to the spermatocyte stages in <i>Drosophila</i> testis. <i>Journal of Biosciences</i> , 2017, 42, 285-297.	0.5	3
1558	PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. <i>Molecular Cancer</i> , 2017, 16, 93.	7.9	18
1559	Deficiency of Phosphatidylinositol 3-Kinase γ Signaling Leads to Diminished Numbers of Regulatory T Cells and Increased Neutrophil Activity Resulting in Mortality Due to Endotoxic Shock. <i>Journal of Immunology</i> , 2017, 199, 1086-1095.	0.4	18
1560	Neomorphic mutations create therapeutic challenges in cancer. <i>Oncogene</i> , 2017, 36, 1607-1618.	2.6	24
1561	Dietary phytochemicals for possible preventive and therapeutic option of uterine fibroids: Signaling pathways as target. <i>Pharmacological Reports</i> , 2017, 69, 57-70.	1.5	22
1562	MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 519-532.	1.5	176
1563	Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway. <i>Clinical Cancer Research</i> , 2017, 23, 575-586.	3.2	28
1564	BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. <i>International Journal of Cancer</i> , 2017, 140, 449-459.	2.3	51

#	ARTICLE	IF	CITATIONS
1565	Recent advances in targeting mTOR signaling pathway using small molecule inhibitors. <i>Journal of Drug Targeting</i> , 2017, 25, 189-201.	2.1	21
1566	ABT-737 and pictilisib synergistically enhance pitavastatin-induced apoptosis in ovarian cancer cells. <i>Oncology Letters</i> , 2018, 15, 1979-1984.	0.8	10
1567	Circulating microRNA expression and their target genes in deep vein thrombosis. <i>Medicine (United States)</i> , 2017, 96, 10000-10006.	0.4	20
1568	Genomic footprints of dryland stress adaptation in Egyptian fat-tail sheep and their divergence from East African and western Asia cohorts. <i>Scientific Reports</i> , 2017, 7, 17647.	1.6	64
1569	Aqueous extract of <i>Cordyceps sinensis</i> potentiates the antitumor effect of DDP and attenuates therapy-associated toxicity in non-small cell lung cancer via β -tubulin/NF- κ B and AKT/MMP2/MMP9 pathways. <i>RSC Advances</i> , 2017, 7, 37743-37754.	1.7	10
1570	Feedback Activation of Basic Fibroblast Growth Factor Signaling via the Wnt/ β -Catenin Pathway in Skin Fibroblasts. <i>Frontiers in Pharmacology</i> , 2017, 08, 32.	1.6	46
1571	Formal Modeling of mTOR Associated Biological Regulatory Network Reveals Novel Therapeutic Strategy for the Treatment of Cancer. <i>Frontiers in Physiology</i> , 2017, 8, 416.	1.3	4
1572	PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain. <i>Current Pharmaceutical Design</i> , 2017, 23, 1860-1868.	0.9	74
1573	MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	15
1574	Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer. <i>Cancers</i> , 2017, 9, 60.	1.7	24
1575	Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. <i>Cancers</i> , 2017, 9, 86.	1.7	28
1576	Cytokine Receptor Endocytosis: New Kinase Activity-Dependent and -Independent Roles of PI3K. <i>Frontiers in Endocrinology</i> , 2017, 8, 78.	1.5	19
1577	Conditional Deletion of PDK1 in the Forebrain Causes Neuron Loss and Increased Apoptosis during Cortical Development. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 330.	1.8	20
1578	Ataxia-Telangiectasia Mutated Modulation of Carbon Metabolism in Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 291.	1.3	36
1579	The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma. <i>Frontiers in Oncology</i> , 2017, 7, 312.	1.3	17
1580	Podocyte Autophagy: A Potential Therapeutic Target to Prevent the Progression of Diabetic Nephropathy. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-6.	1.0	50
1581	AIM2 regulates viability and apoptosis in human colorectal cancer cells via the PI3K/Akt pathway. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 811-817.	1.0	39
1582	The role of lipids in host microbe interactions. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 1581-1598.	3.0	2

#	ARTICLE	IF	CITATIONS
1583	Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 395-403.	0.9	19
1584	PTEN, Insulin Resistance and Cancer. <i>Current Pharmaceutical Design</i> , 2017, 23, 3667-3676.	0.9	63
1585	XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis. <i>BMC Cancer</i> , 2017, 17, 640.	1.1	39
1586	Regulation of Ras signaling and function by plasma membrane microdomains. <i>BioScience Trends</i> , 2017, 11, 23-40.	1.1	13
1587	PirB inhibits axonal outgrowth via the PI3K/Akt/mTOR signaling pathway. <i>Molecular Medicine Reports</i> , 2017, 17, 1093-1098.	1.1	11
1588	Function of miR-152 as a Tumor Suppressor in Human Breast Cancer by Targeting PIK3CA. <i>Oncology Research</i> , 2017, 25, 1363-1371.	0.6	42
1589	Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5077-5087.	1.0	1
1590	ANTITUMOR AND APOPTOTIC EFFECTS OF CUCURBITACIN A IN A-549 LUNG CARCINOMA CELLS IS MEDIATED VIA G2/M CELL CYCLE ARREST AND M-TOR/PI3K/AKT SIGNALLING PATHWAY.. <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2017, 14, 75-82.	0.3	10
1591	<i>PIK3CA</i> gene mutations in Northwest Chinese esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2585.	1.4	9
1592	LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85. <i>Cancer Letters</i> , 2018, 420, 38-48.	3.2	46
1593	PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery. <i>BioEssays</i> , 2018, 40, e1700247.	1.2	151
1594	Determination of Puquitinib in Human Plasma by HPLC–ESI MS/MS: Application to Pharmacokinetic Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 555-564.	0.6	0
1595	Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 256-261.	1.3	13
1596	Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 591-602.	1.9	71
1597	Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma. <i>Cancer Research</i> , 2018, 78, 2179-2190.	0.4	33
1598	Update of pathophysiology and management of diabetic kidney disease. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 662-675.	0.8	325
1599	HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells. <i>Gene</i> , 2018, 663, 9-16.	1.0	17
1600	Canonical PI3K³ signaling in myeloid cells restricts <i>Trypanosoma cruzi</i> infection and dampens chagasic myocarditis. <i>Nature Communications</i> , 2018, 9, 1513.	5.8	19

#	ARTICLE	IF	CITATIONS
1601	Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update. <i>Journal of Cellular Physiology</i> , 2018, 233, 6440-6454.	2.0	35
1602	EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. <i>Molecular Cell</i> , 2018, 70, 197-210.e7.	4.5	116
1603	Ablation of insulin receptor substrates 1 and 2 suppresses <i>Kras</i> -driven lung tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4228-4233.	3.3	22
1604	<i>Lactobacillus fermentum</i> L930BB and <i>Bifidobacterium animalis</i> subsp. <i>animalis</i> IM386 initiate signalling pathways involved in intestinal epithelial barrier protection. <i>Beneficial Microbes</i> , 2018, 9, 515-525.	1.0	23
1605	Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3K. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 460-470.	2.6	16
1606	Asymmetric PI3K Activity in Lymphocytes Organized by a PI3K-Mediated Polarity Pathway. <i>Cell Reports</i> , 2018, 22, 860-868.	2.9	31
1607	Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis. <i>Cancer Research</i> , 2018, 78, 2638-2653.	0.4	30
1608	Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling. <i>Clinical Science</i> , 2018, 132, 381-397.	1.8	17
1609	The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4287-4292.	1.2	69
1610	Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 637-646.	1.4	5
1611	An iridium (III) complex as potent anticancer agent induces apoptosis and autophagy in B16 cells through inhibition of the AKT/mTOR pathway. <i>European Journal of Medicinal Chemistry</i> , 2018, 145, 302-314.	2.6	49
1612	PI3K inhibition to overcome endocrine resistance in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 1-15.	1.9	38
1613	PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer. <i>Aging Male</i> , 2018, 21, 211-222.	0.9	23
1614	BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far. <i>Current Problems in Cancer</i> , 2018, 42, 189-207.	1.0	19
1615	PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. <i>Future Oncology</i> , 2018, 14, 665-674.	1.1	49
1616	Critical molecular pathways in CLL therapy. <i>Molecular Medicine</i> , 2018, 24, 9.	1.9	33
1617	PTEN/PTENP1: Regulating the regulator of RTK-dependent PI3K/Akt signalling™, new targets for cancer therapy. <i>Molecular Cancer</i> , 2018, 17, 37.	7.9	190
1618	The impact of phosphatases on proliferative and survival signaling in cancer. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 2695-2718.	2.4	27

#	ARTICLE	IF	CITATIONS
1620	Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes. <i>Diabetes</i> , 2018, 67, 1297-1309.	0.3	16
1621	Anti-tumour effects of beta-sitosterol are mediated by AMPK/PTEN/HSP90 axis in AGS human gastric adenocarcinoma cells and xenograft mouse models. <i>Biochemical Pharmacology</i> , 2018, 152, 60-70.	2.0	40
1622	Deciphering metabonomics biomarkers-targets interactions for psoriasis vulgaris by network pharmacology. <i>Annals of Medicine</i> , 2018, 50, 323-332.	1.5	10
1623	A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 36-44.	1.2	10
1624	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. <i>Seminars in Cancer Biology</i> , 2018, 48, 91-103.	4.3	257
1625	Cellular Senescence, Neurological Function, and Redox State. <i>Antioxidants and Redox Signaling</i> , 2018, 28, 1704-1723.	2.5	31
1626	Comparative aspects of GnRH-Stimulated signal transduction in the vertebrate pituitary " Contributions from teleost model systems. <i>Molecular and Cellular Endocrinology</i> , 2018, 463, 142-167.	1.6	54
1627	Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 78-91.	0.6	24
1628	A ERK/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K/AKT activation in macrophages. <i>FASEB Journal</i> , 2018, 32, 875-887.	0.2	31
1629	Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. <i>Breast Cancer</i> , 2018, 25, 392-401.	1.3	134
1630	Tyrosines-740/751 of PDGFR ^β contribute to the activation of Akt/Hif1 ^α /TGF ^β 2 nexus to drive high glucose-induced glomerular mesangial cell hypertrophy. <i>Cellular Signalling</i> , 2018, 42, 44-53.	1.7	6
1631	Mechanism of Neonicotinoid Toxicity: Impact on Oxidative Stress and Metabolism. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 471-507.	4.2	195
1632	PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium. <i>International Journal of Pharmaceutics</i> , 2018, 548, 747-758.	2.6	40
1634	Signaling Transduction and Metabolomics. , 2018, , 68-78.		7
1635	Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer. <i>Methods in Molecular Biology</i> , 2018, 1655, 335-350.	0.4	117
1636	Autosomal Recessive Agammaglobulinemia Due to a Homozygous Mutation in PIK3R1. <i>Journal of Clinical Immunology</i> , 2018, 38, 88-95.	2.0	44
1637	Regulation of cellular and PCP signalling by the Scribble polarity module. <i>Seminars in Cell and Developmental Biology</i> , 2018, 81, 33-45.	2.3	19
1638	Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. <i>European Journal of Cancer</i> , 2018, 89, 64-71.	1.3	3

#	ARTICLE	IF	CITATIONS
1639	Effects of PI3K and FSH on steroidogenesis, viability and embryo development of the cumulus-oocyte complex after <i>in vitro</i> culture. <i>Zygote</i> , 2018, 26, 50-61.	0.5	10
1640	Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. <i>Hepatology</i> , 2018, 67, 2271-2286.	3.6	78
1641	A Preclinical Evaluation of the Antitumor Activities of Edible and Medicinal Mushrooms: A Molecular Insight. <i>Integrative Cancer Therapies</i> , 2018, 17, 200-209.	0.8	33
1642	Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 1796-1811.	2.0	28
1643	Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. <i>Oncotarget</i> , 2018, 9, 8810-8822.	0.8	15
1644	Phosphatidylinositol 3-Kinase Inhibitor Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299.	0.8	298
1645	Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 981-990.	0.8	95
1646	PI3K Signaling in Neurons: A Central Node for the Control of Multiple Functions. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3725.	1.8	104
1647	Merkel's Disease Virus Activates the PI3K/Akt Pathway Through Interaction of Its Protein Meq With the P85 Subunit of PI3K to Promote Viral Replication. <i>Frontiers in Microbiology</i> , 2018, 9, 2547.	1.5	18
1648	Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2052-2062.	13.9	211
1649	Proteomic Analysis of Plasma Membrane Proteins of Antler Stem Cells Using Label-Free LC-MS/MS. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3477.	1.8	11
1650	Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania. <i>PLoS ONE</i> , 2018, 13, e0206920.	1.1	17
1651	Src kinase inhibitor PP2 regulates the biological characteristics of A549 cells via the PI3K/Akt signaling pathway. <i>Oncology Letters</i> , 2018, 16, 5059-5065.	0.8	4
1652	PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). <i>Molecular Medicine Reports</i> , 2019, 19, 783-791.	1.1	224
1653	Context-dependent expression of a conditionally-inducible form of active Akt. <i>PLoS ONE</i> , 2018, 13, e0197899.	1.1	3
1654	Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 35-53.	0.8	16
1655	The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β -catenin/SIRT3 signaling pathway in cervical cancer. <i>Journal of Hematology and Oncology</i> , 2018, 11, 139.	6.9	65
1656	PI3Kinases in Diabetes Mellitus and Its Related Complications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4098.	1.8	33

#	ARTICLE	IF	CITATIONS
1657	Insulin-Like Growth Factor I Regulation and Its Actions in Skeletal Muscle. , 2018, 9, 413-438.		26
1658	Down-Regulation of Laminin (LN)- β 5 is Associated with Preeclampsia and Impairs Trophoblast Cell Viability and Invasiveness Through PI3K Signaling Pathway. Cellular Physiology and Biochemistry, 2018, 51, 2030-2040.	1.1	10
1659	Differing Roles of Hyaluronan Molecular Weight on Cancer Cell Behavior and Chemotherapy Resistance. Cancers, 2018, 10, 482.	1.7	54
1660	Discovery of Potent, Efficient, and Selective Inhibitors of Phosphoinositide 3-Kinase β through a Deconstruction and Regrowth Approach. Journal of Medicinal Chemistry, 2018, 61, 11061-11073.	2.9	11
1661	Modified Ginseng Extract Induces Apoptosis in HepG2 Cancer Cells by Blocking the CXCL8-Mediated Akt/Nuclear Factor- κ B Signaling Pathway. The American Journal of Chinese Medicine, 2018, 46, 1645-1662.	1.5	4
1662	Cellular Inflammatory Responses. , 2018, , 475-590.		0
1663	Cancer Metabolism: a Hope for Curing Cancer. Biomolecules and Therapeutics, 2018, 26, 1-3.	1.1	7
1664	Metformin reverses the resistance mechanism of lung adenocarcinoma cells that knocks down the Nrf2 gene. Oncology Letters, 2018, 16, 6071-6080.	0.8	14
1665	Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor. Future Medicinal Chemistry, 2018, 10, 2445-2455.	1.1	7
1666	Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nature Biomedical Engineering, 2018, 2, 850-864.	11.6	214
1667	Spatial alterations of De Novo purine biosynthetic enzymes by Akt-independent PDK1 signaling pathways. PLoS ONE, 2018, 13, e0195989.	1.1	9
1668	MicroRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression. International Journal of Molecular Medicine, 2018, 42, 2503-2514.	1.8	18
1669	Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases “ potentially novel therapeutic targets. Expert Opinion on Therapeutic Targets, 2018, 22, 869-877.	1.5	12
1670	Novel immunotherapy approaches to follicular lymphoma. Hematology American Society of Hematology Education Program, 2018, 2018, 194-199.	0.9	8
1671	Adaptive Group-combined P-values Test for Two-sample Location Problem with Applications to Microarray Data. Scientific Reports, 2018, 8, 8117.	1.6	2
1672	Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent. Cancer Biology and Therapy, 2018, 19, 1015-1022.	1.5	5
1673	mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy. Oncogene, 2018, 37, 5205-5220.	2.6	54
1674	65 YEARS OF THE DOUBLE HELIX: One gene, many endocrine and metabolic syndromes: PTEN-opathies and precision medicine. Endocrine-Related Cancer, 2018, 25, T121-T140.	1.6	45

#	ARTICLE	IF	CITATIONS
1675	PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. <i>Cell Death and Disease</i> , 2018, 9, 739.	2.7	88
1676	Transcriptome analysis reveals candidate genes involved in splay leg syndrome in piglets. <i>Journal of Applied Genetics</i> , 2018, 59, 475-483.	1.0	7
1677	Comparative Analysis of V-Akt Murine Thymoma Viral Oncogene Homolog 3 (AKT3) Gene between Cow and Buffalo Reveals Substantial Differences for Mastitis. <i>BioMed Research International</i> , 2018, 2018, 1-13.	0.9	5
1678	Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. <i>Frontiers in Physiology</i> , 2018, 9, 335.	1.3	66
1679	Genome-Wide Identification and Characterization of Long Non-Coding RNA in Wheat Roots in Response to Ca ²⁺ Channel Blocker. <i>Frontiers in Plant Science</i> , 2018, 9, 244.	1.7	36
1680	Glucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells. <i>International Journal of Biological Sciences</i> , 2018, 14, 418-426.	2.6	59
1681	Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 23-29.	1.0	15
1682	Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases. <i>Physiological Reviews</i> , 2018, 98, 1335-1370.	13.1	70
1683	Synaptopodin-2 plays an important role in the metastasis of breast cancer via PI3K/Akt/mTOR pathway. <i>Cancer Management and Research</i> , 2018, Volume 10, 1575-1583.	0.9	17
1684	MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. <i>BMC Cancer</i> , 2018, 18, 605.	1.1	11
1685	Bapx1 upregulation is associated with ectopic mandibular cartilage development in amphibians. <i>Zoological Letters</i> , 2018, 4, 16.	0.7	10
1686	Detection of Selection Signatures in Chinese Landrace and Yorkshire Pigs Based on Genotyping-by-Sequencing Data. <i>Frontiers in Genetics</i> , 2018, 9, 119.	1.1	41
1687	Fortunellin-Induced Modulation of Phosphatase and Tensin Homolog by MicroRNA-374a Decreases Inflammation and Maintains Intestinal Barrier Function in Colitis. <i>Frontiers in Immunology</i> , 2018, 9, 83.	2.2	14
1688	Reducing the Levels of Akt Activation by PDK1 Knock-in Mutation Protects Neuronal Cultures against Synthetic Amyloid-Beta Peptides. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 435.	1.7	29
1689	Melatonin and Cancer Hallmarks. <i>Molecules</i> , 2018, 23, 518.	1.7	144
1690	LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway. <i>BMC Cancer</i> , 2018, 18, 722.	1.1	26
1691	Simulation Analysis and Experimental Study of the Cooker Hoods of High-Rise Residential Buildings. <i>Applied Sciences (Switzerland)</i> , 2018, 8, 777.	1.3	1
1692	Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. <i>International Journal of Molecular Sciences</i> , 2018, 19, 382.	1.8	20

#	ARTICLE	IF	CITATIONS
1693	The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 778.	1.8	129
1694	Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates. <i>Molecules</i> , 2018, 23, 787.	1.7	38
1695	Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3K δ) inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 831-846.	2.6	8
1696	20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1053.	1.8	32
1697	Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anticancer Potential of Aroma Compounds of Plant Essential Oils. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 87-109.	0.9	13
1698	Autophagy and Liver Disease. , 2018, , 201-210.		1
1699	High-throughput screening campaigns against a PI3K δ isoform bearing the H1047R mutation identified potential inhibitors with novel scaffolds. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1816-1822.	2.8	12
1700	AKT isoform-specific expression and activation across cancer lineages. <i>BMC Cancer</i> , 2018, 18, 742.	1.1	32
1701	CDK5RAP3 suppresses Wnt/ β 2-catenin signaling by inhibiting AKT phosphorylation in gastric cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 59.	3.5	30
1702	The protective effect of some Thai plants and their bioactive compounds in UV light-induced skin carcinogenesis. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2018, 185, 80-89.	1.7	9
1703	PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue. <i>BMC Cancer</i> , 2018, 18, 826.	1.1	11
1704	The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations. <i>Current Cancer Drug Targets</i> , 2018, 18, 355-364.	0.8	23
1705	Role and inhibition of GLI1 protein in cancer. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 35-43.	1.3	29
1706	The Antitumor Effect of Xihuang Pill on Treg Cells Decreased in Tumor Microenvironment of 4T1 Breast Tumor-Bearing Mice by PI3K/AKT-AP-1 Signaling Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-13.	0.5	7
1707	Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis. <i>Cell Research</i> , 2018, 28, 934-951.	5.7	57
1708	Reorganization of Ternary Lipid Mixtures of Nonphosphorylated Phosphatidylinositol Interacting with Angiomotin. <i>Journal of Physical Chemistry B</i> , 2018, 122, 8404-8415.	1.2	4
1709	Functional characterization of lysosomal interaction of Akt with VPK2. <i>Oncogene</i> , 2018, 37, 5367-5386.	2.6	20
1710	Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy. <i>PLoS ONE</i> , 2018, 13, e0190854.	1.1	42

#	ARTICLE	IF	CITATIONS
1711	Feeding state regulates pheromone-mediated avoidance behavior via the insulin signaling pathway in <i>Caenorhabditis elegans</i> . <i>EMBO Journal</i> , 2018, 37, .	3.5	25
1712	Polymicrogyria in association with hypoglycemia points to mutation in the mTOR pathway. <i>European Journal of Medical Genetics</i> , 2018, 61, 738-740.	0.7	12
1713	Pharmacological inactivation of the PI3K p110 β prevents breast tumour progression by targeting cancer cells and macrophages. <i>Cell Death and Disease</i> , 2018, 9, 678.	2.7	37
1714	Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 639-653.	1.5	14
1715	Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6087-6109.	2.9	30
1716	Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3K α inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3982-3991.	1.4	4
1717	PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugs. , 2019, , 123-144.		2
1718	Mitochondrial PIP3-binding protein FUNDC2 supports platelet survival via AKT signaling pathway. <i>Cell Death and Differentiation</i> , 2019, 26, 321-331.	5.0	41
1719	Autophagy in Human Health and Disease: Novel Therapeutic Opportunities. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 577-634.	2.5	96
1720	Relativistic self-focusing of Laguerre-Gaussian beam in an underdense plasma. <i>AIP Conference Proceedings</i> , 2019, , .	0.3	6
1721	The ubiquitination ligase SMURF2 reduces aerobic glycolysis and colorectal cancer cell proliferation by promoting ChREBP ubiquitination and degradation. <i>Journal of Biological Chemistry</i> , 2019, 294, 14745-14756.	1.6	27
1722	Small molecule modulators targeting protein kinase CK1 and CK2. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111581.	2.6	38
1723	Circ-IGF1R has pro-proliferative and anti-apoptotic effects in HCC by activating the PI3K/AKT pathway. <i>Gene</i> , 2019, 716, 144031.	1.0	47
1724	<p>Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5971-5982.	0.9	19
1725	TOR as a Regulatory Target in <i>Rhipicephalus microplus</i> Embryogenesis. <i>Frontiers in Physiology</i> , 2019, 10, 965.	1.3	5
1726	Hyperinsulinemia promotes aberrant histone acetylation in triple-negative breast cancer. <i>Epigenetics and Chromatin</i> , 2019, 12, 44.	1.8	23
1727	<p>Animal models of well-differentiated/dedifferentiated liposarcoma: utility and limitations</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5257-5268.	1.0	10
1728	Cbl-PI3K interaction regulates Cathepsin K secretion in osteoclasts. <i>Bone</i> , 2019, 127, 376-385.	1.4	15

#	ARTICLE	IF	CITATIONS
1729	Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8873-8879.	2.9	19
1730	Apoptosis Induction and Alteration of Cell Adherence in Human Lung Cancer Cells under Simulated Microgravity. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3601.	1.8	31
1731	Identification of RNA aptamer which specifically interacts with PtdIns(3)P. <i>Biochemical and Biophysical Research Communications</i> , 2019, 517, 146-154.	1.0	4
1732	<p>Norcantharidin inhibits the DDR of bladder cancer stem-like cells through cdc6 degradation</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4403-4413.	1.0	9
1733	Phosphatidylinositol Kinases and Phosphatases in <i>Entamoeba histolytica</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 150.	1.8	30
1734	Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches. <i>PLoS ONE</i> , 2019, 14, e0219180.	1.1	27
1735	The microRNAs miR-204 and miR-211 maintain joint homeostasis and protect against osteoarthritis progression. <i>Nature Communications</i> , 2019, 10, 2876.	5.8	112
1736	Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 405-414.	1.1	5
1737	Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 726-732.	1.0	12
1738	Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2051-2059.	1.2	30
1739	Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor. <i>Frontiers in Immunology</i> , 2019, 10, 1399.	2.2	96
1740	Utilising network pharmacology to explore the underlying mechanism of Wumei Pill in treating pancreatic neoplasms. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 158.	3.7	80
1741	Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 945-958.	0.4	7
1742	Management of toxicity to isoform β -specific PI3K inhibitors. <i>Annals of Oncology</i> , 2019, 30, x21-x26.	0.6	70
1743	Multipotent Stromal Cells in a Tumor Microenvironment. , 2019, , .		0
1744	Testis developmental related gene 1 regulates the chemosensitivity of seminoma TCamâ€2 cells to cisplatin via autophagy. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7773-7784.	1.6	17
1745	Silica nanoparticles induce spermatocyte cell autophagy through microRNA-494 targeting AKT in GC-2spd cells. <i>Environmental Pollution</i> , 2019, 255, 113172.	3.7	26
1746	Diet, Microbiota, and Colorectal Cancer. <i>IScience</i> , 2019, 21, 168-187.	1.9	21

#	ARTICLE	IF	CITATIONS
1747	AEBP1 down regulation induced cell death pathway depends on PTEN status of glioma cells. <i>Scientific Reports</i> , 2019, 9, 14577.	1.6	10
1748	The Modulatory Properties of <i>Astragalus membranaceus</i> Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method. <i>Frontiers in Pharmacology</i> , 2019, 10, 1171.	1.6	32
1749	The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities. <i>Biomolecules</i> , 2019, 9, 713.	1.8	17
1750	CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50. <i>Theranostics</i> , 2019, 9, 6840-6855.	4.6	33
1751	Myo-Inositol and Its Derivatives: Their Emerging Role in the Treatment of Human Diseases. <i>Frontiers in Pharmacology</i> , 2019, 10, 1172.	1.6	113
1752	Identification of microRNA in <i>Houttuynia cordata</i> Thunb and prediction of cross kingdom functions. <i>ExRNA</i> , 2019, 1, .	1.0	2
1753	Implication of viral microRNAs in the genesis and diagnosis of Epstein-Barr virus-associated tumors (Review). <i>Oncology Letters</i> , 2019, 18, 3433-3442.	0.8	11
1754	Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2019, 15, 2227-2239.	1.1	13
1755	Chronic Treatment with α -Lipoic Acid Improves Endothelium-Dependent Vasorelaxation of Aortas in High-Fat Diet-Fed Mice. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 1456-1463.	0.6	4
1756	Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4158.	1.8	14
1757	Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 767-774.	1.5	58
1758	A novel miRNA identified in GRSF1 complex drives the metastasis via the PIK3R3/AKT/NF- κ B and TIMP3/MMP9 pathways in cervical cancer cells. <i>Cell Death and Disease</i> , 2019, 10, 636.	2.7	37
1759	Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivatives containing piperazine as inhibitors of PI3K. <i>Bioorganic Chemistry</i> , 2019, 92, 103238.	2.0	7
1760	Effect of the Large and Small T-Antigens of Human Polyomaviruses on Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3914.	1.8	18
1761	Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells. <i>Journal of Experimental Medicine</i> , 2019, 216, 2800-2818.	4.2	59
1762	Network Pharmacology Analysis of Traditional Chinese Medicine Formula Xiao Ke Yin Shui Treating Type 2 Diabetes Mellitus. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-15.	0.5	21
1763	Expression of GR α and HDAC2 in steroid-Sensitive and steroid-Insensitive interstitial lung disease. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109380.	2.5	8
1764	Phosphoinositides: Regulators of Nervous System Function in Health and Disease. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 208.	1.4	76

#	ARTICLE	IF	CITATIONS
1765	Anticonvulsant action of a selective phosphatidylinositol-3-kinase inhibitor LY294002 in pentylenetetrazole-mediated convulsions in zebrafish. <i>Epilepsy Research</i> , 2019, 157, 106207.	0.8	25
1766	Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives. <i>Cancers</i> , 2019, 11, 1401.	1.7	70
1767	TOCOTRIENOL-RICH FRACTION MODULATE THE PHOSPHOINOSITIDE 3-KINASES/AKT SIGNALING PATHWAY GENES AND PREVENT OXIDATIVE STRESS IN NICOTINE-INDUCED PRE-IMPLANTATION EMBRYOS. <i>International Journal of Applied Pharmaceutics</i> , 0, , 80-85.	0.3	0
1768	Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems. <i>Biomolecules</i> , 2019, 9, 530.	1.8	55
1769	Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 1053-1062.	1.0	14
1770	Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3K $\hat{\pm}$) and Its Involvement in Oncogenesis: An in Silico Insight. <i>ACS Omega</i> , 2019, 4, 15815-15823.	1.6	21
1771	PI3K/Akt-Beclin1 signaling pathway positively regulates phagocytosis and negatively mediates NF- $\hat{\rho}$ B-dependent inflammation in <i>Staphylococcus aureus</i> -infected macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2019, 510, 284-289.	1.0	25
1772	Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc. <i>Cellular and Molecular Immunology</i> , 2019, 16, 757-769.	4.8	21
1773	The interface between phosphatidylinositol transfer protein function and phosphoinositide signaling in higher eukaryotes. <i>Journal of Lipid Research</i> , 2019, 60, 242-268.	2.0	59
1774	Proteolysis-targeting chimeras for targeting protein for degradation. <i>Future Medicinal Chemistry</i> , 2019, 11, 723-741.	1.1	14
1775	Conformationally restricted quinazolone derivatives as PI3K $\hat{\pm}$ -selective inhibitors: the design, synthesis and biological evaluation. <i>MedChemComm</i> , 2019, 10, 413-420.	3.5	5
1776	Role of PTP/PTK trans activated insulin-like signalling pathway in regulation of grasshopper (<i>Oedaleus</i>) Tj ETQq1 1 0,784314 rgBT /Over	2.7	9
1777	GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN. <i>Biochemical and Biophysical Research Communications</i> , 2019, 510, 339-344.	1.0	13
1778	MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. <i>Breast Cancer Research</i> , 2019, 21, 20.	2.2	52
1779	Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease?. <i>Experimental Neurology</i> , 2019, 320, 112967.	2.0	38
1780	Functional differentiation of three phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) in response to <i>Vibrio anguillarum</i> infection in turbot (<i>Scophthalmus maximus</i>). <i>Fish and Shellfish Immunology</i> , 2019, 92, 450-459.	1.6	2
1781	Triptonide acts as a novel antiprostata cancer agent mainly through inhibition of mTOR signaling pathway. <i>Prostate</i> , 2019, 79, 1284-1293.	1.2	13
1782	Prenatal and ancestral exposure to di(2-ethylhexyl) phthalate alters gene expression and DNA methylation in mouse ovaries. <i>Toxicology and Applied Pharmacology</i> , 2019, 379, 114629.	1.3	39

#	ARTICLE	IF	CITATIONS
1783	Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 397.	1.3	31
1784	HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy. <i>Cells</i> , 2019, 8, 532.	1.8	68
1785	Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 468-483.	2.6	27
1786	Melatonin: A new inhibitor agent for cervical cancer treatment. <i>Journal of Cellular Physiology</i> , 2019, 234, 21670-21682.	2.0	59
1787	Potential Roles of miR-374a-5p in Mediating Neuroprotective Effects and Related Molecular Mechanism. <i>Journal of Molecular Neuroscience</i> , 2019, 69, 123-132.	1.1	9
1788	Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFN γ receptor signaling. , 2019, 7, 152.		57
1789	Disrupted apolipoprotein L1-miR193a axis dedifferentiates podocytes through autophagy blockade in an APOL1 risk milieu. <i>American Journal of Physiology - Cell Physiology</i> , 2019, 317, C209-C225.	2.1	21
1790	Mechanism of Apoptosis Induced by Curcumin in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2454.	1.8	103
1791	ROS play an important role in ATPR inducing differentiation and inhibiting proliferation of leukemia cells by regulating the PTEN/PI3K/AKT signaling pathway. <i>Biological Research</i> , 2019, 52, 26.	1.5	32
1792	Phosphoinositide 3-kinase is a regulatory T cell target in cancer immunotherapy. <i>Immunology</i> , 2019, 157, 210-218.	2.0	30
1794	Fine-tuning AKT kinase activity through direct lysine methylation. <i>Cell Cycle</i> , 2019, 18, 917-922.	1.3	19
1795	mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro. <i>Cells</i> , 2019, 8, 431.	1.8	19
1796	Aggressive Prolactin-Secreting Pituitary Adenomas and Carcinomas. <i>Contemporary Endocrinology</i> , 2019, , 219-236.	0.3	0
1797	Icariin enhances the chemosensitivity of cisplatin-resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway. <i>International Journal of Oncology</i> , 2019, 54, 1933-1942.	1.4	16
1798	Bombyxin/Akt signaling in relation to the embryonic diapause process of the silkworm, <i>Bombyx mori</i> . <i>Journal of Insect Physiology</i> , 2019, 116, 32-40.	0.9	30
1799	Akt/AS160 Signaling Pathway Inhibition Impairs Infection by Decreasing Rab14-Controlled Sphingolipids Delivery to Chlamydial Inclusions. <i>Frontiers in Microbiology</i> , 2019, 10, 666.	1.5	16
1800	Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. <i>Cells</i> , 2019, 8, 350.	1.8	26
1801	PI3K activation increases SDF-1 production and number of osteoclast precursors, and enhances SDF-1-mediated osteoclast precursor migration. <i>Bone Reports</i> , 2019, 10, 100203.	0.2	11

#	ARTICLE	IF	CITATIONS
1802	Synergic effects of inhibition of glycolysis and multikinase receptor signalling on proliferation and migration of endothelial cells. <i>General Physiology and Biophysics</i> , 2019, 38, 157-163.	0.4	4
1803	Hexadecenal inhibits growth of C6 glioma cells. <i>Cell Biochemistry and Function</i> , 2019, 37, 281-289.	1.4	7
1804	MicroRNA-31 regulating apoptosis by mediating the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in treatment of spinal cord injury. <i>Brain and Development</i> , 2019, 41, 649-661.	0.6	30
1805	Design, synthesis and biological evaluation of novel chromeno[4,3-c]pyrazol-4(2H)-one derivatives containing sulfonamido as potential PI3K inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2261-2267.	1.4	8
1806	Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (<i>ATR</i>) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer. <i>Cancer Research</i> , 2019, 79, 2933-2946.	0.4	46
1807	Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1929-1936.	1.8	53
1808	GRP94 promotes muscle differentiation by inhibiting the PI3K/AKT/mTOR signaling pathway. <i>Journal of Cellular Physiology</i> , 2019, 234, 21211-21223.	2.0	15
1809	ZNF692 promotes colon adenocarcinoma cell growth and metastasis by activating the PI3K/AKT pathway. <i>International Journal of Oncology</i> , 2019, 54, 1691-1703.	1.4	14
1810	miR-142-5p promotes the osteoclast differentiation of bone marrow-derived macrophages via PTEN/PI3K/AKT/FoxO1 pathway. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 815-824.	1.3	39
1811	Chemoproteomic Selectivity Profiling of PIKK and PI3K Kinase Inhibitors. <i>ACS Chemical Biology</i> , 2019, 14, 655-664.	1.6	21
1812	Up regulation of isoleucyl-tRNA synthetase promotes vascular smooth muscle cells dysfunction via p38 MAPK/PI3K signaling pathways. <i>Life Sciences</i> , 2019, 224, 51-57.	2.0	10
1813	Phosphoinositide phosphatases in cancer cell dynamics—Beyond PI3K and PTEN. <i>Seminars in Cancer Biology</i> , 2019, 59, 50-65.	4.3	25
1814	Identification of key pathways and candidate genes in pancreatic ductal adenocarcinoma using bioinformatics analysis. <i>Oncology Letters</i> , 2019, 17, 3751-3764.	0.8	8
1815	Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. <i>European Journal of Medicinal Chemistry</i> , 2019, 170, 55-72.	2.6	67
1816	Wound Healing Potential of Spirulina Protein on CCD-986sk Cells. <i>Marine Drugs</i> , 2019, 17, 130.	2.2	16
1817	Literature data based systems pharmacology uncovers the essence of "body fire" in traditional Chinese medicine: A case by Huang-Lian-Jie-Du-Tang. <i>Journal of Ethnopharmacology</i> , 2019, 237, 266-285.	2.0	12
1818	The kinetics of folding of the NSH2 domain from p85. <i>Scientific Reports</i> , 2019, 9, 4058.	1.6	9
1819	Facile Fabrication of an Amentoflavone-Loaded Micelle System for Oral Delivery To Improve Bioavailability and Hypoglycemic Effects in KKAY Mice. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 12904-12913.	4.0	24

#	ARTICLE	IF	CITATIONS
1820	Signalling circuits that direct early B-cell development. <i>Biochemical Journal</i> , 2019, 476, 769-778.	1.7	13
1821	Deoxypodophyllotoxin inhibits cell viability and invasion by blocking the PI3K/Akt signaling pathway in human glioblastoma cells. <i>Oncology Reports</i> , 2019, 41, 2453-2463.	1.2	7
1822	PI3K activity in dendritic cells exerts paradoxical effects during autoimmune inflammation. <i>Molecular Immunology</i> , 2019, 111, 32-42.	1.0	10
1824	Metabolic regulation of cell growth and proliferation. <i>Nature Reviews Molecular Cell Biology</i> , 2019, 20, 436-450.	16.1	577
1825	In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer. <i>Medical Oncology</i> , 2019, 36, 43.	1.2	6
1826	Influenza Virus Infections and Cellular Kinases. <i>Viruses</i> , 2019, 11, 171.	1.5	93
1827	mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 755.	1.8	406
1828	PIK3CA in cancer: The past 30 years. <i>Seminars in Cancer Biology</i> , 2019, 59, 36-49.	4.3	122
1829	Genome analysis of the rice coral <i>Montipora capitata</i> . <i>Scientific Reports</i> , 2019, 9, 2571.	1.6	53
1830	Targeting PI3K in cancer: mechanisms and advances in clinical trials. <i>Molecular Cancer</i> , 2019, 18, 26.	7.9	940
1831	Targeting PI3K $\hat{\imath}$ function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	2.6	9
1832	Molecular Profiling Establishes Genetic Features Predictive of the Efficacy of the p110 $\hat{\imath}$ 2 Inhibitor KIN-193. <i>Cancer Research</i> , 2019, 79, 4524-4531.	0.4	7
1833	The Prevalence of PIK3CA Biomarker in Tumor Microenvironment of Human non-small Cell Lung Cancer. <i>Journal of Physics: Conference Series</i> , 2019, 1294, 062112.	0.3	0
1834	Design, Synthesis and Preliminary Biological Evaluation of Benzylsulfone Coumarin Derivatives as Anti-Cancer Agents. <i>Molecules</i> , 2019, 24, 4034.	1.7	15
1835	PIK3CA Polymorphism (rs17849079 C/T) and Expression in Breast cancer Patients. <i>Gene Reports</i> , 2019, 17, 100512.	0.4	1
1836	Efficacy of PI3K inhibitors in advanced breast cancer. <i>Annals of Oncology</i> , 2019, 30, x12-x20.	0.6	145
1837	Clinical and Expression Significance of AKT1 by Co-expression Network Analysis in Endometrial Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1147.	1.3	22
1838	Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3K $\hat{\imath}$ Inhibitors. <i>Molecules</i> , 2019, 24, 4299.	1.7	2

#	ARTICLE	IF	CITATIONS
1839	Downregulation of class II phosphoinositide 3-kinase PI3K-C2 β delays cell division and potentiates the effect of docetaxel on cancer cell growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 472.	3.5	14
1840	Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 418-427.	1.0	8
1841	The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases. <i>Cells</i> , 2019, 8, 1597.	1.8	162
1842	PI3K Inhibitors in Breast Cancer Therapy. <i>Current Oncology Reports</i> , 2019, 21, 110.	1.8	120
1843	<p>>CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway</p></p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10135-10143.	0.9	24
1844	Metabolic Syndrome and Skin Diseases. <i>Frontiers in Endocrinology</i> , 2019, 10, 788.	1.5	48
1845	Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 131-142.	1.9	61
1846	FUNDC2 regulates platelet activation through AKT/GSK-3 β /cGMP axis. <i>Cardiovascular Research</i> , 2019, 115, 1672-1679.	1.8	14
1847	Convergent Synthesis of PI3K Inhibitor GDC-0908 Featuring Palladium-Catalyzed Direct C-H Arylation toward Dihydrobenzothienooxepines. <i>Journal of Organic Chemistry</i> , 2019, 84, 4796-4802.	1.7	10
1848	The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. <i>Nature Communications</i> , 2019, 10, 6.	5.8	159
1849	Molecular Pathways in Melanomagenesis. , 2019, , 623-642.		0
1850	Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. <i>Drug Safety</i> , 2019, 42, 247-262.	1.4	66
1851	Identification of potential target genes associated with the reversion of androgen-dependent skeletal muscle atrophy. <i>Archives of Biochemistry and Biophysics</i> , 2019, 663, 173-182.	1.4	6
1852	B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells. <i>Oncogene</i> , 2019, 38, 3371-3386.	2.6	21
1853	Targeting phosphoinositide 3-kinase pathway in biliary tract cancers: A remedial route?. <i>Journal of Cellular Physiology</i> , 2019, 234, 8259-8273.	2.0	5
1854	Dysregulation of Kr β ppel-like factor 12 in the development of endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 152, 177-184.	0.6	22
1855	Changes in Biological Pathways During 6,000 Years of Civilization in Europe. <i>Molecular Biology and Evolution</i> , 2019, 36, 127-140.	3.5	24
1856	Therapeutic potential of pteridine derivatives: A comprehensive review. <i>Medicinal Research Reviews</i> , 2019, 39, 461-516.	5.0	31

#	ARTICLE	IF	CITATIONS
1857	Correlation between microbes and colorectal cancer: tumor apoptosis is induced by sitosterols through promoting gut microbiota to produce short-chain fatty acids. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2019, 24, 168-183.	2.2	33
1858	Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e184475.	3.4	187
1859	Inhibition of MUC1 regulates metabolism by AKT pathway in esophageal squamous cell carcinoma. <i>Journal of Cellular Physiology</i> , 2019, 234, 12019-12028.	2.0	24
1860	The role of PI3K/AKT/FOXO signaling in psoriasis. <i>Archives of Dermatological Research</i> , 2019, 311, 83-91.	1.1	87
1861	p110 ^α and p110 ^β isoforms of PI3K are involved in protection against H ₂ O ₂ induced oxidative stress in cancer cells. <i>Breast Cancer</i> , 2019, 26, 378-385.	1.3	1
1862	PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features. <i>Human Pathology</i> , 2019, 86, 32-37.	1.1	8
1863	Virtual screening of naphthoquinone analogs for potent inhibitors against the cancer signaling PI3K/AKT/mTOR pathway. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 1328-1339.	1.2	32
1864	Metabolic Myopathies and Related Diseases. , 2019, , 217-240.		1
1865	Manganese coordination compounds of mefenamic acid: In vitro screening and in silico prediction of biological activity. <i>Journal of Inorganic Biochemistry</i> , 2019, 190, 1-14.	1.5	17
1866	New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 54-58.	0.6	7
1867	Feedback regulation of RTK signaling in development. <i>Developmental Biology</i> , 2019, 447, 71-89.	0.9	53
1868	A Deregulated PI3K-AKT Signaling Pathway in Patients with Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 35-41.	0.6	40
1869	PI3K Catalytic Subunits α and β Modulate Cell Death and IL-6 Secretion Induced by Talc Particles in Human Lung Carcinoma Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 62, 331-341.	1.4	2
1870	MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB. <i>Cancer Letters</i> , 2020, 469, 54-67.	3.2	45
1871	Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules. <i>Medicinal Research Reviews</i> , 2020, 40, 709-752.	5.0	138
1872	Emerging roles of aerobic glycolysis in breast cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 631-646.	1.2	140
1873	Management of Endometrial Cancer. , 2020, , .		3
1874	Growth hormone deficiency in megalencephaly-capillary malformation syndrome: An association with activating mutations in PIK3CA. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 162-168.	0.7	11

#	ARTICLE	IF	CITATIONS
1875	Hepatotoxic effects of inhalation exposure to polycyclic aromatic hydrocarbons on lipid metabolism of C57BL/6 mice. <i>Environment International</i> , 2020, 134, 105000.	4.8	40
1876	PTEN promotes intervertebral disc degeneration by regulating nucleus pulposus cell behaviors. <i>Cell Biology International</i> , 2020, 44, 583-592.	1.4	21
1877	Specific knockout of p85 β in brown adipose tissue induces resistance to high-fat diet-induced obesity and its metabolic complications in male mice. <i>Molecular Metabolism</i> , 2020, 31, 1-13.	3.0	10
1878	Activated hepatic stellate cells promote angiogenesis in hepatocellular carcinoma by secreting angiopoietin-1. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 1441-1451.	1.2	23
1879	A network analysis revealed the essential and common downstream proteins related to inguinal hernia. <i>PLoS ONE</i> , 2020, 15, e0226885.	1.1	3
1880	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. <i>Seminars in Cancer Biology</i> , 2020, 65, 51-64.	4.3	63
1881	The bovine Lactoferrin-Osteopontin complex increases proliferation of human intestinal epithelial cells by activating the PI3K/Akt signaling pathway. <i>Food Chemistry</i> , 2020, 310, 125919.	4.2	21
1882	A First-in-human Study of Tenisib (RP6530), a Dual PI3K β / δ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 78-86.	0.2	19
1883	The Role of Beclin 1-Dependent Autophagy in Cancer. <i>Biology</i> , 2020, 9, 4.	1.3	58
1884	Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors. <i>Cells</i> , 2020, 9, 10.	1.8	21
1885	Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7198.	1.8	3
1886	Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress. <i>Cancers</i> , 2020, 12, 2972.	1.7	52
1887	iGMDR: Integrated Pharmacogenetic Resource Guide to Cancer Therapy and Research. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 150-160.	3.0	5
1888	Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum. <i>Human Genetics and Genomics Advances</i> , 2020, 1, 100009.	1.0	6
1889	Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 245.	7.1	54
1890	Synergistic Carcinogenesis of HPV18 and MNNG in Het-1A Cells through p62-KEAP1-NRF2 and PI3K/AKT/mTOR Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-13.	1.9	8
1891	The Cosmc-mediated effects of neutrophil elastase on T antigen expression in BEAS-2B cells. <i>Respiratory Physiology and Neurobiology</i> , 2020, 281, 103496.	0.7	3
1892	Role of Phytochemicals in Modulating Signaling Cascades in Cancer Cells. , 2020, , 11-45.		1

#	ARTICLE	IF	CITATIONS
1893	Network pharmacology exploration reveals a common mechanism in the treatment of cardio-cerebrovascular disease with <i>Salvia miltiorrhiza</i> Burge. and <i>Carthamus tinctorius</i> L. BMC Complementary Medicine and Therapies, 2020, 20, 351.	1.2	14
1894	The Pivotal Potentials of Scorpion <i>Buthus Martensii</i> Karsch-Analgesic-Antitumor Peptide in Pain Management and Cancer. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-10.	0.5	11
1895	<p>The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells</p>. OncoTargets and Therapy, 2020, Volume 13, 12225-12241.	1.0	5
1896	miR-29 Sustains B Cell Survival and Controls Terminal Differentiation via Regulation of PI3K Signaling. Cell Reports, 2020, 33, 108436.	2.9	18
1897	PTEN and Other PtdIns(3,4,5)P3 Lipid Phosphatases in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 9189.	1.8	32
1898	Discovery of (<i>S</i>)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4- <i>d</i>]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinoline-3-carboxamide (IHMT-PI3K1-372) as a Potent and Selective PI3K1 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. Journal of Medicinal Chemistry, 2020, 63, 13973-13993.</i>	2.9	12
1899	Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094093.	1.4	55
1900	The Biological Role of Sponge Circular RNAs in Gastric Cancer: Main Players or Coadjuvants?. Cancers, 2020, 12, 1982.	1.7	16
1901	Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics. Drug Discovery Today, 2020, 25, 2294-2306.	3.2	22
1902	Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis. Cancers, 2020, 12, 2042.	1.7	14
1903	CCT128930 induces G1-phase arrest and apoptosis and synergistically enhances the anticancer efficiency of VS5584 in human osteosarcoma cells. Biomedicine and Pharmacotherapy, 2020, 130, 110544.	2.5	8
1904	The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review. Osteoarthritis and Cartilage, 2020, 28, 400-409.	0.6	279
1905	Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. Expert Opinion on Drug Safety, 2020, 19, 1105-1120.	1.0	6
1906	A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors. Cancer Cell International, 2020, 20, 337.	1.8	5
1907	Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. Breast Care, 2020, 15, 347-354.	0.8	46
1908	Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. Biomedicine and Pharmacotherapy, 2020, 130, 110626.	2.5	25
1909	Novel Nanococktail of a Dual PI3K/mTOR Inhibitor and Cabazitaxel for Castration-Resistant Prostate Cancer. Advanced Therapeutics, 2020, 3, 2000075.	1.6	5
1910	<p>Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort</p>. Cancer Management and Research, 2020, Volume 12, 7427-7437.	0.9	2

#	ARTICLE	IF	CITATIONS
1911	Astaxanthin targets PI3K/Akt signaling pathway toward potential therapeutic applications. <i>Food and Chemical Toxicology</i> , 2020, 145, 111714.	1.8	50
1912	Single-cell Sequencing and Methylation. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	4
1913	Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2962-2977.	1.7	15
1914	CD47 Enhances Cell Viability and Migration Ability but Inhibits Apoptosis in Endometrial Carcinoma Cells via the PI3K/Akt/mTOR Signaling Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 1525.	1.3	21
1915	TMT-Based Quantitative Proteomic Analysis Identification of Integrin Alpha 3 and Integrin Alpha 5 as Novel Biomarkers in Pathogenesis of Acute Aortic Dissection. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	10
1916	PIK3R2 / Pik3r2 Activating Mutations Result in Brain Overgrowth and EEG Changes. <i>Annals of Neurology</i> , 2020, 88, 1077-1094.	2.8	10
1917	Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6073.	1.8	19
1918	Apoptotic effect of jaceosidin on MCF-7 human breast cancer cells through modulation of ERK and p38 MAPK pathways. <i>Natural Product Research</i> , 2021, 35, 6049-6053.	1.0	5
1919	Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1395-1402.	2.8	32
1920	Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. <i>Drugs</i> , 2020, 80, 1685-1697.	4.9	72
1921	Proteomic Analysis of Human Endometrial Tissues Reveals the Roles of PI3K/AKT/mTOR Pathway and Tumor Angiogenesis Molecules in the Pathogenesis of Endometrial Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	10
1922	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer. <i>Cancer Cell International</i> , 2020, 20, 560.	1.8	39
1923	Any Role of PIK3CA and PTEN Biomarkers in the Prognosis in Oral Squamous Cell Carcinoma?. <i>Life</i> , 2020, 10, 325.	1.1	8
1924	$\hat{1}^2$ -hydroxybutyrate ($\hat{1}^2$ -HB) exerts anti-inflammatory and antioxidant effects in lipopolysaccharide (LPS)-stimulated macrophages in <i>Liza haematocheila</i> . <i>Fish and Shellfish Immunology</i> , 2020, 107, 444-451.	1.6	12
1925	Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8198.	1.8	17
1926	Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants. <i>Cells</i> , 2020, 9, 1116.	1.8	6
1927	Network pharmacology used to decode potential active ingredients in <i>Ferula assafoetida</i> and mechanisms for the application to Alzheimer's disease. <i>Journal of Traditional Chinese Medical Sciences</i> , 2020, 7, 199-209.	0.1	1
1928	Discovery of selection-driven genetic differences of Duroc, Landrace, and Yorkshire pig breeds by EigenGWAS and χ^2 analyses. <i>Animal Genetics</i> , 2020, 51, 531-540.	0.6	13

#	ARTICLE	IF	CITATIONS
1929	MK2206 Enhances Cisplatin-Induced Cytotoxicity and Apoptosis in Testicular Cancer Through Akt Signaling Pathway Inhibition. <i>Translational Oncology</i> , 2020, 13, 100769.	1.7	5
1930	From Signaling Pathways to Distinct Immune Responses: Key Factors for Establishing or Combating <i>Neospora caninum</i> Infection in Different Susceptible Hosts. <i>Pathogens</i> , 2020, 9, 384.	1.2	26
1931	Abrogating doxorubicin-induced chemobrain by immunomodulators IFN-beta 1a or infliximab: Insights to neuroimmune mechanistic hallmarks. <i>Neurochemistry International</i> , 2020, 138, 104777.	1.9	18
1932	An investigation of the metabolic activity, isozyme contribution, species differences and potential drug-drug interactions of PI-103, and the identification of efflux transporters for PI-103-O-glucuronide in HeLa1A9 cells. <i>RSC Advances</i> , 2020, 10, 9610-9622.	1.7	6
1933	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	1.9	2
1934	Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis. <i>Cancer Cell International</i> , 2020, 20, 165.	1.8	48
1935	ERO1 α inhibits cell apoptosis and regulates steroidogenesis in mouse granulosa cells. <i>Molecular and Cellular Endocrinology</i> , 2020, 511, 110842.	1.6	13
1936	Cre/loxP approach-mediated downregulation of Pik3c3 inhibits the hypertrophic growth of renal proximal tubule cells. <i>Journal of Cellular Physiology</i> , 2020, 235, 9958-9973.	2.0	4
1937	Insulin resistance and Alzheimer's disease. , 2020, , 249-292.		1
1938	Dilp-2-mediated PI3-kinase activation coordinates reactivation of quiescent neuroblasts with growth of their glial stem cell niche. <i>PLoS Biology</i> , 2020, 18, e3000721.	2.6	31
1939	Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer. <i>Pharmaceutics</i> , 2020, 12, 524.	2.0	22
1940	Cadmium exposure activates Akt/ERK Signaling and pro-inflammatory COX-2 expression in human gallbladder epithelial cells via a ROS dependent mechanism. <i>Toxicology in Vitro</i> , 2020, 67, 104912.	1.1	7
1941	A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration. <i>Science Signaling</i> , 2020, 13, .	1.6	11
1942	Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase β . <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1386-1391.	1.3	2
1943	Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration. <i>Theranostics</i> , 2020, 10, 6231-6244.	4.6	20
1944	CREB activity is required for mTORC1 signaling-induced primordial follicle activation in mice. <i>Histochemistry and Cell Biology</i> , 2020, 154, 287-299.	0.8	13
1945	Human Cytomegalovirus Glycoprotein-Initiated Signaling Mediates the Aberrant Activation of Akt. <i>Journal of Virology</i> , 2020, 94, .	1.5	14
1946	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7

#	ARTICLE	IF	CITATIONS
1947	Gene therapy targeting cardiac phosphoinositide 3-kinase (p110 α) attenuates cardiac remodeling in type 2 diabetes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 318, H840-H852.	1.5	32
1948	Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	0.6	125
1949	Phosphoinositide-3-kinase regulatory subunit 1 gene polymorphisms are associated with schizophrenia and bipolar disorder in the Han Chinese population. <i>Metabolic Brain Disease</i> , 2020, 35, 785-792.	1.4	7
1950	MicroRNA-19a-3p regulates cell growth through modulation of the PIK3IP1-AKT pathway in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2020, 11, 2476-2484.	1.2	15
1951	Akt2 Affects Periodontal Inflammation via Altering the M1/M2 Ratio. <i>Journal of Dental Research</i> , 2020, 99, 577-587.	2.5	34
1952	Total Synthesis of (R)-Liphagal via Organic-Redox-Driven Palladium-Catalyzed Hydroxybenzofuran Formation. <i>Journal of Organic Chemistry</i> , 2020, 85, 9064-9070.	1.7	2
1953	Adaptive Molecular Evolution of <i>AKT3</i> Gene for Positive Diversifying Selection in Mammals. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	3
1954	High Light-Induced Nitric Oxide Production Induces Autophagy and Cell Death in <i>Chlamydomonas reinhardtii</i> . <i>Frontiers in Plant Science</i> , 2020, 11, 772.	1.7	22
1955	The MyD88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88/GSK-3 β and MyD88/NF- κ B signalling pathways. <i>Experimental Cell Research</i> , 2020, 394, 112157.	1.2	11
1956	Potential of Tyrosine Kinase Receptor TIE-1 as Novel Therapeutic Target in High-PI3K-Expressing Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1705.	1.7	2
1957	Anticancer fungal natural products: Mechanisms of action and biosynthesis. <i>European Journal of Medicinal Chemistry</i> , 2020, 202, 112502.	2.6	25
1958	Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. <i>Investigational New Drugs</i> , 2020, 38, 1836-1845.	1.2	4
1959	Signaling Inhibitors Accelerate the Conversion of mouse iPS Cells into Cancer Stem Cells in the Tumor Microenvironment. <i>Scientific Reports</i> , 2020, 10, 9955.	1.6	18
1960	Gene expression profiling of tumor stroma interactions in retinoblastoma. <i>Experimental Eye Research</i> , 2020, 197, 108067.	1.2	3
1961	Biology, pathology, and therapeutic targeting of RAS. <i>Advances in Cancer Research</i> , 2020, 148, 69-146.	1.9	17
1962	LZAP promotes the proliferation and invasiveness of cervical carcinoma cells by targeting AKT and EMT. <i>Journal of Cancer</i> , 2020, 11, 1625-1633.	1.2	4
1963	Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition. <i>Cell Reports</i> , 2020, 30, 2729-2742.e4.	2.9	28
1964	Wortmanninol Induces Breast Cancer Cell Death In Vitro and In Vivo by Targeting Phosphoinositide 3-Kinase α . <i>ChemistrySelect</i> , 2020, 5, 2214-2218.	0.7	1

#	ARTICLE	IF	CITATIONS
1965	Insulinâ€“PI3K signalling: an evolutionarily insulated metabolic driver of cancer. <i>Nature Reviews Endocrinology</i> , 2020, 16, 276-283.	4.3	155
1966	The emerging role of precision medicine in the treatment of endometrial cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 87-93.	0.4	1
1967	Allosteric Activation of PI3KÎ± Results in Dynamic Access to Catalytically Competent Conformations. <i>Structure</i> , 2020, 28, 465-474.e5.	1.6	13
1968	Comparative Analysis and Molecular Evolution of Class I PI3K Regulatory Subunit p85Î± Reveal the Structural Similarity Between nSH2 and cSH2 Domains. <i>International Journal of Peptide Research and Therapeutics</i> , 2020, 26, 2555-2569.	0.9	0
1969	LCâ€“MS/MS determination of buparlisib, a phosphoinositide 3 kinase inhibitor in rat plasma: Application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2020, 34, e4816.	0.8	1
1970	Synthesis and biological activity of new 2,4,6-trisubstituted triazines as potential phosphoinositide 3-kinase inhibitors. <i>Journal of Chemical Research</i> , 2020, 44, 393-402.	0.6	1
1971	Genome-wide analysis of mRNAs and lncRNAs in <i>Mycoplasma bovis</i> infected and non-infected bovine mammary gland tissues. <i>Molecular and Cellular Probes</i> , 2020, 50, 101512.	0.9	17
1972	NUPR1 Silencing Induces Autophagy-Mediated Apoptosis in Multiple Myeloma Cells Through the PI3K/AKT/mTOR Pathway. <i>DNA and Cell Biology</i> , 2020, 39, 368-378.	0.9	20
1973	Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. <i>Trends in Cancer</i> , 2020, 6, 111-129.	3.8	9
1974	Dual-Specific Protein and Lipid Phosphatase PTEN and Its Biological Functions. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036301.	2.9	15
1975	Crosstalk between PTEN/PI3K/Akt Signalling and DNA Damage in the Oocyte: Implications for Primordial Follicle Activation, Oocyte Quality and Ageing. <i>Cells</i> , 2020, 9, 200.	1.8	95
1976	Knockdown of TRIM47 inhibits breast cancer tumorigenesis and progression through the inactivation of PI3K/Akt pathway. <i>Chemico-Biological Interactions</i> , 2020, 317, 108960.	1.7	30
1977	Targeting the PI3K/Akt/mTOR pathway in nonâ€“small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2020, 11, 511-518.	0.8	275
1978	Chrelin promotes neural differentiation of adipose tissueâ€“derived mesenchymal stem cell via AKT/mTOR and Î²â€“catenin signaling pathways. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 405-416.	0.8	13
1979	Leucine Improved Growth Performance, Muscle Growth, and Muscle Protein Deposition Through AKT/TOR and AKT/FOXO3a Signaling Pathways in Hybrid Catfish <i>Pelteobagrus vachelli</i> Ã— <i>Leiocassis longirostris</i> . <i>Cells</i> , 2020, 9, 327.	1.8	39
1980	Exploring the controversial role of PI3K signalling in CD4+ regulatory T (T-Reg) cells. <i>Advances in Biological Regulation</i> , 2020, 76, 100722.	1.4	5
1981	Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabiatic acid as PI3KÎ± inhibitors. <i>Bioorganic Chemistry</i> , 2020, 100, 103845.	2.0	20
1982	The Landscape of Targeted Therapies in TNBC. <i>Cancers</i> , 2020, 12, 916.	1.7	232

#	ARTICLE	IF	CITATIONS
1983	Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene. <i>Biomedicine and Pharmacotherapy</i> , 2020, 126, 110107.	2.5	5
1984	Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo[2,1-f][1,2,4]triazine derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127194.	1.0	12
1985	Overlapping phenotypes between SHORT and Noonan syndromes in patients with PTPN11 pathogenic variants. <i>Clinical Genetics</i> , 2020, 98, 10-18.	1.0	9
1986	Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3K $\hat{\pm}$ inhibitors with potent antitumor activity. <i>European Journal of Medicinal Chemistry</i> , 2020, 197, 112309.	2.6	8
1987	TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism. <i>Nature Communications</i> , 2020, 11, 1880.	5.8	65
1988	Ginsenoside Rg3 ameliorates acute exacerbation of COPD by suppressing neutrophil migration. <i>International Immunopharmacology</i> , 2020, 83, 106449.	1.7	19
1989	Duvelisib for the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1299-1309.	0.9	13
1990	N ⁶ -methyladenosine mRNA methylation of <i>PIK3CB</i> regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. <i>Gut</i> , 2020, 69, 2180-2192.	6.1	52
1991	Using Phosphatidylinositol Phosphorylation as Markers for Hyperglycemic Related Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2320.	1.8	4
1992	Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status. <i>Journal of Clinical Pathology</i> , 2021, 74, 216-222.	1.0	11
1993	Segmental Ipsilateral Odontognathic Dysplasia (Mandibular Involvement in Segmental) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 347 Td (O Gingival Tissue. <i>Head and Neck Pathology</i> , 2021, 15, 368-373.	1.3	5
1994	Common Signal Transduction Molecules Activated by Bacterial Entry into a Host Cell and by Reactive Oxygen Species. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 486-503.	2.5	2
1995	The role of PI3K inhibitors in the treatment of malignant lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 517-527.	0.6	5
1996	Poncirin downregulates ATP $\hat{\epsilon}$ binding cassette transporters to enhance cisplatin sensitivity in cisplatin $\hat{\epsilon}$ resistant osteosarcoma cells. <i>Phytotherapy Research</i> , 2021, 35, 278-288.	2.8	13
1997	Hepatoprotective effect of linagliptin against liver fibrosis induced by carbon tetrachloride in mice. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, 99, 294-302.	0.7	7
1998	Ischaemic preconditioning $\hat{\epsilon}$ induced serum exosomes protect against myocardial ischaemia/reperfusion injury in rats by activating the \langle sc \rangle PI3K \langle /sc \rangle / \langle sc \rangle AKT \langle /sc \rangle signalling pathway. <i>Cell Biochemistry and Function</i> , 2021, 39, 287-295.	1.4	16
1999	A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 408-417.	3.2	21
2000	Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 29, 115890.	1.4	12

#	ARTICLE	IF	CITATIONS
2001	Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 15-23.	0.9	6
2002	Deletion of PDK1 in oligodendrocyte lineage cells causes white matter abnormality and myelination defect in the central nervous system. <i>Neurobiology of Disease</i> , 2021, 148, 105212.	2.1	10
2003	A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 139-152.	1.5	5
2004	Polymorphism in the catalytic subunit of the PI3K β gene is associated with <i>Trypanosoma cruzi</i> -induced chronic chagasic cardiomyopathy. <i>Infection, Genetics and Evolution</i> , 2021, 88, 104671.	1.0	2
2005	Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations. <i>Future Oncology</i> , 2021, 17, 13-36.	1.1	9
2006	Involvement of PTEN and FOXO3a Proteins in the Protective Activity of Protocatechuic Acid Against Cisplatin-Induced Ovarian Toxicity in Mice. <i>Reproductive Sciences</i> , 2021, 28, 865-876.	1.1	13
2007	Molecular characterization and expression dynamics of three key genes in the PI3K-AKT pathway reveal its involvement in the immunotoxicological responses of the giant river prawn <i>Macrobrachium rosenbergii</i> to acute ammonia and nitrite stress. <i>Ecotoxicology and Environmental Safety</i> , 2021, 208, 111767.	2.9	6
2008	Identification of circ-FAM169A sponges miR-583 involved in the regulation of intervertebral disc degeneration. <i>Journal of Orthopaedic Translation</i> , 2021, 26, 121-131.	1.9	25
2009	The insulin signaling pathway in <i>Drosophila melanogaster</i> : A nexus revealing an 'Achilles' heel' in DDT resistance. <i>Pesticide Biochemistry and Physiology</i> , 2021, 171, 104727.	1.6	6
2010	Structure-Based Drug Design and Synthesis of PI3K β -Selective Inhibitor (PF-06843195). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 644-661.	2.9	22
2011	Steroid hormones, dietary nutrients, and temporal progression of neurogenesis. <i>Current Opinion in Insect Science</i> , 2021, 43, 70-77.	2.2	8
2012	Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats. <i>Biomedical Chromatography</i> , 2021, 35, e5015.	0.8	9
2013	Higher thyroid hormone levels and cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 808-821.	3.3	16
2014	Nesfatin-1 Promotes Proliferation, Migration and Invasion of HTR-8/SVneo Trophoblast Cells and Inhibits Oxidative Stress via Activation of PI3K/AKT/mTOR and AKT/GSK3 β Pathway. <i>Reproductive Sciences</i> , 2021, 28, 550-561.	1.1	12
2015	Luminal A breast cancer resistance mechanisms and emerging treatments. , 2021, , 1-22.		2
2016	Morrisonide promotes the osteogenesis by activating PI3K/Akt/mTOR signaling. <i>Bioscience, Biotechnology and Biochemistry</i> , 2021, 85, 332-339.	0.6	20
2017	Phosphatidylinositol 3-kinase gamma participates in nimesulide-induced hepatic damage. <i>Journal of Pharmacy and Pharmacology</i> , 2021, 73, 496-504.	1.2	4
2018	KYNU, a novel potential target that underpins CD44-promoted breast tumour cell invasion. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 2309-2314.	1.6	19

#	ARTICLE	IF	CITATIONS
2019	Cytotoxicity of oleanane type triterpene from leaf extract of <i>Pterospermum acerifolium</i> (in vitro) and theoretical investigation of inhibitory signaling pathway. <i>Chinese Herbal Medicines</i> , 2021, 13, 124-130.	1.2	3
2020	Exploring the "Dormancy Activation Switch"™ in the Tumour Microenvironment for Metastatic Lung Cancer: The Possible Role of MicroRNA. , 2021, , 191-215.		0
2021	Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer. <i>RSC Advances</i> , 2021, 11, 25228-25257.	1.7	10
2022	Semaphorin 4D is a potential biomarker in pediatric leukemia and promotes leukemogenesis by activating PI3K/AKT and ERK signaling pathways. <i>Oncology Reports</i> , 2021, 45, .	1.2	29
2023	Comparative hematopoiesis and signal transduction in model organisms. <i>Journal of Cellular Physiology</i> , 2021, 236, 5592-5619.	2.0	6
2024	Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines. <i>Cellular and Molecular Biology Letters</i> , 2021, 26, 3.	2.7	83
2025	Akt regulates RSK2 to alter phosphorylation level of H2A.X in breast cancer. <i>Oncology Letters</i> , 2021, 21, 187.	0.8	10
2026	Pathophysiology and genetics in pituitary tumors. , 2021, , 37-52.		0
2027	Tissue Transglutaminase Impairs HTR-8/SVneo Trophoblast Cell Invasion via the PI3K/AKT Signaling Pathway. <i>Gynecologic and Obstetric Investigation</i> , 2021, 86, 264-272.	0.7	1
2028	Sesquiterpenoid bilobalide inhibits gastric carcinoma cell growth and induces apoptosis both in vitro and in vivo models. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22723.	1.4	13
2029	Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review. <i>Archives of Medical Science</i> , 2021, 17, 207-217.	0.4	13
2030	Morusin inhibits the growth of human colorectal cancer HCT116-derived sphere-forming cells via the inactivation of Akt pathway. <i>International Journal of Molecular Medicine</i> , 2021, 47, 1.	1.8	51
2031	Research update on the anticancer effects of buparlisib (Review). <i>Oncology Letters</i> , 2021, 21, 266.	0.8	14
2032	Transcriptome based analysis of apoptosis genes in chickens co-infected with avian infectious bronchitis virus and pathogenic <i>Escherichia coli</i> . <i>Iranian Journal of Microbiology</i> , 2021, 13, 17-22.	0.8	3
2033	Network Pharmacology Interpretation of Fuzheng "Jiedu Decoction against Colorectal Cancer. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-16.	0.5	12
2034	Redox Regulation of PTEN by Peroxiredoxins. <i>Antioxidants</i> , 2021, 10, 302.	2.2	22
2035	Pathogenetic Features and Current Management of Glioblastoma. <i>Cancers</i> , 2021, 13, 856.	1.7	29
2036	The Role of mTOR Signaling as a Therapeutic Target in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1743.	1.8	128

#	ARTICLE	IF	CITATIONS
2037	PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation. <i>Frontiers in Medicine</i> , 2021, 8, 547849.	1.2	11
2038	Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF- β 21 Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1985.	1.8	16
2039	The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer. <i>Biology</i> , 2021, 10, 146.	1.3	13
2040	Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 610097.	1.8	9
2041	Targeting MUC1-C reverses the cisplatin resistance of esophageal squamous cell carcinoma in vitro and in vivo. <i>Translational Cancer Research</i> , 2021, 10, 645-655.	0.4	4
2042	SOX2 enhances cell survival and induces resistance to apoptosis under serum starvation conditions through the AKT/GSK β 3 signaling pathway in esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2021, 21, 269.	0.8	2
2043	Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3567.	1.8	5
2044	Validated LC-MS/MS Method for Simultaneous Quantitation of Three PI3K Inhibitors, Copanlisib, Duvelisib and Idelalisib in Mouse Plasma: Application to a Pharmacokinetic Study in Mice. <i>Analytical Chemistry Letters</i> , 2021, 11, 140-152.	0.4	4
2045	Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 193-207.	0.9	34
2046	Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. <i>Cancers</i> , 2021, 13, 1538.	1.7	37
2047	Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 618522.	1.6	19
2048	Exploring the Mechanism of Action of Banxia Baizhu Tianma Decoction against Preeclampsia by a Network Pharmacology Approach. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-15.	0.5	1
2049	Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 624686.	1.5	13
2050	Kinome-wide analysis of the effect of statins in colorectal cancer. <i>British Journal of Cancer</i> , 2021, 124, 1978-1987.	2.9	8
2051	Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.4	20
2052	HUMAN Schlafen 5 Inhibits Proliferation and Promotes Apoptosis in Lung Adenocarcinoma via the PTEN/PI3K/AKT/mTOR Pathway. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	10
2053	Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 433-468.	0.9	7
2054	Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL. <i>Cancers</i> , 2021, 13, 1280.	1.7	14

#	ARTICLE	IF	CITATIONS
2055	Changes in Oviductal Cells and Small Extracellular Vesicles miRNAs in Pregnant Cows. <i>Frontiers in Veterinary Science</i> , 2021, 8, 639752.	0.9	19
2056	Expanding the View of IKK: New Substrates and New Biology. <i>Trends in Cell Biology</i> , 2021, 31, 166-178.	3.6	54
2057	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2625.	1.8	38
2058	AKT-dependent signaling of extracellular cues through telomeres impact on tumorigenesis. <i>PLoS Genetics</i> , 2021, 17, e1009410.	1.5	8
2059	Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. <i>Targeted Oncology</i> , 2021, 16, 295-308.	1.7	14
2060	Genetic variants associated with expression of TCF19 contribute to the risk of head and neck cancer in Chinese population. <i>Journal of Medical Genetics</i> , 2021, , jmedgenet-2020-107410.	1.5	7
2061	Anticancer potential of metformin: focusing on gastrointestinal cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 587-598.	1.1	11
2062	Organismal roles for the PI3K α and β isoforms: their specificity, redundancy or cooperation is context-dependent. <i>Biochemical Journal</i> , 2021, 478, 1199-1225.	1.7	12
2063	Anticancer Mechanism of Curcumin on Human Glioblastoma. <i>Nutrients</i> , 2021, 13, 950.	1.7	47
2064	How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 605-619.	1.1	23
2065	Cell signaling pathways as molecular targets to eliminate AML stem cells. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103277.	2.0	20
2066	Hypoglycemia due to PI3K/AKT/mTOR signaling pathway defects: two PI3K novel cases and review of the literature. <i>Hormones</i> , 2021, 20, 623-640.	0.9	10
2067	LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis. <i>Aging</i> , 2021, 13, 12113-12128.	1.4	8
2069	ESM1 promotes triple-negative breast cancer cell proliferation through activating AKT/NF- κ B/Cyclin D1 pathway. <i>Annals of Translational Medicine</i> , 2021, 9, 533-533.	0.7	14
2070	Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PI3KCA mutations. <i>Journal of Clinical Pathology</i> , 2022, 75, 488-492.	1.0	4
2071	Actin-Like Protein 8 Promotes the Progression of Triple-Negative Breast Cancer via Activating PI3K/AKT/mTOR Pathway. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2463-2473.	1.0	10
2072	Biotechnologically Produced <i>Lavandula angustifolia</i> Mill. Extract Rich in Rosmarinic Acid Resolves Psoriasis-Related Inflammation Through Janus Kinase/Signal Transducer and Activator of Transcription Signaling. <i>Frontiers in Pharmacology</i> , 2021, 12, 680168.	1.6	11
2073	The Keap1-Nrf2 System: A Mediator between Oxidative Stress and Aging. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-16.	1.9	162

#	ARTICLE	IF	CITATIONS
2074	The importance of Ras in drug resistance in cancer. <i>British Journal of Pharmacology</i> , 2022, 179, 2844-2867.	2.7	26
2075	From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy. <i>Molecules</i> , 2021, 26, 2278.	1.7	31
2076	Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance. <i>Cancers</i> , 2021, 13, 1792.	1.7	15
2077	Transcriptome analysis identifies the differentially expressed genes related to the stemness of limbic stem cells in mice. <i>Gene</i> , 2021, 775, 145447.	1.0	4
2078	Oncofertility Information Available for Recently Approved Novel Non Cytotoxic and Immunotherapy Oncology Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 382-390.	2.3	7
2079	DHEA inhibits proliferation, migration and alters mesenchymal-epithelial transition proteins through the PI3K/Akt pathway in MDA-MB-231 cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 208, 105818.	1.2	3
2080	Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans. <i>Xenobiotica</i> , 2021, 51, 796-810.	0.5	5
2081	Somatic PIK3R1 variation as a cause of vascular malformations and overgrowth. <i>Genetics in Medicine</i> , 2021, 23, 1882-1888.	1.1	26
2082	Maternal preconception PFOS exposure of <i>Drosophila melanogaster</i> alters reproductive capacity, development, morphology and nutrient regulation. <i>Food and Chemical Toxicology</i> , 2021, 151, 112153.	1.8	11
2083	Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4899.	1.8	69
2084	The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions. <i>European Journal of Pharmacology</i> , 2021, 898, 173983.	1.7	47
2086	Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges. <i>Frontiers in Pharmacology</i> , 2021, 12, 675675.	1.6	11
2087	Kinase Inhibitors as Underexplored Antiviral Agents. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 935-954.	2.9	30
2088	Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support effector T helper 17 cell responses. <i>Immunity</i> , 2021, 54, 976-987.e7.	6.6	56
2089	Autophagy-related signaling pathways are involved in cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 710.	0.8	31
2090	Manipulating oligodendrocyte intrinsic regeneration mechanism to promote remyelination. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5257-5273.	2.4	3
2091	Protein kinase inhibitors for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1889-1899.	0.9	8
2092	The Glucosylceramide Synthase Inhibitor PDMP Causes Lysosomal Lipid Accumulation and mTOR Inactivation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7065.	1.8	13

#	ARTICLE	IF	CITATIONS
2093	Current Understandings of Core Pathways for the Activation of Mammalian Primordial Follicles. <i>Cells</i> , 2021, 10, 1491.	1.8	20
2094	Pieces of the Complex Puzzle of Cancer Cell Energy Metabolism: An Overview of Energy Metabolism and Alternatives for Targeted Cancer Therapy. <i>Current Medicinal Chemistry</i> , 2021, 28, 3514-3534.	1.2	4
2095	EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. <i>Cancers</i> , 2021, 13, 2748.	1.7	148
2096	The Long-Term DEHP Exposure Confers Multidrug Resistance of Triple-Negative Breast Cancer Cells through ABC Transporters and Intracellular ROS. <i>Antioxidants</i> , 2021, 10, 949.	2.2	14
2097	PHLPP2 gene L1016S (rs61733127) and PIK3R1 gene Met326Ile (rs3730089) polymorphisms are associated with the risk of colon and breast cancers. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021, 40, 767-778.	0.4	1
2098	Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway. <i>Hereditas</i> , 2021, 158, 18.	0.5	5
2099	PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation. <i>Frontiers in Oncology</i> , 2021, 11, 668247.	1.3	7
2101	Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8951-8970.	2.9	19
2102	Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a037838.	2.9	2
2103	Targeting Leader Cells in Ovarian Cancer as an Effective Therapeutic Option. , 0, , .		0
2104	Leptin and Melanocortin Signaling Mediates Hypertension in Offspring From Female Rabbits Fed a High-Fat Diet During Gestation and Lactation. <i>Frontiers in Physiology</i> , 2021, 12, 693157.	1.3	7
2105	Lacrimal gland budding requires PI3K-dependent suppression of EGF signaling. <i>Science Advances</i> , 2021, 7, .	4.7	2
2106	Two Monogenetic Disorders, Activated PI3-Kinase-Î Syndrome 2 and Smithâ€Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling. <i>Frontiers in Pediatrics</i> , 2021, 9, 688022.	0.9	2
2107	Therapeutic modulation of the phosphatidylinositol 3-kinases (PI3K) pathway in cerebral ischemic injury. <i>Brain Research</i> , 2021, 1761, 147399.	1.1	32
2108	Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7963-7990.	2.9	69
2109	Tumor Growth in the High Frequency Medulloblastoma Mouse Model Ptch1+/ ^{+/+} Tis21KO Has a Specific Activation Signature of the PI3K/AKT/mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611. <i>Frontiers in Oncology</i> , 2021, 11, 692053.	1.3	4
2110	Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products. <i>Molecules</i> , 2021, 26, 4100.	1.7	96
2111	Cowden Syndrome and Lhermitte-Duclos Diseaseâ€a Case Report and Review of the Literature. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 2373-2377.	0.3	1

#	ARTICLE	IF	CITATIONS
2112	TWEAKing the Hippocampus: The Effects of TWEAK on the Genomic Fabric of the Hippocampus in a Neuropsychiatric Lupus Mouse Model. <i>Genes</i> , 2021, 12, 1172.	1.0	5
2113	Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 138, 1110-1119.	0.6	30
2114	<i>NEIL3</i> contributes toward the carcinogenesis of liver cancer and regulates PI3K/Akt/mTOR signaling. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1053.	0.8	11
2115	<i>Antrodia cinnamomea</i> exerts an anti-hepatoma effect by targeting PI3K/AKT-mediated cell cycle progression <i>in vitro</i> and <i>in vivo</i> . <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 890-906.	5.7	19
2116	Effects of dietary methionine on growth performance and metabolism through modulating nutrient-related pathways in largemouth bass (<i>Micropterus salmoides</i>). <i>Aquaculture Reports</i> , 2021, 20, 100642.	0.7	11
2117	Role of PI3K/Akt signaling pathway in cardiac fibrosis. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 4045-4059.	1.4	94
2118	Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 18-32.	5.7	103
2119	Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 5223-5237.	0.9	30
2120	Tacrolimus inhibits insulin release and promotes apoptosis of Min6 cells through the inhibition of the PI3K/Akt/mTOR pathway. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	11
2121	Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?. <i>Cancers</i> , 2021, 13, 3351.	1.7	10
2122	Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse. <i>Leukemia and Lymphoma</i> , 2021, 62, 2690-2702.	0.6	2
2123	Investigating the Mechanism of <i>Scutellariae barbata</i> Herba in the Treatment of Colorectal Cancer by Network Pharmacology and Molecular Docking. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-18.	0.5	8
2124	Inhibition of phosphatidylinositol 3-kinase (PI3K) enzyme and human skin carcinoma cell growth by <i>Combretum apiculatum</i> Sond.. <i>South African Journal of Botany</i> , 2021, 140, 95-102.	1.2	2
2125	mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2021, 81, 5652-5665.	0.4	12
2126	Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis. <i>Hepatology</i> , 2022, 75, 1123-1138.	3.6	9
2127	Role of Sulfur Metabolism Gene and High-Sulfur Gene Expression in Wool Growth Regulation in the Cashmere Goat. <i>Frontiers in Genetics</i> , 2021, 12, 715526.	1.1	1
2128	A Review: Mechanism of <i>Phyllanthus urinaria</i> in Cancersâ€”NF- κ B, P13K/AKT, and MAPKs Signaling Activation. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-9.	0.5	6
2129	Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 262.	3.5	2

#	ARTICLE	IF	CITATIONS
2130	Role of PTEN-less in cardiac injury, hypertrophy and regeneration. <i>Cell Regeneration</i> , 2021, 10, 25.	1.1	15
2131	Enzymatic Metabolism of Flavonoids by Gut Microbiota and Its Impact on Gastrointestinal Cancer. <i>Cancers</i> , 2021, 13, 3934.	1.7	40
2132	PI3K β /AKT Signaling in High Molecular Weight Hyaluronan (HMWH)-Induced Anti-Hyperalgesia and Reversal of Nociceptor Sensitization. <i>Journal of Neuroscience</i> , 2021, 41, 8414-8426.	1.7	5
2133	The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy. <i>Frontiers in Oncology</i> , 2021, 11, 697967.	1.3	11
2134	Recent contributions of quinolines to antimalarial and anticancer drug discovery research. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113865.	2.6	31
2135	Dieckol exerts anticancer activity in human osteosarcoma (MG-63) cells through the inhibition of PI3K/AKT/mTOR signaling pathway. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 4908-4915.	1.8	12
2136	Glucose Metabolism and Glucose Transporters in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 728759.	1.8	69
2137	Identification of Ent-Kaurane Diterpenoid Compounds as Potential Inhibitors of the PI3K Pathway in Nonsmall Cell Lung Cancer Through Molecular Docking Simulations. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110332.	0.2	0
2138	AKT1 and PTEN show the highest affinities among phosphoinositide binding proteins for the second messengers PtdIns(3,4,5)P ₃ and PtdIns(3,4)P ₂ . <i>Biochemical and Biophysical Research Communications</i> , 2021, 568, 110-115.	1.0	5
2139	Targeted Sequencing Revealed Distinct Mutational Profiles of Ocular and Extraocular Sebaceous Carcinomas. <i>Cancers</i> , 2021, 13, 4810.	1.7	5
2140	UPF1 impacts on mTOR signaling pathway and autophagy in endometrioid endometrial carcinoma. <i>Aging</i> , 2021, 13, 21202-21215.	1.4	6
2141	Molecular mechanisms involved in DNA repair in human cancers: An overview of PI3k/Akt signaling and PIKKs crosstalk. <i>Journal of Cellular Physiology</i> , 2022, 237, 313-328.	2.0	15
2142	3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway. <i>Life Sciences</i> , 2021, 285, 119995.	2.0	1
2143	Cancers associated with human gammaherpesviruses. <i>FEBS Journal</i> , 2022, 289, 7631-7669.	2.2	36
2144	Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3K β -specific inhibitors for the treatment of hematologic malignancies. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 45, 116312.	1.4	4
2145	Gansui-Banxia Decoction extraction inhibits MDSCs accumulation via AKT /STAT3/ERK signaling pathways to regulate antitumor immunity in C57bl/6 mice. <i>Phytomedicine</i> , 2021, 93, 153779.	2.3	9
2146	The impact of microRNAs on myeloid-derived suppressor cells in cancer. <i>Human Immunology</i> , 2021, 82, 668-678.	1.2	5
2147	Double-edged effects caused by magnesium ions and alkaline environment regulate bioactivities of magnesium-incorporated silicocarnotite <i>in vitro</i> . <i>International Journal of Energy Production and Management</i> , 2021, 8, rbab016.	1.9	12

#	ARTICLE	IF	CITATIONS
2148	Design, Synthesis and SAR in 2,4,7-Trisubstituted Pyrido[3,2-d]Pyrimidine Series as Novel PI3K/mTOR Inhibitors. <i>Molecules</i> , 2021, 26, 5349.	1.7	0
2150	A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo. <i>Frontiers in Pharmacology</i> , 2021, 12, 741697.	1.6	7
2151	Review: Schistosoma mansoni phosphatidylinositol 3 kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathway. <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 2021, 256, 110632.	0.7	3
2152	Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3K ^Î inhibitor: Design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2021, 223, 113661.	2.6	10
2153	KRAS: The Art of Understanding a Complex Gene. , 2022, , 876-888.		0
2154	Proteomic Analysis of the Secretome and Exosomes of Feline Adipose-Derived Mesenchymal Stem Cells. <i>Animals</i> , 2021, 11, 295.	1.0	7
2156	Construction of a TF ^Î miRNA ^Î gene feed-forward loop network predicts biomarkers and potential drugs for myasthenia gravis. <i>Scientific Reports</i> , 2021, 11, 2416.	1.6	15
2157	Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 817.	1.8	12
2158	TSPAN7 Exerts Anti-Tumor Effects in Bladder Cancer Through the PTEN/PI3K/AKT Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 613869.	1.3	22
2159	Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age. <i>JAMA Network Open</i> , 2020, 3, e2028644.	2.8	9
2161	Advances in drug development for targeted therapies for glioblastoma. <i>Medicinal Research Reviews</i> , 2020, 40, 1950-1972.	5.0	7
2162	Implications of Thyroid Hormone Signaling Through the Phosphoinositide-3 Kinase for Xenobiotic Disruption of Human Health. , 2007, , 193-202.		2
2163	VEGF Signal Tranduction in Angiogenesis. , 2008, , 205-216.		2
2164	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. , 2010, , 37-83.		2
2165	Crosstalk Between Mitogen-Activated Protein Kinase and Phosphoinositide-3 Kinase Signaling Pathways in Development and Disease. <i>Systems Biology</i> , 2010, , 505-529.	0.1	1
2166	Insulin/IGF-1 Signaling Nodes and their Role in Carcinogenesis. <i>Energy Balance and Cancer</i> , 2011, , 53-76.	0.2	2
2167	Calories and Cancer: The Role of Insulin-Like Growth Factor-1. , 2012, , 231-243.		1
2168	The PI3K Pathway in Colorectal Cancers. , 2013, , 157-199.		1

#	ARTICLE	IF	CITATIONS
2170	Assays to Measure PTEN Lipid Phosphatase Activity In Vitro from Purified Enzyme or Immunoprecipitates. <i>Methods in Molecular Biology</i> , 2016, 1447, 95-105.	0.4	2
2171	Fluorescence Polarization and Time-Resolved Fluorescence Resonance Energy Transfer Techniques for PI3K Assays. <i>Methods in Molecular Biology</i> , 2010, 572, 161-176.	0.4	1
2172	Multistage Carcinogenesis. , 2011, , 27-51.		4
2173	Measuring PI3K Lipid Kinase Activity. <i>Methods in Molecular Biology</i> , 2012, 795, 55-67.	0.4	6
2174	Hereditary Renal Cell Carcinoma. , 2017, , 19-82.		1
2175	Epithelial Cell Signalling in Colorectal Cancer Metastasis. <i>Cancer Metastasis - Biology and Treatment</i> , 2010, , 205-241.	0.1	5
2176	Phosphoinositide 3-Kinases in Health and Disease. <i>Sub-Cellular Biochemistry</i> , 2012, 58, 183-213.	1.0	24
2177	Genetic Alterations and Checkpoint Expression: Mechanisms and Models for Drug Discovery. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 227-250.	0.8	1
2178	PI3K Isoform-Selective Inhibitors in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1255, 165-173.	0.8	7
2179	Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability. <i>American Journal of Human Genetics</i> , 2017, 100, 725-736.	2.6	168
2180	Profiling analysis reveals the potential contribution of long non-coding RNAs to preterm white matter injury. <i>Life Sciences</i> , 2020, 255, 117815.	2.0	5
2181	Cancer metabolism. , 0, , 295-308.		1
2182	Obesity: stressing about unfolded proteins. , 0, .		1
2183	Class IA PI3K regulatory subunits: p110-independent roles and structures. <i>Biochemical Society Transactions</i> , 2020, 48, 1397-1417.	1.6	34
2184	p110 ^α PI3K as a therapeutic target of solid tumours. <i>Clinical Science</i> , 2020, 134, 1377-1397.	1.8	15
2185	Cardiovascular toxicity of PI3K ^α inhibitors. <i>Clinical Science</i> , 2020, 134, 2595-2622.	1.8	11
2186	Differential metabolic sensitivity of insulin-like-response- and TORC1-dependent overgrowth in <i>Drosophila</i> fat cells. <i>Genetics</i> , 2021, 217, 1-12.	1.2	3
2187	Cell Death and Survival Mechanisms after Single and Repeated Brief Seizures. , 2012, , 362-376.		10

#	ARTICLE	IF	CITATIONS
2188	Epidermal growth factor regulates the development of stem and progenitor Leydig cells in rats. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7313-7330.	1.6	9
2189	Assessing the Anti-inflammatory Mechanism of Reduning Injection by Network Pharmacology. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	11
2190	PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. <i>JCI Insight</i> , 2016, 1, .	2.3	134
2191	IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	18
2192	Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. <i>Journal of Clinical Investigation</i> , 2008, 118, 3038-3050.	3.9	148
2193	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. <i>Journal of Clinical Investigation</i> , 2008, 118, 2609-19.	3.9	443
2194	Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 2497-2507.	3.9	74
2195	PI3-kinase mutation linked to insulin and growth factor resistance in vivo. <i>Journal of Clinical Investigation</i> , 2016, 126, 1401-1412.	3.9	51
2196	Phospholipid signaling in innate immune cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 2670-2679.	3.9	71
2197	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e395-e401.	1.8	67
2198	HOTAIR Promotes Proliferation, Migration, and Invasion of Ovarian Cancer SKOV3 Cells Through Regulating PIK3R3. <i>Medical Science Monitor</i> , 2016, 22, 325-331.	0.5	57
2199	Hepatic deletion of p110 α and p85 β results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity. <i>F1000Research</i> , 2017, 6, 1600.	0.8	3
2200	Transcriptional Regulation of PIK3CA Oncogene by NF- κ B in Ovarian Cancer Microenvironment. <i>PLoS ONE</i> , 2008, 3, e1758.	1.1	41
2201	Selective Inhibition of Retinal Angiogenesis by Targeting PI3 Kinase. <i>PLoS ONE</i> , 2009, 4, e7867.	1.1	65
2202	Accelerated Wound Healing by mTOR Activation in Genetically Defined Mouse Models. <i>PLoS ONE</i> , 2010, 5, e10643.	1.1	158
2203	A Gammaherpesvirus Complement Regulatory Protein Promotes Initiation of Infection by Activation of Protein Kinase Akt/PKB. <i>PLoS ONE</i> , 2010, 5, e11672.	1.1	6
2204	Casein Kinase 2 Dependent Phosphorylation of Neprilysin Regulates Receptor Tyrosine Kinase Signaling to Akt. <i>PLoS ONE</i> , 2010, 5, e13134.	1.1	22
2205	NAVIGATING the Micronome – Using Multiple MicroRNA Prediction Databases to Identify Signalling Pathway-Associated MicroRNAs. <i>PLoS ONE</i> , 2011, 6, e17429.	1.1	207

#	ARTICLE	IF	CITATIONS
2206	Activated Protein Synthesis and Suppressed Protein Breakdown Signaling in Skeletal Muscle of Critically Ill Patients. PLoS ONE, 2011, 6, e18090.	1.1	41
2207	The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer. PLoS ONE, 2011, 6, e25132.	1.1	117
2208	PI3K-Dependent GSK3 β (Ser9)-Phosphorylation Is Implicated in the Intestinal Epithelial Cell Wound-Healing Response. PLoS ONE, 2011, 6, e26340.	1.1	37
2209	FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer. PLoS ONE, 2012, 7, e36252.	1.1	48
2210	Strongyloides stercoralis age-1: A Potential Regulator of Infective Larval Development in a Parasitic Nematode. PLoS ONE, 2012, 7, e38587.	1.1	44
2211	Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors. PLoS ONE, 2012, 7, e43171.	1.1	3
2212	Somatic Mutations of PIK3R1 Promote Gliomagenesis. PLoS ONE, 2012, 7, e49466.	1.1	49
2213	mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms. PLoS ONE, 2013, 8, e54826.	1.1	80
2214	Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma. PLoS ONE, 2013, 8, e59879.	1.1	44
2215	Lysosomal Interaction of Akt with Phafin2: A Critical Step in the Induction of Autophagy. PLoS ONE, 2014, 9, e79795.	1.1	37
2216	Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo. PLoS ONE, 2014, 9, e105280.	1.1	34
2217	MK591, a Second Generation Leukotriene Biosynthesis Inhibitor, Prevents Invasion and Induces Apoptosis in the Bone-Invasive C4-2B Human Prostate Cancer Cells: Implications for the Treatment of Castration-Resistant, Bone-Metastatic Prostate Cancer. PLoS ONE, 2015, 10, e0122805.	1.1	9
2218	Coordinated Expression of Phosphoinositide Metabolic Genes during Development and Aging of Human Dorsolateral Prefrontal Cortex. PLoS ONE, 2015, 10, e0132675.	1.1	16
2219	A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PLoS ONE, 2017, 12, e0178593.	1.1	38
2220	BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma. PLoS ONE, 2017, 12, e0179948.	1.1	13
2221	A Viral microRNA Cluster Regulates the Expression of PTEN, p27 and of a bcl-2 Homolog. PLoS Pathogens, 2016, 12, e1005405.	2.1	43
2222	PI3King the right partner: unique interactions and signaling by p110 β . Postdoc Journal, 2015, 3, 71-87.	0.4	2
2223	Integrated extracellular matrix signaling in mammary gland development and breast cancer progression. Histology and Histopathology, 2014, 29, 1083-92.	0.5	41

#	ARTICLE	IF	CITATIONS
2224	PI3K Pathway in Gynecologic Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e218-e221.	1.8	11
2225	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e395-e401.	1.8	51
2226	Class IA PI3Ks regulate subcellular and functional dynamics of IDO1. EMBO Reports, 2020, 21, e49756.	2.0	24
2227	Cancer-secreted miRNAs regulate amino-acid-induced mTORC1 signaling and fibroblast protein synthesis. EMBO Reports, 2021, 22, e51239.	2.0	17
2228	Oleic acid induces migration through a FFAR1/4, EGFR and AKT-dependent pathway in breast cancer cells. Endocrine Connections, 2019, 8, 252-265.	0.8	27
2229	Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, R109-R130.	1.6	24
2230	Platinum-resistance and AKT Over-expression in Ovarian Cancer. International Journal of Gynecology & Clinical Practices, 2015, 2, .	0.1	2
2231	Autophagy in tumor suppression and cancer therapy. Critical Reviews in Eukaryotic Gene Expression, 2011, 21, 71-100.	0.4	142
2232	Role of different genetic alterations in the pathogenesis of uterine myoma and secondary messenger systems as potential pharmacodynamic targets. Russian Bulletin of Obstetrician-Gynecologist, 2018, 18, 41.	0.0	2
2233	NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma.. Genes and Cancer, 2014, 5, 293-302.	0.6	40
2234	Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget, 2010, 1, 530-43.	0.8	192
2235	Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis. Oncotarget, 2016, 7, 46384-46400.	0.8	62
2236	Phosphatidylinositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells. Oncotarget, 2016, 7, 82424-82439.	0.8	33
2237	Targeting TOR dependence in cancer. Oncotarget, 2010, 1, 69-76.	0.8	43
2238	Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells. Oncotarget, 2016, 7, 61229-61245.	0.8	45
2239	Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF- β 2 pathway. Oncotarget, 2016, 7, 71309-71329.	0.8	27
2240	Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?. Oncotarget, 2017, 8, 14173-14191.	0.8	31
2241	Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Oncotarget, 2017, 8, 7878-7890.	0.8	17

#	ARTICLE	IF	CITATIONS
2242	Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 22203-22217.	0.8	81
2243	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. <i>Oncotarget</i> , 2017, 8, 23213-23227.	0.8	15
2244	EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy. <i>Oncotarget</i> , 2017, 8, 48820-48831.	0.8	72
2245	PI3K Inhibitors That Inhibit Metastasis. <i>Oncotarget</i> , 2010, 1, 339-348.	0.8	42
2246	PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line. <i>Oncotarget</i> , 2017, 8, 45323-45334.	0.8	10
2247	Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients. <i>Oncotarget</i> , 2017, 8, 75914-75923.	0.8	5
2248	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2014, 5, 1846-1855.	0.8	28
2249	Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs. <i>Oncotarget</i> , 2010, 1, 530-543.	0.8	278
2250	FKBP51 decreases cell proliferation and increases progesterin sensitivity of human endometrial adenocarcinomas by inhibiting Akt. <i>Oncotarget</i> , 2017, 8, 80405-80415.	0.8	8
2251	Targeting Phosphatidylinositol 3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. <i>Oncotarget</i> , 2014, 5, 3662-3672.	0.8	40
2252	A beta version of life: p110 ² takes center stage. <i>Oncotarget</i> , 2010, 1, 729-733.	0.8	35
2253	Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A2 ¹ via AKT in prostate cancer cells. <i>Oncotarget</i> , 2014, 5, 6289-6299.	0.8	22
2254	Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin. <i>Oncotarget</i> , 2017, 8, 107977-107990.	0.8	6
2255	Insight into the PTEN - p85 ¹ interaction and lipid binding properties of the p85 ¹ BH domain. <i>Oncotarget</i> , 2018, 9, 36975-36992.	0.8	3
2256	Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma. <i>Oncotarget</i> , 2015, 6, 196-206.	0.8	52
2257	PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies. <i>Oncotarget</i> , 2015, 6, 1315-1326.	0.8	105
2258	Targeting mTOR for the treatment of AML. New agents and new directions. <i>Oncotarget</i> , 2011, 2, 510-517.	0.8	85
2259	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. <i>Oncotarget</i> , 2012, 3, 371-394.	0.8	109

#	ARTICLE	IF	CITATIONS
2260	A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. <i>Oncotarget</i> , 2015, 6, 41736-41749.	0.8	22
2261	NDRG4 stratifies the prognostic value of body mass index in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 1311-1322.	0.8	13
2262	NRF2 and p53: Januses in cancer?. <i>Oncotarget</i> , 2012, 3, 1272-1283.	0.8	88
2263	Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. <i>Oncotarget</i> , 2013, 4, 277-288.	0.8	36
2264	Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells. <i>Oncotarget</i> , 2016, 7, 40362-40376.	0.8	50
2265	PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells. <i>Oncotarget</i> , 0, 7, 42393-42407.	0.8	41
2266	Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors. <i>Mini-Reviews in Medicinal Chemistry</i> , 2013, 13, 2047-2059.	1.1	13
2267	The PIK3CA Gene as a Mutated Target for Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2008, 8, 733-740.	0.8	41
2268	Akt Pathway Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 883-900.	1.0	58
2269	The Endeavours in RAS Inhibition - the Past, Present, and Future. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2708-2722.	1.0	3
2270	An Overview of Privileged Scaffold: Quinolines and Isoquinolines in Medicinal Chemistry as Anticancer Agents. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2599-2633.	1.0	28
2271	Innate Immune System Modulation During Aging: Contributions of Macrophages and Dendritic Cells. <i>Current Immunology Reviews</i> , 2010, 6, 329-338.	1.2	3
2272	Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation. <i>Current Stem Cell Research and Therapy</i> , 2014, 9, 366-387.	0.6	9
2273	Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1552-1564.	0.9	25
2274	The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. <i>Open Rheumatology Journal</i> , 2012, 6, 245-258.	0.1	82
2275	Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2018, 8, 68-75.	0.6	14
2276	PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 57-64.	0.5	8
2277	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2016, 13, 87-100.	1.4	21

#	ARTICLE	IF	CITATIONS
2278	PIK3CA and PTEN Genes Expressions in Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2841-2846.	0.5	7
2279	From microcephaly to megalencephaly: determinants of brain size. <i>Dialogues in Clinical Neuroscience</i> , 2018, 20, 267-282.	1.8	61
2280	PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. <i>Cellular Oncology</i> , 2010, 32, 11-27.	1.9	44
2281	Autophagy and liver cancer. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 606-617.	4.5	46
2282	Macrophage-Bacteria Interactions: A Lipid-Centric Relationship. <i>Frontiers in Immunology</i> , 2017, 8, 1836.	2.2	49
2283	Demonstration of Binding Induced Structural Plasticity in a SH2 Domain. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 89.	1.6	5
2284	Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors. <i>Cancers</i> , 2020, 12, 1278.	1.7	45
2285	Comparative Transcriptome Profiling of Ovary Tissue between Black Muscovy Duck and White Muscovy Duck with High- and Low-Egg Production. <i>Genes</i> , 2021, 12, 57.	1.0	17
2286	Yak IGF2 Promotes Fibroblast Proliferation Via Suppression of IGF1R and PI3KCG Expression. <i>Genes</i> , 2018, 9, 169.	1.0	16
2287	Apelin-13 Promotes Monocyte Adhesion to Human Umbilical Vein Endothelial Cell Mediated by Phosphatidylinositol 3-Kinase Signaling Pathway*. <i>Progress in Biochemistry and Biophysics</i> , 2012, 38, 1162-1170.	0.3	12
2288	The Comparison of RhoC and PI3K Gene Expression on the Breast Cancer Tissue and Benign Tumour Tissue. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2019, 7, 1911-1916.	0.1	2
2289	Baicalin alleviates TNBS-induced colitis by inhibiting PI3K/AKT pathway activation. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 581-590.	0.8	34
2290	Knockdown of ROS1 gene sensitizes breast tumor growth to doxorubicin in a syngeneic mouse model. <i>International Journal of Oncology</i> , 2016, 48, 2359-2366.	1.4	28
2291	Laminin $\hat{\pm}$ 5 modulates fibroblast proliferation in epidural fibrosis through the PI3K/AKT/mTOR signaling pathway. <i>Molecular Medicine Reports</i> , 2020, 21, 1491-1500.	1.1	5
2292	Paired-related homeobox1 overexpression promotes multidrug resistance via PTEN/PI3K/AKT signaling in MCF7 breast cancer cells. <i>Molecular Medicine Reports</i> , 2020, 22, 3183-3190.	1.1	7
2293	Emerging role of circular RNA in intervertebral disc degeneration: Knowns and unknowns (Review). <i>Molecular Medicine Reports</i> , 2020, 22, 3057-3065.	1.1	6
2294	Akt inhibitor MK2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine. <i>Oncology Letters</i> , 2020, 19, 1999-2004.	0.8	12
2295	Shank-associated RH domain interactor signaling in tumorigenesis (Review). <i>Oncology Letters</i> , 2020, 20, 2579-2586.	0.8	9

#	ARTICLE	IF	CITATIONS
2296	Genetic profiling of somatic alterations by OncoPrint Focus Assay in Korean patients with advanced gastric cancer. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	7
2297	Ginsenoside CK induces apoptosis and suppresses proliferation and invasion of human osteosarcoma cells through the PI3K/mTOR/p70S6K1 pathway. <i>Oncology Reports</i> , 2020, 43, 886-896.	1.2	13
2298	Diverse molecular functions of aspartate β -hydroxylase in cancer (Review). <i>Oncology Reports</i> , 2020, 44, 2364-2372.	1.2	17
2299	Molecular biology of lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S479-90.	0.6	173
2300	Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 20-9.	0.6	22
2301	Phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 165-76.	1.3	103
2302	Allele frequencies of the epidermal growth factor receptors polymorphism rs21k in colorectal cancer patients and healthy subjects indicate a risk-reducing effect of rs21 in Syrian population. <i>North American Journal of Medical Sciences</i> , 2013, 5, 202.	1.7	5
2303	IGF-1 Mediates Exercise-Induced Phospholipid Alteration in the Murine Skin Tissues. <i>Journal of Nutrition & Food Sciences</i> , 2012, S2, .	1.0	5
2304	The Determinants of Head and Neck Cancer: Unmasking the PI3K Pathway Mutations. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2013, Suppl 5, .	0.3	23
2305	PIK3CA/AKT1 Mutations in Breast Carcinoma: a Comprehensive Review of Experimental and Clinical Studies. , 2012, 02, .		6
2306	PIK3CD (phosphoinositide-3-kinase, catalytic, delta polypeptide). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2012, , .	0.1	1
2307	Genomic analysis of GBS data reveals genes associated with facial pigmentation in Xinyang blue-shelled layers. <i>Archives Animal Breeding</i> , 2020, 63, 483-491.	0.5	8
2308	Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?. <i>International Neurourology Journal</i> , 2016, 20, S131-140.	0.5	20
2309	Role of Akt signaling in resistance to DNA-targeted therapy. <i>World Journal of Clinical Oncology</i> , 2016, 7, 352.	0.9	48
2310	Upstream signalling of mTORC1 and its hyperactivation in type 2 diabetes (T2D). <i>BMB Reports</i> , 2017, 50, 601-609.	1.1	23
2311	The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. <i>Chinese Journal of Cancer</i> , 2012, 31, 327-334.	4.9	43
2312	Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy. <i>Chinese Journal of Cancer</i> , 2013, 32, 376-379.	4.9	32
2313	Cavin-3 dictates the balance between ERK and Akt signaling. <i>ELife</i> , 2013, 2, e00905.	2.8	68

#	ARTICLE	IF	CITATIONS
2314	Rac1-mediated membrane raft localization of PI3K/p110 ^β is required for its activation by GPCRs or PTEN loss. <i>ELife</i> , 2016, 5, .	2.8	25
2315	Eyeless uncouples mushroom body neuroblast proliferation from dietary amino acids in <i>Drosophila</i> . <i>ELife</i> , 2017, 6, .	2.8	18
2316	Fetal and trophoblast PI3K p110 ^β have distinct roles in regulating resource supply to the growing fetus in mice. <i>ELife</i> , 2019, 8, .	2.8	36
2317	FoxO suppresses endoplasmic reticulum stress to inhibit growth of Tsc1-deficient tissues under nutrient restriction. <i>ELife</i> , 2020, 9, .	2.8	5
2318	A genome engineering resource to uncover principles of cellular organization and tissue architecture by lipid signaling. <i>ELife</i> , 2020, 9, .	2.8	14
2319	Effects of two dietary crude protein levels on finishing performance, meat quality, and gene expression of market lambs. <i>Animal Science Journal</i> , 2021, 92, e13641.	0.6	3
2322	Regulation of autophagy as a therapeutic option in glioblastoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2021, 26, 574-599.	2.2	12
2323	Implications of Phosphoinositide 3-Kinase-Akt (PI3K-Akt) Pathway in the Pathogenesis of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2022, 59, 354-385.	1.9	58
2324	Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2021, 12, 920.	2.7	13
2325	Palmitic acid inhibits prostate cancer cell proliferation and metastasis by suppressing the PI3K/Akt pathway. <i>Life Sciences</i> , 2021, 286, 120046.	2.0	68
2328	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. , 2008, , 81-114.		2
2330	Pten-Deficient Mouse Models for High-Grade Astrocytomas. , 2009, , 77-92.		2
2331	SIGNAL TRANSDUCTION. , 2009, , 67-81.		0
2332	mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside. , 2009, , 99-111.		0
2333	mTOR and Cancer Therapy: General Principles. , 2009, , 113-131.		0
2334	Molecular Basis of Human Malignancy. , 2009, , 41-55.		1
2335	Factors in the Causation of Female Cancers and Prevention. , 2010, , 175-194.		0
2336	A Role for eNOS in Oncogenic Ras-Driven Cancer. , 2010, , 23-38.		1

#	ARTICLE	IF	CITATIONS
2337	Targeting the PI3K/Akt/mTOR Pathway in AIDS-Associated Malignancies. , 2010, , 153-166.		0
2338	The PI3K/Akt-NF-kappa B Signaling Pathway and Hypoxia-induced Mitogenic Factor in Vascular Adhesion Molecule 1 Gene Expression. , 2010, , 87-102.		0
2339	Effects and Therapeutic Potential of Targeting Dysregulated Signaling Axes in Squamous Cell Carcinoma: Another Kinase of Transcription and Mammalian Target of Rapamycin. , 2011, , 383-405.		0
2340	No Association between PIK3CA Polymorphism and Lung Cancer Risk in the Korean Population. Genomics and Informatics, 2010, 8, 194-200.	0.4	1
2341	PI3K Signaling. , 2011, , 2887-2892.		0
2342	Cancer Cell Metabolism. , 2012, , 245-261.		0
2343	Embryonic Stem Cells - Basic Biology to Bioengineering. , 2011, , .		15
2344	Targeting HER-2 Signaling Network: Implication in Radiation Response. , 0, , .		0
2346	UPR Activation in Cancer Cells: A Double-Edged Sword. , 2012, , 383-412.		1
2347	Phosphoinositide 3-Kinase. , 2012, , 1392-1400.		0
2349	Prognostic Markers in Colon Cancer. , 2013, , 131-162.		0
2350	Usefulness of Molecular Biology in Follicular-Derived Thyroid Tumors: From Translational Research to Clinical Practice. , 2013, , 391-428.		0
2351	AKT. , 2013, , 1-10.		0
2353	Personalized prostate cancer therapy based on systems analysis of the apoptosis regulatory network. Asian Journal of Andrology, 2015, 17, 471.	0.8	3
2355	Strategies in Patients with Other Molecular Alterations. , 2015, , 187-202.		0
2356	Novel Targets for Future Medical Treatments. , 2015, , 145-162.		0
2358	The Role of PI3K Signaling Pathway in Intestinal Tumorigenesis. , 2015, , 101-135.		0
2359	PI3K Signaling. , 2015, , 1-6.		0

#	ARTICLE	IF	CITATIONS
2360	Management of Advanced Endometrial Cancer and Inhibitors of the PI3K/AKT/mTOR Pathway. , 2015, , 327-341.		0
2362	PTEN at 18: Still Growing. <i>Methods in Molecular Biology</i> , 2016, 1388, 13-19.	0.4	2
2363	Combination Therapies Targeting the PI3K/AKT/mTOR Pathways. <i>Cancer Drug Discovery and Development</i> , 2016, , 151-180.	0.2	0
2364	The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities. <i>Cancer Drug Discovery and Development</i> , 2016, , 263-289.	0.2	0
2365	Targeted Therapy in Melanoma. , 2016, , 237-265.		0
2366	Glucose-induced lipid deposition in goose primary hepatocytes is dependent on the PI3K-Akt-mTOR signaling pathway. <i>Archives of Biological Sciences</i> , 2016, 68, 853-861.	0.2	1
2367	The Role of mTOR Inhibitors in Neuroendocrine Tumors. , 2016, , 93-112.		0
2369	Targeting the Androgen Receptor Signaling Axis. , 2017, , 134-153.		0
2370	Molecular Pathogenesis of Prostate Cancer. , 2017, , 171-189.		0
2371	PI3K Signaling. , 2017, , 3576-3581.		0
2372	THE ROLE OF PHOSPHATIDYLINOSITOL-3-KINASE IN CARCINOGENESIS. <i>Voprosy Onkologii</i> , 2017, 63, 545-556.	0.1	1
2373	Hepatic deletion of p110 α and p85 β results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity. <i>F1000Research</i> , 2017, 6, 1600.	0.8	1
2378	Targeted Therapy in Management of Endometrial Cancer. , 2020, , 249-276.		1
2379	Docking Study to Predict the Efficacy of Phosphatidylinositol 3-Kinase β Inhibitors. <i>ARO-the Scientific Journal of Koya University</i> , 2019, 7, 47-52.	0.2	0
2380	Case Report: Sustained Complete Response to PI3K Inhibition in a Patient with Metastatic Breast Cancer Harboring PIK3CA, NF1, and CDH1 Mutations. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 133-136.	0.6	0
2382	Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling. <i>Medical Science Monitor</i> , 2020, 26, e927106.	0.5	7
2383	Exploring the selective mechanism of inhibitors towards different subtypes of class I PI3K. <i>Chemical Physics Letters</i> , 2021, , 139174.	1.2	1
2384	The role of PI3K β lipid signalling in melanoma initiation, progression and maintenance. <i>Experimental Dermatology</i> , 2022, 31, 43-56.	1.4	7

#	ARTICLE	IF	CITATIONS
2385	Estrogen receptor α -36 is involved in diallyl sulfide α -induced inhibition of malignant growth of HepG2 and Huh7 hepatocellular carcinoma cells. <i>Environmental Toxicology</i> , 2022, 37, 270-281.	2.1	11
2386	Growth Factors and Osteoarthritis. , 2020, , 632-640.		1
2387	Molecular and Biological Basis of Lung Cancer-Part I. , 2020, 01, .		0
2388	Targeting protein kinases for anti-glioma treatment. <i>Folia Neuropathologica</i> , 2020, 58, 287-298.	0.5	2
2389	Spirulina protein promotes skin wound repair in a mouse model of full-thickness dermal excisional wound. <i>International Journal of Molecular Medicine</i> , 2020, 46, 351-359.	1.8	4
2390	LukS-PV Induces Apoptosis via the SET8-H4K20me1-PIK3CB Axis in Human Acute Myeloid Leukemia Cells. <i>Frontiers in Oncology</i> , 2021, 11, 718791.	1.3	4
2391	PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11878.	1.8	1
2392	Overview of the regulation of the class IA PI3K/AKT pathway by SUMO. <i>Seminars in Cell and Developmental Biology</i> , 2022, 132, 51-61.	2.3	9
2393	The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19. <i>Drug Discovery Today</i> , 2022, 27, 848-856.	3.2	45
2394	Targeting Signaling Pathways “ In the Search of Melanoma’s Achilles’ Heel. , 2008, , 27-42.		0
2397	Membrane Recruitment as a Cancer Mechanism: A Case Study of Akt PH Domain. <i>Cellscience</i> , 2007, 4, 25-30.	0.3	7
2398	Physiological regulation of Akt activity and stability. <i>American Journal of Translational Research (discontinued)</i> , 2010, 2, 19-42.	0.0	212
2400	New horizons in melanoma treatment: targeting molecular pathways. <i>Ochsner Journal</i> , 2010, 10, 93-8.	0.5	1
2401	A beta version of life: p110 ² takes center stage. <i>Oncotarget</i> , 2010, 1, 729-33.	0.8	29
2402	Therapy of adrenocortical cancer: present and future. <i>American Journal of Cancer Research</i> , 2011, 1, 222-232.	1.4	12
2403	Class II phosphoinositide 3-kinase C2alpha: what we learned so far. <i>International Journal of Biochemistry and Molecular Biology</i> , 2011, 2, 168-182.	0.1	15
2405	Rho kinase proteins–pleiotropic modulators of cell survival and apoptosis. <i>Anticancer Research</i> , 2011, 31, 3645-57.	0.5	95
2407	Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 418-31.	1.0	16

#	ARTICLE	IF	CITATIONS
2408	Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 217-24.	0.3	18
2409	PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 8295-303.	0.5	18
2410	Lipid Signaling in Tumorigenesis. <i>Molecular and Cellular Pharmacology</i> , 2014, 6, 1-9.	1.7	5
2412	FK506-binding protein 5 inhibits proliferation and stimulates apoptosis of glioma cells. <i>Archives of Medical Science</i> , 2015, 11, 1074-80.	0.4	7
2413	Long noncoding RNA AK056155 involved in the development of Loeys-Dietz syndrome through AKT/PI3K signaling pathway. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 10768-75.	0.5	14
2414	Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers. <i>American Journal of Cancer Research</i> , 2016, 6, 714-46.	1.4	19
2416	A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. <i>American Journal of Cancer Research</i> , 2018, 8, 2359-2376.	1.4	24
2417	New insights into autophagy in hepatocellular carcinoma: mechanisms and therapeutic strategies. <i>American Journal of Cancer Research</i> , 2019, 9, 1329-1353.	1.4	25
2418	The dysfunctional lipids in prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2019, 7, 273-280.	0.4	11
2419	Prognostic significance of phosphoinositide 3-kinase p110 ^α and p110 ^β isoforms in non-small cell lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 1554-1561.	0.5	1
2420	Alpelisib: A Novel Therapy for Patients With Mutated Metastatic Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 768-775.	0.2	3
2422	Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 15330338211038488.	0.8	0
2423	SGK1, autophagy and cancer: an overview. <i>Molecular Biology Reports</i> , 2022, 49, 675-685.	1.0	7
2424	Leucosceptoside A from <i>Devil's Claw</i> Modulates Psoriasis-like Inflammation via Suppression of the PI3K/AKT Signaling Pathway in Keratinocytes. <i>Molecules</i> , 2021, 26, 7014.	1.7	5
2425	Mechanistic Target of Rapamycin Complex 2 Regulation of the Primary Human Trophoblast Cell Transcriptome. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 670980.	1.8	6
2426	PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway. <i>Molecular Biology Reports</i> , 2021, , 1.	1.0	14
2427	RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues. <i>Molecular Oncology</i> , 2022, 16, 1091-1118.	2.1	8
2428	Dysregulated phosphoinositide 3-kinase signaling in microglia: shaping chronic neuroinflammation. <i>Journal of Neuroinflammation</i> , 2021, 18, 276.	3.1	36

#	ARTICLE	IF	CITATIONS
2429	Targeted Therapy in HR+ HER2 ⁺ Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options. <i>Cancers</i> , 2021, 13, 5994.	1.7	11
2430	Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1632-1647.	0.8	5
2431	Can We Use mTOR Inhibitors for COVID-19 Therapy?. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 1805-1808.	0.6	4
2432	VLX1570 regulates the proliferation and apoptosis of human lung cancer cells through modulating ER stress and the AKT pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2021, , .	1.6	6
2433	Resolving hepatic fibrosis <i>via</i> suppressing oxidative stress and an inflammatory response using a novel hyaluronic acid modified nanocomplex. <i>Biomaterials Science</i> , 2021, 9, 8259-8269.	2.6	9
2434	Design, synthesis, anticancer activity and mechanism studies of novel 2-amino-4-aryl-pyrimidine derivatives of ursolic acid. <i>New Journal of Chemistry</i> , 2022, 46, 2335-2350.	1.4	4
2435	Identification and optimization of a novel series of selective PIP5K inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 54, 116557.	1.4	5
2436	Corticotropin releasing hormone receptor 2 antagonist, RQ-00490721, for the prevention of pressure overload-induced cardiac dysfunction. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112566.	2.5	0
2437	The two faces of autophagy in oral squamous cell carcinoma. <i>Archives of Oral Biology</i> , 2022, 134, 105321.	0.8	5
2438	Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 768-775.	0.2	8
2439	Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110384.	0.8	2
2440	LINC02381 aggravates breast cancer through the miR-1271/FN1 axis to activate PI3K/AKT pathway. <i>Molecular Carcinogenesis</i> , 2022, 61, 346-358.	1.3	15
2441	Targeting PI3K by Natural Products: A potential therapeutic strategy for Attention-Deficit Hyperactivity Disorder?. <i>Current Neuropharmacology</i> , 2022, 20, .	1.4	1
2442	Endosomal cargo recycling mediated by Gpa1 and phosphatidylinositol 3-kinase is inhibited by glucose starvation. <i>Molecular Biology of the Cell</i> , 2022, 33, mbcE21040163.	0.9	3
2443	Neuroprotective Effect of Chrysophanol as a PI3K/AKT/mTOR Signaling Inhibitor in an Experimental Model of Autologous Blood-induced Intracerebral Hemorrhage. <i>Current Medical Science</i> , 2022, , 1.	0.7	4
2444	Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. <i>Cancers</i> , 2022, 14, 664.	1.7	7
2445	Integrins as a drug target in liver fibrosis. <i>Liver International</i> , 2022, 42, 507-521.	1.9	27
2447	Alteration in major cell signaling pathways in cancer. , 2022, , 159-186.		0

#	ARTICLE	IF	CITATIONS
2448	The contribution of exbB gene to pathogenicity of <i>Pseudomonas plecoglossicida</i> and its interactions with <i>Epinephelus coioides</i> . <i>Fish and Shellfish Immunology</i> , 2022, 120, 610-619.	1.6	8
2449	Overexpression of ultraconserved region 83- induces lung cancer tumorigenesis. <i>PLoS ONE</i> , 2022, 17, e0261464.	1.1	4
2450	Interpreting Functional Impact of Genetic Variations by Network QTL for Genotypeâ€“Phenotype Association Study. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 720321.	1.8	3
2451	Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 114039.	2.6	18
2452	Downregulation of PIK3CB Involved in Alzheimerâ€™s Disease via Apoptosis, Axon Guidance, and FoxO Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-15.	1.9	5
2453	Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention. <i>Medical Oncology</i> , 2022, 39, 30.	1.2	8
2454	Oncogenic potential of BEST4 in colorectal cancer via activation of PI3K/Akt signaling. <i>Oncogene</i> , 2022, 41, 1166-1177.	2.6	13
2455	Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 600.	1.7	14
2456	Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542110731.	0.8	3
2457	Neuroprotective Effect of Chrysophanol as a PI3K/AKT/mTOR Signaling Inhibitor in an Experimental Model of Autologous Blood-induced Intracerebral Hemorrhage. <i>Current Medical Science</i> , 2022, 42, 249-266.	0.7	11
2458	Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis via Regulation of the PI3K/AKT/mTOR Signaling Pathway. <i>Frontiers in Oncology</i> , 2022, 12, 833719.	1.3	6
2459	Amphioxus muscle transcriptomes reveal vertebrate-like myoblast fusion genes and a highly conserved role of insulin signalling in the metabolism of muscle. <i>BMC Genomics</i> , 2022, 23, 93.	1.2	1
2460	Long-term monitoring of blood biomarkers related to intrauterine growth restriction using AgNPs SERS tags-based lateral flow assay. <i>Talanta</i> , 2022, 241, 123128.	2.9	10
2461	Optochemical Control of mTOR Signaling and mTOR-Dependent Autophagy. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 149-155.	2.5	2
2462	Recent Advances in Dual BRD4â€™Kinase Inhibitors Based on Polypharmacology. <i>ChemMedChem</i> , 2022, 17, .	1.6	6
2463	Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities. <i>Molecular Genetics and Genomics</i> , 2022, 297, 387-396.	1.0	3
2464	<i>Escherichia coli</i> succinic thiolinase. Stoichiometry of phosphorylation and coenzyme A binding. <i>Journal of Biological Chemistry</i> , 1975, 250, 5609-13.	1.6	20
2465	Proliferative signaling pathways in hepatocellular carcinoma. , 2022, , 255-271.		0

#	ARTICLE	IF	CITATIONS
2466	Signaling Pathways that Regulate Macropinocytosis in Mammalian Cells. <i>Sub-Cellular Biochemistry</i> , 2022, 98, 143-167.	1.0	5
2467	Immunofluorescence Detection of Plasma Membranous PTEN in Cultured Cells. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 289-297.	1.3	0
2468	Sumoylation in Physiology, Pathology and Therapy. <i>Cells</i> , 2022, 11, 814.	1.8	24
2469	Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine. <i>EPMA Journal</i> , 2022, 13, 9-37.	3.3	6
2470	The phosphoinositide 3-kinase (PI3K) inhibitor seletalisib impairs monocyte-derived dendritic cells maturation, APC function, and promotes their migration to CCR7 and CXCR4 ligands. <i>Journal of Leukocyte Biology</i> , 2022, , .	1.5	0
2471	Dissecting the Polygenic Basis of Primary Hypertension: Identification of Key Pathway-Specific Components. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 814502.	1.1	5
2472	Molecular and cellular mechanisms of melatonin in breast cancer. <i>Biochimie</i> , 2022, , .	1.3	7
2473	Integrated Analysis of Ulcerative Colitis Revealed an Association between PHLPP2 and Immune Infiltration. <i>Disease Markers</i> , 2022, 2022, 1-15.	0.6	2
2474	<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100370.	1.5	17
2475	Searching for a Link between Bone Decay and Diabetes Type 2. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 904-910.	0.6	1
2476	PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. <i>Cancers</i> , 2022, 14, 1652.	1.7	23
2478	Human umbilical vein endothelial cells-derived exosomes enhance cardiac function after acute myocardial infarction by activating the PI3K/AKT signaling pathway. <i>Bioengineered</i> , 2022, 13, 8850-8865.	1.4	11
2479	ZDQ-0620, a Novel Phosphatidylinositol 3-Kinase Inhibitor, Inhibits Colorectal Carcinoma Cell Proliferation and Suppresses Angiogenesis by Attenuating PI3K/AKT/mTOR Pathway. <i>Frontiers in Oncology</i> , 2022, 12, 848952.	1.3	5
2480	The reliability of biomedical science: A case history of a maturing experimental field. <i>BioEssays</i> , 2022, 44, e2200020.	1.2	1
2481	Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors. <i>Breast Cancer Research</i> , 2022, 24, 23.	2.2	5
2482	Cáncer de próstata de inicio temprano. ¿Una nueva entidad?. <i>Revista Mexicana De Urologia</i> , 2021, 81, 1-13.	0.0	0
2483	WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	7
2484	Untangling the KRAS mutated lung cancer subsets and its therapeutic implications. <i>Molecular Biomedicine</i> , 2021, 2, 40.	1.7	3

#	ARTICLE	IF	CITATIONS
2486	Metformin alleviates the calcification of aortic valve interstitial cells through activating the PI3K/AKT pathway in an AMPK dependent way. <i>Molecular Medicine</i> , 2021, 27, 156.	1.9	12
2487	Influence of Charge Lipid Head Group Structures on Electric Double Layer Properties. <i>Journal of Chemical Theory and Computation</i> , 2022, 18, 448-460.	2.3	5
2488	Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 124.	1.0	9
2489	Recent advances of fluorescent biosensors based on cyclic signal amplification technology in biomedical detection. <i>Journal of Nanobiotechnology</i> , 2021, 19, 403.	4.2	25
2490	La vía canónica PI3K/AKT/mTOR y sus alteraciones en cáncer. <i>Horizonte Médico</i> , 2021, 21, e1547.	0.1	1
2491	Combination Therapy with PIK3R3-siRNA and EGFR-TKI Erlotinib Synergistically Suppresses Glioblastoma Cell Growth In Vitro. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 3993-4000.	0.5	4
2492	Research Status of the Correlation between Type 2 Diabetes Mellitus and the Occurrence and Development of Breast Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 3010-3017.	0.0	0
2493	Towards Kinase Inhibitor Therapies for Fragile X Syndrome: Tweaking Twists in the Autism Spectrum Kinase Signaling Network. <i>Cells</i> , 2022, 11, 1325.	1.8	13
2494	Genetic Alteration and Their Significance on Clinical Events in Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 1493-1505.	0.9	3
2495	miR-1227-3p participates in the development of fetal growth restriction via regulating trophoblast cell proliferation and apoptosis. <i>Scientific Reports</i> , 2022, 12, 6374.	1.6	4
2496	Kindlin-2 Promotes Chondrogenesis and Ameliorates IL-1beta-Induced Inflammation in Chondrocytes Cultured with BMSCs in the Direct Contact Coculture System. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-13.	1.9	1
2497	QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3K γ) inhibitors using MLR and ANN methods. <i>Scientific Reports</i> , 2022, 12, 6090.	1.6	9
2539	Genetic analysis of <i>daf-18/PTEN</i> missense mutants for starvation resistance and developmental regulation during <i>Caenorhabditis elegans</i> L1 arrest. <i>G3: Genes, Genomes, Genetics</i> , 2022, 12, .	0.8	4
2543	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. <i>Cancers</i> , 2022, 14, 2161.	1.7	15
2544	Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma. <i>Cancer Medicine</i> , 2022, , .	1.3	2
2545	Proteolytic Activity-Independent Activation of the Immune Response by Gingipains from <i>Porphyromonas gingivalis</i> . <i>MBio</i> , 2022, 13, e0378721.	1.8	5
2546	Identification of a Cancer Stem Cells Signature of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	3
2547	Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8345-8379.	2.9	3

#	ARTICLE	IF	CITATIONS
2548	Plasma membrane phosphatidylinositol (4,5)-bisphosphate is critical for determination of epithelial characteristics. <i>Nature Communications</i> , 2022, 13, 2347.	5.8	9
2549	Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response. <i>Biologics: Targets and Therapy</i> , 2022, Volume 16, 35-45.	3.0	3
2550	Saucerneol attenuates nasopharyngeal carcinoma cells proliferation and metastasis through selectively targeting Grp94. <i>Phytomedicine</i> , 2022, 101, 154133.	2.3	1
2551	The Importance of RTK Signaling Genes and their Inhibitors in Breast Cancer. <i>Journal of Obstetrics, Gynecology and Cancer Research</i> , 2022, 7, 258-271.	0.0	0
2552	Picalima nitida leaf extract ameliorates oxidative stress and modulates insulin signaling pathway in high fat-diet/STZ induced diabetic rats. <i>South African Journal of Botany</i> , 2022, 148, 268-282.	1.2	3
2553	Effects of air pollution on human health – Mechanistic evidence suggested by in vitro and in vivo modelling. <i>Environmental Research</i> , 2022, 212, 113378.	3.7	27
2554	Idelalisib activates AKT via increased recruitment of PI3K $\hat{1}$ /PI3K $\hat{2}$ to BCR signalosome while reducing PDK1 in post-therapy CLL cells. <i>Leukemia</i> , 2022, 36, 1806-1817.	3.3	2
2556	Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3K $\hat{1}$ Inhibitors for the Treatment of B-Cell Malignancies. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8011-8028.	2.9	7
2557	Molecular Docking and Simulation Studies of Flavanone and its Derived Compounds on PI3K-AKT Pathway Targeting against Cancer. <i>Current Drug Discovery Technologies</i> , 2023, 20, .	0.6	2
2558	Polyamine synthesis enzyme AMD1 is closely related to the tumorigenesis and prognosis of human breast cancer. <i>Experimental Cell Research</i> , 2022, 417, 113235.	1.2	3
2559	Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 131, 105939.	0.8	5
2562	Vitamin B6 rescues insulin resistance and glucose-induced DNA damage caused by reduced activity of <i>Drosophila</i> PI3K. <i>Journal of Cellular Physiology</i> , 2022, 237, 3578-3586.	2.0	3
2563	PI3King the Environment for Growth: PI3K Activation Drives Transcriptome Changes That Support Oncogenic Growth. <i>Cancer Research</i> , 2022, 82, 2216-2218.	0.4	1
2564	Discovery of potential mTOR inhibitors from <i>Cichorium intybus</i> to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach. <i>Molecular Diversity</i> , 2023, 27, 1141-1162.	2.1	9
2565	Small extracellular vesicles derived from dermal fibroblasts promote fibroblast activity and skin development through carrying miR-218 and ITGBL1. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	5
2566	Role of phosphoinositide 3-kinase/ protein kinase B/ phosphatase and tensin homologue (PI3K/AKT/PTEN) pathway inhibitors during in vitro maturation of mammalian oocytes on in vitro embryo production: A systematic review. <i>Theriogenology</i> , 2022, 189, 42-52.	0.9	5
2567	Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis. <i>Annals of Hematology</i> , 2022, 101, 1741-1753.	0.8	1
2568	Recent trends in cancer immunotherapy: Pathways and inhibitors. , 2022, , 39-50.		0

#	ARTICLE	IF	CITATIONS
2569	Anti-cancerous medications and PTEN treatment modalities for the control of endometrial malignancy. <i>International Journal of Health Sciences</i> , 0, , 14393-14406.	0.0	0
2570	Four-octyl itaconate improves osteoarthritis by enhancing autophagy in chondrocytes via PI3K/AKT/mTOR signalling pathway inhibition. <i>Communications Biology</i> , 2022, 5, .	2.0	17
2571	PIK3R3, a regulatory subunit of PI3K, modulates ovarian cancer stem cells and ovarian cancer development and progression by integrative analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
2573	Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. <i>Cancer Discovery</i> , 2022, 12, 2058-2073.	7.7	16
2574	Atypical PIK3CA Positive Hemangioma Refractory to Propranolol. <i>Journal of Vascular Anomalies</i> , 2022, 3, e044.	0.1	0
2575	ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair. <i>BioMed Research International</i> , 2022, 2022, 1-17.	0.9	4
2576	Discovery, Optimization, and Evaluation of Potent and Selective PI3KÎ³ Dual Inhibitors for the Treatment of B-cell Malignancies. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9893-9917.	2.9	2
2577	Patient Derived Organoids Confirm That PI3K/AKT Signalling Is an Escape Pathway for Radioresistance and a Target for Therapy in Rectal Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
2578	Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations. <i>Proteomics</i> , 0, , 2200077.	1.3	2
2579	Ablation of PI3K-p110alpha Impairs Maternal Metabolic Adaptations to Pregnancy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	5
2580	Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	11
2581	Pharmacological Properties of 4,5,7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways. <i>Molecules</i> , 2022, 27, 4304.	1.7	20
2582	Lipodystrophy-associated progeroid syndromes. <i>Hormones</i> , 2022, 21, 555-571.	0.9	4
2583	The role of phosphoinositide 3-kinases in immune-inflammatory responses: potential therapeutic targets for abdominal aortic aneurysm. <i>Cell Cycle</i> , 2022, 21, 2339-2364.	1.3	1
2584	The PH Domain and C-Terminal polyD Motif of Phafin2 Exhibit a Unique Concurrence in Animals. <i>Membranes</i> , 2022, 12, 696.	1.4	1
2585	Cross-regulation between microRNAs and key proteins of signaling pathways in hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 753-765.	1.4	0
2586	Extraterrestrial Gynecology: Could Spaceflight Increase the Risk of Developing Cancer in Female Astronauts? An Updated Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7465.	1.8	7
2587	Functional roles of E3 ubiquitin ligases in prostate cancer. <i>Journal of Molecular Medicine</i> , 2022, 100, 1125-1144.	1.7	6

#	ARTICLE	IF	CITATIONS
2588	Genetic inhibition of PDK1 robustly reduces plaque deposition and ameliorates gliosis in the 5Å–FAD mouse model of Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	2
2589	Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3K γ Inhibitors: Part IIâ€™ Benzimidazole Derivatives. <i>Pharmaceutics</i> , 2022, 15, 927.	1.7	5
2590	Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2022, 14, 3744.	1.7	10
2591	Ultraviolet Radiation Exposure and its Impacts on Cutaneous Phosphorylation Signaling in Carcinogenesis: Focusing on Protein Tyrosine Phosphatases^{â€‹}. <i>Photochemistry and Photobiology</i> , 2023, 99, 344-355.	1.3	1
2592	Long Noncoding RNA LEMD1-AS1 Increases LEMD1 Expression and Activates PI3K-AKT Pathway to Promote Metastasis in Oral Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2022, 2022, 1-12.	0.9	2
2593	Advances in the Discovery of Novel Inhaled PI3K γ Inhibitors for the Treatment of Asthma. <i>Current Medicinal Chemistry</i> , 2023, 30, 1971-1992.	1.2	0
2594	Nicotinic receptor components of amyloid beta 42 proteome regulation in human neural cells. <i>PLoS ONE</i> , 2022, 17, e0270479.	1.1	4
2595	Advances in the use of exosomes for the treatment of ALI/ARDS. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
2596	The Effect of Metabolites on Mitochondrial Functions in the Pathogenesis of Skeletal Muscle Aging. <i>Clinical Interventions in Aging</i> , 0, Volume 17, 1275-1295.	1.3	2
2598	Clinicopathological characteristics and prognostic analysis of PIK3CA mutation in breast cancer patients in Northwest China. <i>Pathology Research and Practice</i> , 2022, 238, 154063.	1.0	1
2599	Maternal and Fetal PI3K-p110 α ± Deficiency Induces Sex-Specific Changes in Conceptus Growth and Placental Mitochondrial Bioenergetic Reserve in Mice. <i>Veterinary Sciences</i> , 2022, 9, 501.	0.6	3
2600	The subversion of toll-like receptor signaling by bacterial and viral proteases during the development of infectious diseases. <i>Molecular Aspects of Medicine</i> , 2022, 88, 101143.	2.7	3
2601	Understanding the Molecular Kinetics in NSCLC Through Computational Method. , 2022, , 129-163.		0
2602	Possible Mechanisms and Molecular Signaling of Incretins against the Development of Type 2 Diabetes Mellitus. <i>Current Molecular Pharmacology</i> , 2023, 16, 448-464.	0.7	1
2603	Double Deletion of PI3K and PTEN Modifies Lens Postnatal Growth and Homeostasis. <i>Cells</i> , 2022, 11, 2708.	1.8	0
2604	The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. <i>Cancers</i> , 2022, 14, 4203.	1.7	5
2605	Deoxy podophyllotoxin Induces ROS-Mediated Apoptosis by Modulating the PI3K/AKT and p38 MAPK-Dependent Signaling in Oral Squamous Cell Carcinoma. <i>Journal of Microbiology and Biotechnology</i> , 2022, 32, 1103-1109.	0.9	1
2606	LincRNA RMRP regulates phenylephrine-induced cardiomyocyte hypertrophy via targeting miR-1. <i>Journal of Cardiovascular Pharmacology</i> , 2022, Publish Ahead of Print, .	0.8	3

#	ARTICLE	IF	CITATIONS
2607	CircSEMA4B inhibits the progression of breast cancer by encoding a novel protein SEMA4B-211aa and regulating AKT phosphorylation. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	31
2608	A LETM2-Regulated PI3K-Akt Signaling Axis Reveals a Prognostic and Therapeutic Target in Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 4722.	1.7	3
2609	Insulin Resistance and Type 2 Diabetes Mellitus: An Ultimatum to Renal Physiology. <i>Cureus</i> , 2022, , .	0.2	1
2610	Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways. <i>Molecules</i> , 2022, 27, 5889.	1.7	17
2611	Insulinemic potential of diet and risk of total and subtypes of breast cancer among US females. <i>American Journal of Clinical Nutrition</i> , 2022, 116, 1530-1539.	2.2	5
2612	The ubiquitous microtubule-associated protein 4 (MAP4) controls organelle distribution by regulating the activity of the kinesin motor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	4
2613	Spatiotemporal lipidomics reveals key features of brain lipid dynamic changes after cerebral ischemia and reperfusion therapy. <i>Pharmacological Research</i> , 2022, 185, 106482.	3.1	8
2614	Relationship between the microRNAs and PI3K/AKT/mTOR axis: Focus on non-small cell lung cancer. <i>Pathology Research and Practice</i> , 2022, 239, 154093.	1.0	1
2615	Choline kinase: An underappreciated rheumatoid arthritis therapeutic target. <i>Life Sciences</i> , 2022, 309, 121031.	2.0	1
2616	An Overview of Class II Phosphoinositide 3-Kinases. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 51-68.	0.7	2
2617	Emerging genetic biomarkers in lung adenocarcinoma. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211323.	0.7	1
2618	Akt Inhibition Promotes Autophagy and Clearance of Group B Streptococcus from the Alveolar Epithelium. <i>Pathogens</i> , 2022, 11, 1134.	1.2	1
2619	Proteomics as a tool to improve novel insights into skin diseases: what we know and where we should be going. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	4
2620	Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5160.	1.7	7
2621	Immune Pathway and Gene Database (IMPAGT) Revealed the Immune Dysregulation Dynamics and Overactivation of the PI3K/Akt Pathway in Tumor Buddings of Cervical Cancer. <i>Current Issues in Molecular Biology</i> , 2022, 44, 5139-5152.	1.0	4
2622	ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer. <i>Aging</i> , 2022, 14, 7941-7958.	1.4	2
2623	Computational Design of Phosphatidylinositol 3-Kinase Inhibitors. <i>Assay and Drug Development Technologies</i> , 2022, 20, 317-337.	0.6	6
2625	PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative. <i>Journal of Personalized Medicine</i> , 2022, 12, 1793.	1.1	2

#	ARTICLE	IF	CITATIONS
2626	Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3K α selective inhibitors. <i>Bioorganic Chemistry</i> , 2023, 130, 106211.	2.0	6
2628	Potential role of Marine Bioactive Compounds in cancer signaling pathways: A review. <i>European Journal of Pharmacology</i> , 2022, 936, 175330.	1.7	8
2629	Chemopreventive and anti-tumor potential of vitamin E in preclinical breast cancer studies: A systematic review. <i>Clinical Nutrition ESPEN</i> , 2023, 53, 60-73.	0.5	5
2630	Screening the possible anti-cancer constituents of <i>Hibiscus rosa-sinensis</i> flower to address mammalian target of rapamycin: an in silico molecular docking, HYDE scoring, dynamic studies, and pharmacokinetic prediction. <i>Molecular Diversity</i> , 2023, 27, 2273-2296.	2.1	6
2631	RNA m6A methylation regulators in endometrial cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	3
2632	FOXK2 transcription factor and its roles in tumorigenesis (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	0
2633	Co-encapsulation of PI3-K α /HDAC6 dual inhibitor and Navitoclax in Quatramer α , β nanoparticles for synergistic effect in ER+ breast cancer. <i>International Journal of Pharmaceutics</i> , 2022, 628, 122343.	2.6	2
2634	The role of PI3K/Akt signalling pathway in spinal cord injury. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113881.	2.5	17
2635	Molecular hallmarks of cancer. , 2023, , 489-505.e5.		0
2636	Transcriptomic Analysis of Large Yellow Croaker (<i>Larimichthys crocea</i>) during Early Development under Hypoxia and Acidification Stress. <i>Veterinary Sciences</i> , 2022, 9, 632.	0.6	5
2637	Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2638	Molecular genetic abnormalities in patients with T-cell acute lymphoblastic leukemia: a literature review. <i>Oncogematologiya</i> , 2022, 17, 166-176.	0.1	0
2639	Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges. <i>Pharmacological Research</i> , 2023, 187, 106553.	3.1	34
2640	Zishen Pill alleviates diabetes in Db/db mice via activation of PI3K/AKT pathway in the liver. <i>Chinese Medicine</i> , 2022, 17, .	1.6	0
2641	Neuroinflammation regulates the balance between hippocampal neuron death and neurogenesis in an ex vivo model of thiamine deficiency. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	4
2642	Laminin β 1 as a target for the treatment of epidural fibrosis by regulating fibrotic mechanisms. <i>International Journal of Molecular Medicine</i> , 2022, 51, .	1.8	0
2643	The design of experiments (DoE) in optimization of an aerobic flow Pd-catalyzed oxidation of alcohol towards an important aldehyde precursor in the synthesis of phosphatidylinositide 3-kinase inhibitor (CPL302415). <i>RSC Advances</i> , 2022, 12, 33605-33611.	1.7	4
2644	Design, synthesis and molecular docking of novel substituted azepines as inhibitors of PI3K/Akt/TSC2/mTOR signaling pathway in colorectal carcinoma. <i>Bioorganic Chemistry</i> , 2023, 131, 106299.	2.0	11

#	ARTICLE	IF	CITATIONS
2645	Exploration the role of INHBA in Hu sheep granulosa cells using RNA-Seq. <i>Theriogenology</i> , 2023, 197, 198-208.	0.9	1
2646	Potential target identification for osteosarcoma treatment: Gene expression re-analysis and drug repurposing. <i>Gene</i> , 2023, 856, 147106.	1.0	0
2647	Treatment Options in BRAF-mutant Metastatic Colorectal Cancer. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 103.	0.1	0
2648	MIG-6 Is Critical for Progesterone Responsiveness in Human Complex Atypical Hyperplasia and Early-Stage Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14596.	1.8	3
2649	Transcriptome analysis revealed the role of mTOR and MAPK signaling pathways in the white strain of <i>Hypsizygus marmoreus</i> extracts-induced cell death of human hepatoma Hep3B cells. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2650	Mitochondrial respiration inhibitor enhances the anti-tumor effect of high-dose ascorbic acid in castration-resistant prostate cancer. <i>Journal of Molecular Medicine</i> , 2023, 101, 125-138.	1.7	2
2651	The PI3K-AKT pathway: A plausible therapeutic target in Parkinson's disease. <i>Experimental and Molecular Pathology</i> , 2023, 129, 104846.	0.9	13
2652	Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). <i>Oncology Letters</i> , 2022, 25, .	0.8	7
2653	Membrane-to-Nucleus Signaling in Human Blood Progenitor Cells Reveals an Efficient GM-Free Reprogramming to Pluripotency. <i>Biochemistry</i> , 0, , .	0.8	0
2654	Clinical and functional characterization of germline <i>PIK3CA</i> variants in patients with <i>PIK3CA</i> -related overgrowth Spectrum disorders. <i>Human Molecular Genetics</i> , 0, , .	1.4	0
2655	CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway. <i>Analytical Cellular Pathology</i> , 2022, 2022, 1-8.	0.7	1
2656	PIK3R2 predicts poor outcomes for patients with melanoma and contributes to the malignant progression via PI3K/AKT/NF- κ B axis. <i>Clinical and Translational Oncology</i> , 2023, 25, 1402-1412.	1.2	4
2657	Stelletin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair. <i>Advanced Science</i> , 2023, 10, .	5.6	6
2658	Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases. <i>Inflammopharmacology</i> , 2023, 31, 57-75.	1.9	10
2659	Targeted therapy for head and neck cancer: signaling pathways and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	27
2660	Impediment of Cancer by Dietary Plant-derived Alkaloids Through Oxidative Stress: Implications of PI3K/AKT Pathway in Apoptosis, Autophagy, and Ferroptosis. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, 860-877.	1.0	5
2661	<i>Drosophila</i> postembryonic nervous system development: a model for the endocrine control of development. <i>Genetics</i> , 2023, 223, .	1.2	13
2662	Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. <i>Biomedicines</i> , 2023, 11, 109.	1.4	18

#	ARTICLE	IF	CITATIONS
2663	The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1506.	1.8	2
2664	RNF7 Facilitated the Tumorigenesis of Pancreatic Cancer by Activating PI3K/Akt Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-17.	1.9	1
2665	Liver Regeneration and Immunity: A Tale to Tell. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1176.	1.8	6
2666	Endothelial cell-derived exosomes boost and maintain repair-related phenotypes of Schwann cells via miR199-5p to promote nerve regeneration. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	15
2667	2D-CuPd nanozyme overcome tamoxifen resistance in breast cancer by regulating the PI3K/AKT/mTOR pathway. <i>Biomaterials</i> , 2023, 294, 121986.	5.7	10
2668	Metastatic Breast Cancer: Cytology Diagnosis with Implications for Treatment. <i>Journal of Molecular Pathology</i> , 2023, 4, 1-14.	0.5	3
2669	Ampelopsin induces MDA-MB-231 cell cycle arrest through cyclin B1-mediated PI3K/AKT/mTOR pathway <i>in vitro</i> and <i>in vivo</i> . <i>Acta Pharmaceutica</i> , 2023, 73, 75-90.	0.9	1
2670	Dieckol, a natural polyphenolic drug, inhibits the proliferation and migration of colon cancer cells by inhibiting PI3K, AKT, and mTOR phosphorylation. <i>Journal of Biochemical and Molecular Toxicology</i> , 2023, 37, .	1.4	3
2671	Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K \pm inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2023, 38, .	2.5	3
2672	Implicaciones en el tratamiento de pacientes con c�ncer de mama y alteraciones en ARID1A. <i>Revista Universitas Medica</i> , 2023, 64, .	0.0	0
2673	Targeted cancer therapy: The future of drug combinations. , 2023, , 189-217.		0
2674	Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy. <i>Bioorganic Chemistry</i> , 2023, 133, 106425.	2.0	22
2675	Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review. <i>Toxicology in Vitro</i> , 2023, 88, 105558.	1.1	0
2676	Alpelisib-induced thyroiditis in a patient with metastatic breast cancer: Is routine monitoring of thyroid function required?. <i>Current Problems in Cancer Case Reports</i> , 2023, 9, 100219.	0.1	0
2677	Wnt-associated adult stem cell marker Lgr6 is required for osteogenesis and fracture healing. <i>Bone</i> , 2023, 169, 116681.	1.4	4
2678	Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3K inhibitors for hematological cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2023, 82, 129152.	1.0	3
2679	Methionine in fish health and nutrition: Potential mechanisms, affecting factors, and future perspectives. <i>Aquaculture</i> , 2023, 568, 739310.	1.7	6
2680	Development and optimization of a continuous flow ester reduction with LiAlH ₄ in the synthesis of a key intermediate for a PI3K inhibitor (CPL302415). <i>Reaction Chemistry and Engineering</i> , 0, , .	1.9	0

#	ARTICLE	IF	CITATIONS
2681	Recent advance of herbal medicines in cancer- a molecular approach. <i>Heliyon</i> , 2023, 9, e13684.	1.4	12
2682	Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. <i>Pharmaceutics</i> , 2023, 15, 664.	2.0	2
2683	Integrative ATAC-seq and RNA-seq analyses of IPEC-J2 cells reveals porcine transcription and chromatin accessibility changes associated with <i>Escherichia coli</i> F18ac inhibited by <i>Lactobacillus reuteri</i> . <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	1
2684	Therapeutic potential of extracellular vesicles in neurodegenerative disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 243-266.	1.0	5
2685	PI3-kinase deletion promotes myelodysplasia by dysregulating autophagy in hematopoietic stem cells. <i>Science Advances</i> , 2023, 9, .	4.7	3
2686	Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4522.	1.8	16
2687	3-kinase Inhibitors for Treating Cancer and Other Diseases. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2024, 19, 253-255.	0.8	0
2688	Recent updates on thienopyrimidine derivatives as anticancer agents. <i>Medicinal Chemistry Research</i> , 2023, 32, 659-681.	1.1	6
2689	Maternal and Intrauterine Influences on Feto-Placental Growth Are Accompanied by Sexually Dimorphic Changes in Placental Mitochondrial Respiration, and Metabolic Signalling Pathways. <i>Cells</i> , 2023, 12, 797.	1.8	2
2690	Multi-Targeted and On-Demand Non-Coding RNA Regulation Nanoplatfrom against Metastasis and Recurrence of Triple-Negative Breast Cancer. <i>Small</i> , 2023, 19, .	5.2	3
2691	An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5648.	1.8	2
2692	Oxymatrine inhibits TGF β 1-mediated mitochondrial apoptotic signaling in alveolar epithelial cells via activation of PI3K/AKT signaling. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	1
2693	Chromatin Accessibility and Transcriptional Landscape during Inhibition of <i>Salmonella enterica</i> by <i>Lactobacillus reuteri</i> in IPEC-J2 Cells. <i>Cells</i> , 2023, 12, 968.	1.8	2
2694	Antitumor activity of the PI3K γ -sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	1
2695	Long Non-Coding RNAs (lncRNAs) as Regulators of the PI3K/AKT/mTOR Pathway in Gastric Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6294.	1.8	11
2696	Human menstrual blood-derived stem cells alleviate autoimmune hepatitis via JNK/MAPK signaling pathway in vivo and in vitro. <i>Frontiers of Medicine</i> , 0, , .	1.5	0
2697	Novel Sulfonamide-Triazine Hybrid Derivatives: Docking, Synthesis, and Biological Evaluation as Anticancer Agents. <i>ACS Omega</i> , 2023, 8, 14247-14263.	1.6	8
2698	Comparative transcriptome and antioxidant biomarker response reveal molecular mechanisms to cope with zinc ion exposure in the unicellular eukaryote <i>Paramecium</i> . <i>Journal of Hazardous Materials</i> , 2023, 453, 131364.	6.5	1

#	ARTICLE	IF	CITATIONS
2699	The prognostic value and biological functions of <i>HFM1</i> in breast cancer. <i>Epigenomics</i> , 0, , .	1.0	0
2700	Connecting developmental defects and evolutionary findings. , 2023, , 327-357.		0
2701	Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study. <i>JCO Precision Oncology</i> , 2023, , .	1.5	3
2702	Mitochondrial, cell cycle control and neuritogenesis alterations in an iPSC-based neurodevelopmental model for schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 1649-1664.	1.8	3
2703	Detailed curriculum vitae of HER2-targeted therapy. , 2023, 245, 108417.		4
2704	A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer. , 2023, 40, .		4
2705	Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway. <i>Mediators of Inflammation</i> , 2023, 2023, 1-20.	1.4	6
2706	Concurrent induction of apoptosis and necroptosis in <i>apigenin</i> -treated malignant mesothelioma cells: Reversal of Warburg effect through Akt inhibition and p53 upregulation. <i>Oncology Reports</i> , 2023, 49, .	1.2	2
2707	Compared to Fishmeal, Dietary Soybean Meal Improves the Reproductive Performance of Female Yellow Catfish (<i>Pelteobagrus fulvidraco</i>) Broodstock. <i>Aquaculture Nutrition</i> , 2023, 2023, 1-12.	1.1	0
2708	Cancer resistance via the downregulation of the tumor suppressors RKIP and PTEN expressions: therapeutic implications. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 170-207.	0.5	1
2711	Genetic and Epigenetic Dysregulation in Environmental Disease. , 2024, , 465-492.		0
2738	The Dominant Mechanism of Cyclophosphamide-Induced Damage to Ovarian Reserve: Premature Activation or Apoptosis of Primordial Follicles?. <i>Reproductive Sciences</i> , 0, , .	1.1	2
2764	Role of phospholipases in chronic inflammatory diseases: A systems biology perspective. , 2023, , 219-236.		0
2784	Cancer stem cells, signalling pathways and chemopreventive effects of phytochemicals in androgen-regulated cancers. , 2024, , 409-437.		0
2806	Signaling pathway and pharmacology. , 2024, , 395-601.		0
2809	Molecular Implications of BCR-ABL1 in Hematological Malignancies. , 2023, , .		0
2823	Stem Cells Signaling Modulators in Hematological Diseases. , 2024, , .		0